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ABSTRACT 
Background 
Hereditary haemorrhagic telangiectasia (HHT) is a dominantly inherited genetic 
disorder of blood vessel development characterised by mucocutaneous 
telangiectasia and arteriovenous malformations (AVMs). There are no recent 
epidemiological studies of the prevalence of HHT in the UK, and no population-
based studies investigating the burden of disease complications and mortality in 
this country.  
Some of the most devastating complications of HHT such as stroke and cerebral 
abscess arise as a result of AVMs developing in the pulmonary circulation. 
Current evidence for the management of pulmonary AVMs using percutaneous 
embolisation derives from relatively small cohorts published by specialist centres 
worldwide. No studies have attempted to pool this published literature to 
summarise the complication rates and efficacy of embolisation. Additionally, 
there is uncertainty as to whether the apparent low mortality associated with 
treatment of PAVMs (published in the worldwide literature) is also replicated in 
the experiences of UK centres currently undertaking the procedure.  
Methodology 
This research project used large-scale, representative primary care (The Health 
Improvement Network - THIN) and secondary care (Health Episode Statistics - 
HES) databases to investigate the prevalence, comorbidities and mortality 
related to HHT, and the mortality related to treatment for pulmonary AVMs. We 
further used epidemiological methods to summarise the worldwide published 
literature regarding the safety and efficacy of percutaneous embolisation as a 
treatment for pulmonary AVMs.  
The specific questions addressed in the studies were; 
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1. What is the current UK prevalence of HHT and how does this vary 
with respect to sociodemographic factors? 
Using a primary care database (THIN), prevalence rates and adjusted prevalence 
rate ratios were calculated for HHT and pulmonary AVMs stratified for age group, 
sex, calendar year, socioeconomic status and geographical location. 
2. What are the significant complications and comorbidities associated 
with HHT? 
A case-control study using THIN examined the common complications associated 
with a diagnosis of HHT and looked at commoner cardiovascular and malignant 
comorbidities that may be associated with a diagnosis of HHT.  
3. What is the mortality related to HHT in the UK? 
A case-control study in THIN compared mortality between over 600 cases of 
HHT with age, sex and primary care practice matched controls, analysing 
mortality trends by age, sex and socioeconomic status. 
4. What is the safety and effectiveness of percutaneous embolisation as 
a treatment for pulmonary arteriovenous malformations? 
A systematic review and meta-analysis of published studies worldwide looking at 
safety and effectiveness of embolisation was undertaken. 
5. What are the current mortality trends in England for patients 
undergoing percutaneous embolisation for treatment of pulmonary 
arteriovenous malformations? 
Using an extract from the HES database linked to Office for National Statistics 
death data we investigated mortality associated with embolisation for 
arteriovenous malformation in England over a 15 year period.  
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Results  
1. The minimum prevalence of diagnosed HHT in the UK was calculated to be 1 
in 9,400, with the disease more commonly diagnosed in the female sex, those 
from older age groups,  those from higher socioeconomic groups and patients 
from certain geographical areas of the UK.   
2. A variety of haemorrhagic and neurological complications were commoner in 
HHT than matched controls including stroke (odds ratio (OR) 1.81) , cerebral 
abscess (OR 30), epistaxis (OR 11.6)  and gastrointestinal haemorrhage (OR 
6.08). The odds of cardiac failure (OR 2.36) and colon cancer (OR 2.76) were 
significantly higher in those with HHT when compared to controls.  
3. The hazard ratio for death in HHT cases was twice as high as their matched 
controls. The median age at death in HHT cases was three years younger than 
their matched controls.  
4. Percutaneous embolisation appears to be a safe procedure for embolisation of 
pulmonary arteriovenous malformations with a major complication in less than 
1% of procedures undertaken. It is effective in 84% of patients who undergo 
embolisation, or in 90% of lesions treated.  
5. The mortality associated with percutaneous embolisation between 1997 and 
2011 in England is very low and may be zero. 
 
Conclusions 
HHT has a UK prevalence in line with that described in studies from other 
countries worldwide, though as this prevalence is only in those with diagnosed 
disease, the true prevalence is likely to be significantly higher. HHT is associated 
with significant haemorrhagic and neurological complications and HHT cases 
have a higher mortality than their matched controls. Percutaneous embolisation 
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appears to be a safe and effective treatment for pulmonary AVMs worldwide and 
is associated with a very low mortality in England.  
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 CHAPTER 1: INTRODUCTION 
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1.1 Definitions 
1.1.1 Hereditary haemorrhagic telangiectasia 
Hereditary haemorrhagic telangiectasia is an autosomal dominant genetic 
disorder of blood vessel development characterised by epistaxis, the 
development of mucocutaneous telangiectases and by arteriovenous 
malformations in solid organs. HHT is also known as Osler-Weber-Rendu 
disease, named after the three physicians who characterised it at the turn of the 
20th Century. Rendu first described HHT as a distinct clinical entity, reporting the 
case of a man with repeated attacks of epistaxis and multiple superficial 
angiomas on the face, neck and thorax and noticed the familial link (with 
affected first degree relatives)1. Osler also noted a familial link to epistaxis and 
the presence of telangiectasia and differentiated the disease from that of 
haemophilia as haemorrhage did not occur from sites of obvious trauma2. Weber 
was the first to describe in detail the dermatological manifestations of the 
disease3. It was Frederic Hanes, Osler’s Chief resident, who in 1909 first 
proposed the term “hereditary hemorrhagic telangiectasia” as the definitive 
name for the condition4.  
1.1.2 Arteriovenous malformations 
The normal vascular structure is altered in AVMs such that an artery or arteriole 
connects directly to a vein or venule, bypassing the capillary bed and preventing 
physiological functions such as the exchange of nutrients and wastes and of 
oxygen and carbon dioxide5. AVMs are clusters of dilated feeding 
arteries/arterioles that collect to a nidus which then connects to a draining vein 
or system of veins (Figure 1.1). The lesion is termed an “arteriovenous fistula” if 
there is a connection between a single dilated artery and a single vein6. AVMs 
associated with HHT are found in both the pulmonary and systemic circulations. 
They arise most commonly in the lungs, liver and brain but have also been 
documented in the spine7, kidneys8 and pancreas9,10. AVMs may also be 
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associated with other inherited vascular disorders such as capillary 
malformation-AVM and can also be acquired (for example, PAVMs arising as a 
consequence  of liver cirrhosis, thoracic  surgery, cardiac surgery for congenital 
heart disease or infections such as actinomycosis11). 
Figure 1.1. Diagrammatic representation of a) normal subcutaneous vascular 
structures and b) a mucocutaneous telangiectatic lesion 
a) 
 
b) 
 
Reproduced with permission from Guttmacher et al NEJM (1995) 333:918-924, Copyright 
Massachusetts Medical Society. 
A=arteriole, C=capillary, L=lumen, V=venule 
 
 
1.1.3 Telangiectasia 
Telangiectases are visible dilated blood vessels of the face, lips, nose, tongue 
oral mucosa and fingers that may also be present in the luminal gastrointestinal 
system (Figure 1.2). Telangiectases are thought of as small AVMs and are at 
most a few millimetres in diameter whilst larger AVMs can measure up to several 
centimetres in size.  Telangiectases appear as small pinpoint pink or red lesions 
which blanche on pressure and immediately refill. They are prone to bleeding 
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due to the friable nature of the vessel structure and bleeding is often profuse 
and harder to stem given their direct connection to the arterial circulation12.  
Figure 1.2. Telangiectasia of a) the tongue and lips, and b) the hands 
a) 
 
Copyright Herbert L. Fred, MD and Hendrik A. 
van Dijk. Reproduced under Creative Commons 
licence from Wikipedia. 
http://en.wikipedia.org/wiki/File:TongueTelang
.JPG 
 
b) 
 
Reproduced with permission from Nicoleau and 
Nicoleau NEJM (1999) 340:1800, Copyright 
Massachusetts Medical Society. 
 
 
 
1.2 Clinical presentation and progression 
The location of potential vascular malformations in HHT, together with possible 
ensuing complications are summarised in Table 1.1. HHT is highly penetrant with 
variable expressivity13 and affected individuals are often asymptomatic in early 
childhood but become increasingly clinically affected throughout life. Data 
suggest that approximately 71% of cases will exhibit symptoms by the age of 
16, with almost 90% showing signs of the disease by age 40 years14. The 
presence, severity and the age of onset of various manifestations can vary 
significantly even between members of the same family who have the same 
identified mutation15. 
 
4 
 
Table 1.1. Complications arising in patients with Hereditary haemorrhagic 
telangiectasia 
Clinical 
Manifestation 
Frequency (%) Complications 
 
Telangiectasia 
90 
 
 
 
80 
Nasal  
 Spontaneous, recurrent epistaxis 
 Acute anaemia or chronic iron deficiency 
anaemia 
Other mucocutaneous lesions  
 Cosmetic issues 
 
Pulmonary AVMs 
 
50 
Many asymptomatic 
Right-to-left shunt 
1.2 Dyspnoea / hypoxaemia 
2.2 Stroke / TIA 
3.2 Brain abscess 
4.2 Migraine 
Haemorrhagic; 
 Haemoptysis 
 Haemothorax 
 
Hepatic AVMs 
 
>= 30 
Many asymptomatic  
Hepatic AVMs 
 Post capillary pulmonary hypertension  
 High output cardiac failure 
Hepato-portal VMs 
 Portal hypertension 
Porto-venous VMs 
 Biliary ischaemia 
Gastrointestinal  
telangiectasia 
20 Chronic gastrointestinal haemorrhage 
Iron deficiency anaemia 
 
Cerebral AVMs 
 
10 
Intracerebral haemorrhage 
Headache 
Seizures 
 
Spinal AVMs 
 
< 1 
Space occupying lesion 
 Pain 
 Progressive myelopathy 
Haemorrhage 
 Spinal stroke 
Adapted from Shovlin, Blood Reviews (2010) 24:203-219, Copyright with permission from 
Elsevier. 
 
Telangiectases 
The commonest first symptom in HHT is spontaneous recurrent epistaxis in later 
childhood, with 50% of individuals reporting nosebleeds before the age of 10 
years, rising to 80-90% by the age of 2112. Telangiectases are similar in 
frequency to epistaxis but with an average delay of onset between 5 and 30 
years after epistaxis begins (and usually developing around the third decade of 
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life). Gastrointestinal lesions can be seen endoscopically in 15-30% of those with 
HHT, but rarely bleed before the age of 30 years16.  
Arteriovenous malformations  
Cerebral AVM development occurs during childhood and most lesions that will 
ever exist have formed early in life. It is estimated that CNS involvement occurs 
in between 10-23% of those with HHT17,18. The annual risk of CAVM rupture and 
haemorrhagic stroke appears to vary between as low as 0.9% in those with 
small superficially located lesions with no previous history of rupture, to as high 
as 34% in those with more deep seated lesions with a past history of rupture19.  
Pulmonary AVM development begins during puberty. The prevalence of PAVMs in 
a general population (in one study using thoracic CT to screen for possible lung 
cancer) was noted to be as high as 1 per 2,50020. At least 80% of PAVMs 
diagnosed in a general population are associated with HHT as the underlying 
cause21.  The prevalence of HHT-associated PAVMs varies between studies and is 
related to the mutation identified, being present in between 48-75% of patients 
with HHT 1 mutations and 5-44% with HHT 2. Transthoracic contrast 
echocardiography identified right-to-left shunts in 85% and 35% of HHT 1 and 
HHT 2 patients respectively22. Major complications resulting from PAVMs include 
paradoxical embolic stroke, cerebral abscess, significant hypoxaemia and 
haemorrhagic consequences11. One study noted a gradual cumulative increased 
incidence of respiratory complications over the course of life, with median onset 
of cerebral abscess at 31 years and ischaemic stroke at 5423. There is evidence 
that untreated PAVMs can progress in size if left untreated24.  
Hepatic vascular abnormalities were identified in 74% of HHT-affected 
individuals when the liver was imaged with CT, and 41% when ultrasound was 
used as the modality of choice, though only a minority (8% of patients from the 
CT imaged group) were symptomatic12.    
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1.3 Diagnosis 
HHT is diagnosed clinically on the basis of a set of criteria proposed in 2000, 
known as the Curaḉao criteria25 (Table 1.2). A diagnosis is considered; 
Definite   if 3 or 4 criteria are present, 
Possible or suspected if 2 criteria are present, 
Unlikely   if fewer than 2 criteria are present 
A recent study looking at the validity of these clinical criteria in first degree 
family members of HHT mutation carriers found a 100% positive predictive value 
of a ‘definite’ diagnosis of HHT and a 97.7% negative predictive value for an 
‘unlikely’ diagnosis26. The Curaḉao criteria are considered to be particularly 
useful in two scenarios; firstly, discriminating affected from non-affected older 
adults and, secondly, for ruling-in the diagnosis in younger adults and children27.   
Table 1.2. The Curaḉao criteria 
Criteria Description 
1. Epistaxis Spontaneous, recurrent nosebleeds 
2. Telangiectases Multiple, at characteristic sites; 
 Lips 
 Oral cavity 
 Fingers 
 Nose 
3. Visceral lesions Such as; 
 Gastrointestinal telangiectasia (with or without 
bleeding) 
 Pulmonary AVM 
 Hepatic AVM 
 Cerebral AVM 
 Spinal AVM 
4. Family history A first degree relative with HHT according to these criteria 
 
HHT can also be diagnosed as a result of genetic testing. Currently, in the UK, 
genetic testing is not universally offered but is utilised mainly to clarify the 
specific HHT mutation in an HHT family, allowing diagnosis among relatives 
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(often children and young adults) who do not meet clinical diagnostic criteria27. 
It has been suggested the addition of genetic testing to the Curaḉao criteria (in 
those patients classified clinically as ‘possible’ HHT) may improve diagnostic 
sensitivity28. Likewise, the addition of pulmonary shunting (grade 2 or above) on 
transthoracic contrast echocardiography to the clinical criteria has been shown 
to slightly increase diagnostic sensitivity from 88% to 90% with no loss of 
specificity (74%)29.  
Irrespective of the method of diagnosis, most studies recognise that HHT is 
substantially under-diagnosed30 for several reasons; it is a relatively rare disease 
that is little known amongst most primary care practitioners, the diagnosis may 
be overlooked if HHT-associated symptoms are attributed to a commoner cause, 
there is no active national screening programme, and some clinical genetics 
services do not contact-trace potentially affected relatives of a newly diagnosed 
index case. It is no surprise that the average time-lag between first onset of 
symptoms and diagnosis is 25 years31.  
 
1.4 Genetics 
Identified mutations 
To date five mutations associated with HHT have been identified. Genetic 
analysis involves targeted DNA sequencing and deletion/duplication analysis of 
coding exons of candidate genes. HHT 1 is due to a mutation in the ENG gene 
which codes for the protein endoglin and is present on chromosome 932. HHT 2 
is a mutation in the ACVRL1 gene on chromosome 12 which encodes the activin-
like kinase 1 protein (ALK-1)33. Together, these two mutations account for 
approximately 80% of all known disease carriers in HHT34 with ENG mutations 
(61%) being commoner than those of ACVRL (37%)35. Currently, over 375 
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different mutations have been reported for ACVRL 1 (with at least half being 
suspected pathogenic) and 470 variants detected in the ENG gene (with almost 
three-quarters thought to be pathogenic)36. All mutations types have been 
observed in both genes; deletions, insertions, missense, nonsense and splice 
site. The majority of mutations are unique and specific to the family tested, and 
most have been reported only once37. In addition to the common scenario of 
familial mutations, there are documented de novo mutational events that have 
resulted in the HHT phenotype in sporadic cases38. Mutations of the gene SMAD4 
are identified in 1-2% of patients with HHT and are associated with Juvenile 
Polyposis Syndrome, a condition of multiple intestinal polyps in young people 
which carries a significantly increased risk of developing colonic carcinoma39. 
Two further HHT loci have been described (HHT 3 on chromosome 5 and HHT4 
on chromosome 7) but remain unmapped to known defective genes40,41. A 
recently discovered mutation in BMP9 (also known as GDF2) on chromosome 10 
is associated with a vascular-anomaly syndrome which has phenotypic overlap 
with HHT and is considered to represent HHT type 542.  
Genotype-phenotype relationship 
Some studies have sought to determine whether the gene mutation has any 
predictive role in the likely clinical manifestations of HHT. It seems that PAVMs 
and CAVMs are more commonly seen in the HHT 1 phenotype whilst hepatic 
AVMs occurred with greater frequency in the HHT 2 phenotype43. Spinal AVMs 
were noted, in one study, only in those with HHT 244. All AVM lesions are 
possible in both types of HHT. Work has sought to identify moderator genes that 
govern expression of a particular phenotype in an individual HHT patient. A 
recent study identified one particular gene polymorphism that, when detected, 
appeared to influence the prevalence of PAVMs in HHT patients45. 
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Pathophysiology 
The question as to how ‘abnormal’ genes result in abnormal blood vessel 
development is key and remains partly elusive. The genes so far identified 
encode for cell receptor bindings via the TGF-β superfamily and perturbations in 
this pathway have been suggested to affect the stability of angiogenesis46. Both 
ENG and ALK-1 are predominantly expressed on vascular endothelium (Figure 
1.3).  
Figure 1.3. Gene interactions in downstream signaling in HHT 
 
Reproduced with permission from Wooderchak-Donohue et al Am J Hum Genet (2013) 93:530-537, 
Copyright Elsevier  
R-I and R-II are type I and type II cell surface receptors, respectively. Id1 is an intracellular target 
gene with transcriptional activity regulated by SMAD4. GTM = general transcription machinery. 
See abbreviations section for clarification of all other abbreviations. 
  
 
Endoglin is a co-receptor for TGF-β1 and TGF-β3 isoforms, whilst ALK-1 is an 
alternate type 1 serine-threonine kinase receptor which signals through 
SMAD1/534. There is a final common signaling pathway in SMAD4. Studies 
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measuring the functional levels of endoglin and ALK-1 proteins in HHT 1 and 
HHT 2 mutants respectively support haploinsufficiency as the mechanism for 
HHT pathology. In this model, mutations in ENG or ACVRL1 genes lead to a 
significant reduction of functional endoglin and ALK-1 proteins and to 
dysregulation of the TGF-β signaling pathways as the remaining non-mutated 
allele is unable to produce sufficient protein for normal function46. Homozygosity 
for either ENG or ACVRL1 is believed to result in either in utero or early post-
natal lethality47. The GDF2 mutation affecting BMP9 also appears to signal 
though this pathway. It is thought that impaired TGF-β/BMP affects mural cell 
attachment and vessel stablilisation, leaving HHT vessels more sensitive to 
angiogenic stimuli. Thus, in addition to the genetic component which predisposes 
to the formation of focal vascular lesions, it is postulated that an additional 
vascular stressor is needed to trigger lesion development, given that most blood 
vessels in an HHT patient are normal in structure and function. Suggestions 
including local tissue inflammation and vascular endothelial injury (secondary to 
either hypoxia or haemodynamic changes) have been proposed34. 
Mechanism of action of potential disease modifying therapies 
Certain therapies in HHT have been suggested to influence the process of 
angiogenesis and therefore impact on the development of aberrant blood vessels 
that are characteristic of the disease. These drug therapies have been used most 
commonly in the management of epistaxis associated with HHT. Oestrogen 
(either alone or in combination with progestogens) appears to reduce both 
epistaxis and gastrointestinal haemorrhage. One postulated mechanism is 
through induction of mucosal metaplasia by systemic oestrogens resulting in 
thickened layers of keratinizing squamous epithelium that protect against local 
vessel trauma59. Raloxifene, a SERM, appears to have in vitro effects to 
stimulate protein and mRNA expression of ENG and ALK1, and the promoter 
activity of these genes, in cultured endothelial cells. This may counteract the 
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haploinsufficiency of ENG and ALK1 seen in HHT60. Thalidomide has anti-
angiogenic properties through promoting expression of PDGF-β in endothelial 
cells which increases mural cell coverage of HHT vasculature and appears to 
render the vessels less sensitive to unwanted angiogenic stimuli67. Bevacizumab, 
an anti-VEGF drug initially used in the treatment of cancer, has shown some 
promise both topically and intravenously in the treatment of epistaxis by 
blocking TGF-B stimulated VEGF production which promotes neovascularization 
and potentially vascular haemorrhage66. 
1.5 Screening for arteriovenous malformations 
The initial work-up for any patient with suspected or presumed HHT will involve 
history, physical examination, full blood count (for anaemia) and possible 
genetic testing if clinically indicated. Given the relative frequency of PAVMs, 
CAVMs and hepatic AVMs in HHT, interest has developed in the role of screening 
for each of these lesions in patients with suspected or confirmed HHT. The 
usefulness of screening depends partly on the risk-benefit balance of therapeutic 
interventions for any identified AVM lesions, as well as the potential 
consequences of leaving identified AVMs ‘untreated’. International guidelines, 
published in 2011, suggest strategies for the screening and management of 
various AVMs and complications arising as a result of HHT27. 
Pulmonary AVMs 
A variety of investigations have been used to screen for PAVMs. Some provide 
anatomical detail to look for lesions suggestive of PAVMs, including chest 
radiography48, thoracic CT49, magnetic resonance imaging50, magnetic resonance 
angiography51 and pulmonary arteriography. Oxygen shunt studies, 
transthoracic contrast echocardiography (TTCE) and radionucleotide perfusion 
lung scanning52 quantify shunt which may be associated with the presence of a 
PAVM. Most centres now use TTCE and/or thoracic CT as the primary screening 
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modality. TTCE detects right-to-left shunting of blood bypassing the effective 
pulmonary circulation. Saline (agitated with air) is injected into a peripheral vein 
whilst keeping the cardiac atria under direct visualisation with ultrasound. 
Contrast bubbles appear first in the right atrium and then rapidly dissipate as 
they are filtered by the pulmonary circulation. In patients with a right-to-left 
shunt these microbubbles pass through the circulation and are subsequently 
visualised in the left atrium. The operator counts the number of cardiac cycles 
that pass before bubbles appear in the left atrium, after their first appearance in 
the right atrium. A positive study is generally defined as one in which bubbles 
appear in the left atrium after three cardiac cycles.  A positive right-to-left shunt 
may be associated with a patent foramen ovale (PFO) which must be ruled out 
before looking for any PAVMs. In one study the sensitivity of TTCE in detecting 
PAVMs was 97% (95% CI, 93.6-98.3) and negative predictive value 99% (95% 
CI, 96.9-99.8)53. CT imaging involves a radiation burden and many centres will 
perform TTCE first, moving on to CT if TTCE is positive. CT imaging permits 
sizing and localisation of any PAVMs which helps determine their suitability for 
treatment. It has been suggested that shunt grade on TTCE can predict the size 
of PAVMs subsequently seen on CT, and in those patients with grade 1 shunts 
(the smallest size) CT may not be necessary as any identified PAVM lesions 
would be too small for PCE54. Current guidelines suggest all patients with 
possible or confirmed HHT should be screened for the evidence of PAVMs, with 
further screening intervals determined by whether any PAVMs are identified 
initially and if any therapeutic intervention is undertaken. Suggested screening 
intervals are not currently evidence-based and derive mainly from expert 
recommendations from HHT specialist centres. A recent publication has 
suggested that in one HHT cohort studied the cumulative effective dose of 
radiation received (from screening, diagnostic and therapeutic procedures) was 
in excess of 100 millisieverts in over 10% of the cohort, and that this level of 
radiation exposure may be associated with significant harms55. This has led to 
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suggestions that future guidelines consider lower radiation dose screening 
protocols56. 
Cerebral AVMs 
Screening for CAVMs is most commonly undertaken using MRI18, although both 
CT and cerebral angiography have been utilised. The recent international 
consensus guidance suggests that patients with possible or definite HHT should 
undergo screening on one occasion following diagnosis27, though this is a 
recommendation with low level evidence supporting it and there is no guidance 
as to at what age an MRI should be considered. There is no evidence for 
repeating an MRI scan later in life if the initial scan is negative though some 
centres offer regular screening with MRI (for example, every 5 years).  
Hepatic AVMs 
As hepatic AVMs are common, but usually asymptomatic, guidelines suggest 
screening only in circumstances where liver enzymes are abnormal and/or the 
clinical picture in a patient with HHT is suggestive of complications of liver AVMs 
(high output cardiac failure, portal hypertension, jaundice, portosystemic 
encephalopathy, steal syndrome). Both CT and doppler ultrasound have been 
used successfully to detect liver AVMs57,58. 
 
1.6 Treatments  
There is currently no cure for HHT. Most treatments available are targeted 
towards the site of the AVMs or telangiectasia and are designed either to 
manage complications already arisen or to reduce risk of future significant 
complications occurring.  
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Epistaxis and anaemia 
Routine therapy for acute epistaxis involves compression and packing of the 
nose with resorbable materials and bilateral embolisation or surgical ligation of 
bleeding vessels. Longer-term management is more varied. Preventative 
strategies involve nasal humidification or emollients in order to prevent drying 
and crusting of the nasal mucosa. Medical therapies include hormone treatment 
(with oestrogen59,60, oestrogen-modifiers61 and oestrogen antagonists62,63), 
tranexamic acid64,65, sclerotherapy66, and antiangiogenic drugs such as 
bevacizumab67 and thalidomide68.  Surgical therapies include bipolar69 or laser 
photocoagulation70,71, endovascular embolisation72, septodermoplasty70, or nasal 
closure (known as Young’s procedure)73. Anaemia is most commonly as a result 
of epistaxis, though can be secondary to gastrointestinal blood loss. Iron 
replacement therapy in the form of oral iron supplements, intravenous iron or 
intermittent red cell transfusions may be necessary. If blood loss is due to 
gastric lesions then local endoscopic therapy with plasma argon laser or Nd:YAG 
laser has been shown to prevent recurrence of gastrointestinal bleeding74,75.  
Pulmonary AVMs 
Pulmonary AVMs are associated with an increased risk of both neurological and 
haemorrhagic complications including haemoptysis, haemothorax, seizures, 
migraine, cerebral abscess and stroke76-78 and are managed using an 
interventional radiological procedure known as percutaneous embolisation 
(PCE)79. A catheter is inserted into the femoral artery which tracks up into the 
lung to the afferent vessels of the AVM. The AVM is then occluded via the 
application of any one of the following; a detachable silicon balloon, a platinum 
coil, a specifically designed vascular occlusion device (the Amplatzer device) or a 
coagulable glue (named Onyx). In recent years the majority of patients are 
managed with either coils or the Amplatzer device. PCE can successfully 
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obliterate lesions as small as 2mm in diameter and appears to reduce the risk of 
neurological sequelae80.   
Cerebral AVMs 
Cerebral AVMs can be detected following a complication such as intracerebral 
haemorrhage, seizure, headache or onset of focal neurological deficit or may be 
detected pre-symptomatically both incidentally or by screening. Most centres 
advocate intervention in eligible patients who have bled secondary to a CAVM as 
the subsequent rebleed rate is high. However, there is controversy surrounding 
the management of asymptomatic CAVMs. In addition, there are several 
potential therapies for CAVMs and no clear evidence for the superiority of one 
particular treatment. Management options include the conservative approach, 
microsurgery, stereotactic radiosurgery, microcatheter embolisation or mixed 
modality treatment. This area of the literature suffers from a lack of prospective 
studies. A recent systematic review of retrospective observational literature of 
patients with both ruptured and unruptured CAVMs noted a reduction in case 
fatality over time but there was no clear superior treatment modality in terms of 
survival81. A recently published randomised multicentre trial of management of 
unruptured CAVMs was halted early due to an excess of deaths in the 
intervention arm when compared to the conservatively managed arm, leading 
some to argue against any intervention for this patient group82.  
Hepatic AVMs 
Whilst asymptomatic liver involvement is common, in the minority for whom it 
becomes clinically significant it can lead to considerable morbidity and mortality. 
Invasive therapies for liver involvement which include transarterial embolisation 
of liver AVMs and liver transplantation are high risk procedures and should only 
be considered when intensive medical management is unsuccessful83. 
16 
 
1.7 Objectives 
1. Determine the prevalence of HHT in the UK and its association with age, sex, 
socioeconomic status and region of residence. 
2. Construct a case-control study using The Health Improvement Network 
(THIN) database to look at the relative risks of major comorbidities associated 
with HHT (such as stroke and anaemia) and the overall survival in this 
population. 
3. Undertake a systematic review and meta-analysis of the observational 
literature for percutaneous embolization looking at the safety and efficacy of 
embolisation as a treatment for pulmonary arteriovenous malformations. 
4. Use the Health Episodes Statistics (HES) database to investigate the mortality 
rate and incidence of complications associated with percutaneous embolisation in 
the management of pulmonary AVMs in the UK. 
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 CHAPTER 2: DATABASES AND METHODOLOGY 
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The research presented in this thesis uses data from three main sources: The 
Health Improvement Network, Health Episodes Statistics and death certificate 
data from the Office for National Statistics. This chapter introduces each of these 
information resources.  
2.1 The Health Improvement Network  
Computerised records are used by all general practices in the UK, by medical, 
nursing and administrative staff, to record important patient data for the 
purposes of improving clinical care, demonstrating clinical activity and allowing 
financial renumeration and planning. Approximately 98% of the UK population 
are registered with a general practice84.  The Heath Improvement Network 
(THIN) is a UK computerised, longitudinal primary care database which collects 
anonymised data entered by general practitioners as part of routine clinical care 
via a computerised software interface. THIN is a joint venture between two 
companies; In Practice Systems Ltd (INPS) - who developed the Vision software 
used by general practitioners in the UK to manage patient data - and Cegedim 
Strategic Data Medical Research UK (formerly known as the Epidemiology and 
Pharmacology Information Core, or EPIC) who provide access to the data for use 
in medical research. The THIN database was set up in 2002. 
Data is collected on a daily basis and is entered either by physicians following 
patient’s consultations in primary care, or is entered by administrators if derived 
following correspondence from secondary care. Information collected includes 
patient demographics, medical diagnoses, prescriptions, investigations and 
additional health data (such as smoking status and alcohol intake). Financial 
incentives exist, through the GP contract and the Quality and Outcomes 
Framework (QOF)85, to ensure the data is complete and accurate. In addition, 
CSD Medical Research, the company which runs and administers the database, 
makes regular checks on practices to ensure quality coding is maintained, with 
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the option to remove practices from contributing to the database if data is 
persistently incomplete or inaccurate. Data are recorded from both primary care 
consultations and secondary care correspondence in the form of Read codes86 
which are specific alphanumeric codes pertaining to various medical diagnoses, 
investigations and medications.  
2.1.1 Structure of THIN data 
A THIN data extract is provided in 5 main files; the patient file, medical file, 
therapy file, additional health data file and the consultation file. Each patient in 
THIN has a unique identifier which allows data for one individual to be linked 
across all 5 files.   
Patient file 
The patient file contains information on patient characteristics and registration 
details, including a unique patient identifier, year of birth, year of death (if 
relevant), sex, marital status and registration date at practice.  
Medical file  
This file contains symptoms, diagnoses and interventions recorded by the GP 
and primary care team and information transcribed from discharge summaries 
following hospital stays or from letters sent by secondary care specialists. 
Hierarchical Read codes cover all terms relating to observations (signs and 
symptoms), diagnoses, procedures and investigations.   
Therapy file 
The therapy file records details of prescriptions issued to patients from primary 
care. It does not necessarily contain information on prescriptions issued from 
secondary care unless they are to be continued by GPs in the primary care 
setting. Information recorded includes formulation, strength, dose and quantity 
prescribed.   
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Additional health data (AHD) 
This is a collection of lifestyle data, preventative healthcare interventions, 
immunisations, test results and death details. Examples include; smoking status, 
alcohol intake and levels of exercise frequency. Access to some laboratory 
investigations is also available.  
Consultation data 
Information on the date, time, circumstances and duration of any consultations 
occurring in primary care is recorded in this file.  
Other data 
Within THIN, categorisation of patients by socioeconomic status is accomplished 
by assigning a Townsend score87. The Townsend score is a material measure of 
deprivation and disadvantage based on the composite score of four variables;  
 Unemployment as a percentage of those aged 16 and over who are 
economically active.  
 Non-car ownership, as a percentage of all households.  
 Non-home ownership, as a percentage of all households.  
 Household overcrowding. 
 
THIN does not collect individual data on patient address or postcode, but 
instead, residential areas are divided into Lower Super Output Areas (LSOAs) by 
postcode with approximately 1500 homes in each. Each area is then linked with 
a Townsend score for deprivation. We further grouped LSOAs into one of 10 UK 
Health Authority areas.  
The higher the Townsend Index score, the more deprived and disadvantaged an 
area is thought to be. The overall score is expressed in quintiles with those in 
quintile 1 considered the most affluent and those in quintile 5 the least affluent.  
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The advantages of the Townsend score are its relative ease of calculation, close 
correlation with measures of ill health (such as standardised mortality ratios) 
and the fact that it can be used to look at relatively small geographical areas. 
The drawbacks are it appears to be a better indicator of deprivation in urban  
areas, rather than rural ones, and that some information on which the score 
relies (such as housing tenure data from the 1991 Census) is now significantly 
out of date.  
2.1.2 Data collection 
Once a practice joins THIN an initial full data collection occurs which retrieves all 
retrospective data from the practice. Following this, incremental data are 
collected automatically and unobtrusively on a daily basis. THIN processes the 
data and updates the research dataset every three months. Data collection 
under the guise of THIN commenced officially in 2003, though many practises 
had already been using the Vision software when THIN came into being and 
some have computerised patient records dating back as far as 1985. At the time 
of data extraction for this thesis (September 2011) THIN covered over 5% of the 
UK population with 3.6 million people prospectively contributing data across 532 
primary care practices88. Data presented in this thesis span the time period of 
1988 to 2010 (the last complete data year extracted).  
2.1.3 Data quality in THIN 
THIN provides training on the use of the Vision software and on how to achieve 
good quality data recording. Practices receive feedback on the quality and 
completeness of their coding. Practices that routinely demonstrate poorer coding 
efficacy and accuracy could potentially be excluded from further contributions to 
THIN until they can show coding practices have improved. Audit of the THIN 
database has shown a generally high level of completeness and accuracy of the 
data89. 
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2.1.4 Validity and generalisability of the THIN database 
Data validity is defined as the correctness and reasonableness of the data. Data 
generalisability refers to a broad concern that findings or insights derived from a 
population database sample apply to the general population. It is more or less 
synonymous with external validation. Studies have investigated the 
generalisability of the THIN population by comparing observed population 
demographics90, chronic disease prevalences90-93, prescriptions assigned94,95 and 
deprivation and mortality estimates90 with those derived from the other UK 
datasets.   
The THIN population and the UK population (derived from the UK QOF database) 
were similarly distributed across age groups though in THIN there is a slight 
underrepresentation of those under the age of 25 (of both sexes), and the 
match between populations slightly less good for males compared with females 
(Figure 2.1 and Figure 2.2).  
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Figure 2.1. Comparison of THIN population and UK QOF population of males in 
2009 with respect to age and gender 
 
Reproduced with permission from CSD Medical Research UK’s THIN Database. CSD MR UK 
accepts no responsibility for any additional interpretation.  
 
 
Figure 2.2. Comparison of THIN population and UK QOF population of females in 
2009 with respect to age and gender 
 
Reproduced with permission from CSD Medical Research UK’s THIN Database. CSD MR UK 
accepts no responsibility for any additional interpretation.  
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Although some THIN patients do not have a Townsend score recorded, it 
appears that there is a slight over-representation of the least deprived quintile in 
the THIN database, and an under-representation of those from the most 
deprived quintile (Table 2.1).   
 
Table 2.1. THIN population (2009) by Townsend quintile 
Townsend quintile 2009 THIN population (%) 
1 = Most affluent 21.9 
2 19.8 
3 19.5 
4 18.3 
5 = Least affluent 13.6 
Missing a Townsend score 7.0 
  Data for table derived from90 
 
THIN uses the Acceptable Mortality Reporting year (AMR) as a way of identifying 
practices where mortality reporting is as expected, as over- or under-reporting 
of mortality may bias disease rates and lead to erroneous denominators. The 
AMR is defined as the first year that the practice’s reported number of deaths 
was as expected, according to national statistics and the demographic structure 
of the practice, and remains so until the last data collection. The AMR allows the 
option to restrict data analysis to the period in which the mortality reporting is 
considered acceptable (often leading to a loss of data from the 1990’s when 
mortality reporting was less comprehensive).  
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2.1.5 Strengths and limitations of the THIN database 
Strengths 
The main strengths of THIN are that it includes an unselected population of 
patients that appears broadly representative of the UK population as a whole, 
meaning findings from THIN should be generalisable, less subject to selection 
bias and have improved validity. The size of the database is an advantage - 
containing data on over 10.5 million patients, with over 3.6 million actively 
followed - meaning it can be used to study rare diseases or outcomes such as 
those seen in HHT. The data are collected prospectively, minimising recall bias, 
and in a non-interventional way during routine practice in primary care and 
therefore reflect ‘Real Life’. The breadth of information collected in the THIN 
database, including demographic data, medical diagnoses and conditions, 
primary care prescribing information, details of hospital admissions and 
outpatient consultation diagnosis and treatment, and additional health data 
provide a vast resource of information for academic research.  
Limitations 
Potential limitations of THIN include possible incompleteness of data. Although 
the data entered into THIN is used by the GP as the patient’s medical record, 
and therefore information generated by the general practitioner is expected to 
be complete, information from specialists as well as events that occur in the 
hospital may not be fully captured in the electronic medical record. The database 
may not contain data on every patient characteristic or disease characteristic 
that may be required for a study (information on occupation, employment, and 
individual socioeconomic status is not always available electronically). 
Communication from specialists, discharge summaries from hospitals, and test 
results from pathology laboratories are often received in hard copy and must be 
manually entered into the computer. Since this can be a time consuming 
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process, some practices will only enter information that will affect the care of the 
patient in the future. However, current data is now more likely to be received 
and recorded electronically so the bias is reduced in more recent data. Minor 
medical events are more likely to be missed than medically significant diagnoses 
or events. Information on treatments that are restricted by the National Health 
Service to specialist care (e.g. cytotoxics or chemotherapy or biologic therapies) 
may be particularly problematic. Data on non-significant medical events and 
exposures to medications that occurred prior to enrolment in THIN and are no 
longer active clinical issues may also not be documented in the electronic 
medical record, though may be available as ‘historical data’ if transferred into 
the current electronic record. Data on important confounding variables 
(smoking96, alcohol use97, body mass index98) are not available for all patients, 
thought this is improving due to data collection initiatives driven by the Quality 
and Outcomes Framework99.  
2.1.6 Ethical approval  
THIN data collection for use in research was approved by the NHS South-East 
Multi-centre Research Ethics Committee (MREC) in 2008 (See Appendix 4). 
Under the terms of this ethical approval, studies using pre-collected, 
anonymised data must undergo scientific review to help ensure appropriate 
analysis and interpretation of the data. This is overseen by the independent CSD 
Medical Research Scientific Review Committee (SRC) which provided approval 
for the analysis of data presented in this thesis in 2011. No data provided to me 
or any of the researchers involved in this thesis was individually patient 
identifiable.   
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2.2 Hospital Episode Statistics 
The HES database collects information on all inpatient admissions, outpatient 
clinics and Accident and Emergency attendances in NHS hospitals in England. 
This data is collected prospectively, with over 18 million new inpatient records 
and 40 million new outpatient records added each year. Data is released on a 
monthly basis following a 6 month time delay (required for data cleaning and 
processing). Information is entered by trained clinical coding staff working in 
each hospital and all NHS hospitals are required to participate. The database is 
managed and administered by the Health and Social Care Information Centre 
and access to the data is permitted for the purposes of research. Data on 
hospital admissions is available for every financial year from 1989-1990 onwards 
and data from outpatient attendances has been collected since 2003. Inpatient 
data was not considered to be of a suitable standard for use in research until 
1997. 
Data is coded by spells and episodes. A spell is the complete period of a time a 
patient is admitted (i.e. from admission to discharge). An episode is the period 
of time a patient is under the care of a particular named consultant or is under 
the care of a particular hospital. If a patient is transferred to the care of a 
different consultant, or moved to a hospital in a different NHS trust, they would 
have entered a new episode, though still be in the same spell. An inpatient spell 
or episode ends with either discharge or a death. In the database, there is one 
row of data for each individual episode. Data is collected in several domains 
including clinical information, socioeconomic data, patient pathway, maternity 
data, geographical location and many others. Clinical data is coded using the 
International Statistical Classification of Diseases and Health Related Problems 
(ICD-10). Coders can enter one primary diagnosis and up to 20 secondary 
diagnoses per episode. Procedures undertaken during an episode are coded 
according to the OPCS Classification of Interventions and Procedures (Version 
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4.6, April 2011), and include operations, diagnostic procedures, therapeutic 
procedures and other non-operative treatments (for example, cognitive 
behavioural therapy). 
2.2.1 Strengths and limitations of the HES database 
The major strength of the database is its size, the largely prospective nature of 
data collection and the fact that all NHS trusts, including mental health and 
community health services are obliged to participate. Most secondary care trusts 
use HES data to charge for their services and, as such, there is an incentive to 
ensure complete data collection. It should be underlined that the reason for data 
collection in HES is not specifically for its value in research. Other weaknesses 
include the lack of detail of extracted data in certain clinical areas and the fact 
that data extraction from non-standardised, largely unstructured paper records 
may lead to under-recording or miscoding of data100. There are internal 
processes at work to ensure coding accuracy and completeness is monitored 
within HES101 and the use of HES data has been validated by studies in 
comparison to other databases102,103.   
2.2.2 Ethical approval 
Data from both the HES and ONS databases are available in the public domain 
and provided in an anonymised fashion. Our first HES-linked ONS extract was 
requested in 2011 and did not require ethical approval. A subsequent request for 
additional HES data in 2013, because of its use of only pseudonymised data, was 
also exempt from NHS REC ethics approval.  
 
 
29 
 
2.3 The Office for National Statistics and death certificate data 
The Office for National Statistics (ONS) collects information on cause of death 
from the death certificate, which in the case of registered deaths (the vast 
majority) is completed either by a doctor or coroner. In part 1 of the death 
certificate the underlying cause of death is derived from the documented 
sequence of conditions leading directly to the death. In part 2 any other 
conditions or comorbidities that the patient had at the time of death, which may 
or may not have directly contributed to the death, are recorded.  
The HES database may contain information on the circumstances under which 
the patient was admitted (elective, emergency etc.) or discharged (discharged 
with clinical consent, died etc.) but it cannot, alone, be used to identify the 
cause of death, nor does it capture deaths that occur outside the hospital. These 
limitations can be overcome by linking the ONS mortality data described above, 
through a unique and anonymous identifier, to the HES inpatient or outpatient 
episodes data104.  
2.3.1 Strengths and limitations of ONS death certificate data 
The advantage of ONS mortality data is that death registration is a mandatory 
process to be undertaken in the UK. This means that missing data is rare. The 
accuracy of the data, however, cannot be quite so confidently assured. 
Approximately 22% of registered deaths in England undergo subsequent post-
mortem105, and in these cases, the overall sensitivity of the death certificate for 
predicting an individual cause of death found at post mortem was only 47% 
(though varied between 98% in neurological disease to 28% in diseases of the 
cardiovascular system)106.  
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 CHAPTER 3: THE PREVALENCE OF HEREDITARY 
HAEMORRHAGIC TELANGIECTASIA IN THE UK 
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3.1 Introduction 
This chapter will examine the descriptive epidemiology of HHT in the UK. 
Worldwide, epidemiological studies estimate the prevalence of HHT to be 
between 1 in 5,000 and 1 in 8,000 (Table 3.1). The only UK estimate of 
prevalence in 1992 in the ‘Northern region’ of England calculated a much lower 
prevalence of 1 in 40,000107, though this was acknowledged at the time to likely 
represent a significant underestimate. Population-based epidemiological studies 
in HHT are the essential first step in understanding and quantifying the burden 
of disease and informing healthcare planning.   
The major limitations of the current literature are the relatively small sample 
sizes, their inherent selection bias (some studies deliberately conducted in high 
prevalence areas, in individuals from specific ethnic groups or from selected 
tertiary centre populations) and concerns over whether findings from overseas 
studies are generalisable to the UK population.  
There are few data regarding differences in geographical prevalence of HHT in 
the UK or associations with sex, age and socioeconomic status, and this is 
important as understanding these relations may increase knowledge of factors 
that modify both development and diagnosis of the disease. 
Hence, the aim of this chapter is to determine, using a representative sample of 
the UK population obtained via an electronic general practice database, a 
contemporary prevalence of diagnosed HHT and its association with age, sex, 
geographical location and deprivation status.
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Table 3.1. Summary of prevalence studies of HHT (including data from this thesis) 
Year of 
study 
Year of 
estimate 
Authors Study setting and 
methodology 
Study 
size 
Prevalence 
rate 
(per 10,000) 
Prevalence rate 
2014 2010 Donaldson et al108 UK primary care database 365 1.06 1 per 9,400 
2013 2005-2010 Grosse et al109 US health insurance database 1203 0.3 1 per 33,000 
2003 1998 Westermann  et al 110 Screening extended pedigree of 
previously identified cases in Antilles, 
Netherlands 
112 7.51 1 per 1,300 
2002 2002 Dakeishi et al111 Screening extended pedigree of cases 
referred to tertiary centre in Akita 
prefecture, Northern Japan 
23 1.25 
 
1 per 8,000 
1999 1995 Kjeldsen et al112 Regional patient database, Fyne 
county, Denmark 
73 1.56 
 
1 per 6,400 
1995 1994 Guttmacher et al113 Postal questionnaire of identified 
cases in Vermont, USA 
34 0.61 1 per 16,400 
1992 1991 Jessurun et al114 Study of cases hospitalised to one 
centre in Leeward Islands, Antilles, 
Netherlands 
32 1.94 1 per 5,200 
1992 1990 Porteous et al107 Postal questionnaire study of cases in 
Newcastle, “Northern Region”, UK 
79 0.25 
 
1 per 40,000 
1989 1989 Bideau et al115 Postal questionnaire study of cases 
identified by physicians in France (52 
departments) 
406 
 
1.20 
 
1 per 8,300 
1984 1983 Plauchu et al116 Postal questionnaire study of cases 
identified by physicians in Ain 
department, France 
150 
 
4.25 1 per 2,400 
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3.2 Methods 
3.2.1 Study population 
This study utilised an anonymised, computerised, longitudinal general practice 
database known as The Heath Improvement Network (THIN). 
3.2.2 Definition of disease 
We identified all recorded diagnoses (by medical Read codes) between the years 
2000 and 2010 of Hereditary Haemorrhagic Telangiectasia (G770.00) and 
Rendu- Osler-Weber Disease (G770.11) available in the THIN database. Given 
the high prevalence of HHT in individuals with pulmonary AVMs117 we also 
searched for Read codes pertinent to pulmonary AVMs (we excluded any 
individuals previously identified as having Read codes for HHT or Rendu-Osler-
Weber disease to prevent double-counting) (see Appendix 1). Population 
denominator values were derived from the annual mid-year populations 
contributing to THIN. The results presented in this chapter are for patients coded 
as Hereditary Haemorrhagic Telangiectasia (G770.00) or Rendu- Osler-Weber 
Disease (G770.11) only. A repeat analysis of a wider population was conducted 
which included all the Read codes listed in Table 3.2. 
3.2.3 Statistical methods 
Data for 2010 (the most recent complete data year) were used to calculate a 
point prevalence for HHT.  We stratified our results by sex, age group (<15 
years, 15-49 years and 50+ years), geographical location and socioeconomic 
status. Geographical location was defined by UK Health Authority areas and 
socioeconomic status was based on the Townsend index score in quintiles87. 
Given the relatively small numbers available for analysis by health authority in 
2010, we used combined data from 2000-2010 to calculate prevalence estimates 
for HHT between different health authorities in the UK adjusting for the use of 
repeated measures (see below). We were able to look for any significant 
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changes in the prevalence of HHT over the 10 year period between 2000 and 
2010. Prevalence estimates taken over multiple years were adjusted by direct 
standardisation to the 2010 THIN population. Random effects modelling (Huber’s 
Method) allowed for the non-independent nature of the cases contributing each 
year to the overall disease prevalence estimate, adjusting the standard errors of 
the final model. We used Poisson regression to compare prevalence rate ratios, 
controlling for year, age, sex, Townsend score and health authority. Statistical 
tests of significance were performed using the likelihood ratio method unless 
otherwise stated.  All analyses were carried out in Stata SE12 (Stata Statistical 
Software: Stata/SE12.0 for Windows; Stata Corporation, College Station, Texas, 
USA).  
3.3 Results 
We identified a total of 563 individuals diagnosed with HHT/Rendu-Osler-Weber 
disease in the THIN database from the years 2000–2010 with 365 cases 
contributing to the calculated point prevalence in 2010. Table 3.2 presents the 
total number of diagnosed cases identified in 2010 stratified by Read code.   
Table 3.2. Prevalent cases of HHT identified between 2000-2010 from the THIN 
database summarised by Read code 
Disease Read Code Year 
(2010) 
Years 
(2000-
2010) 
N % N % 
Hereditary haemorrhagic telangiectasia G770.00 342 86.4 513 83.3 
Rendu-Osler-Weber disease G770.11 23 5.8 50 8.1 
Sub total  365  563  
Arteriovenous fistula of pulmonary vessels G420.00 17 4.3 34 5.5 
Pulmonary arterio-venous malformation P736.12 5 1.3 9 1.5 
Pulmonary arterio-venous fistula P736.11 6 1.5 6 1.0 
Pulmonary arterio-venous aneurysm P736.00 3 0.8 4 0.7 
Total  396  616  
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3.3.1 Overall prevalence of HHT 
The point prevalence of HHT in 2010 was 1.06 per 10,000 (95% CI: 0.95-1.17) 
or 1 per 9,400.  In the sensitivity analysis using broader diagnostic criteria 
(combining all Read codes from Table 3.2) the point prevalence in 2010 
increased to 1.15 per 10,000 (95% CI: 1.04-1.26) or 1 per 8,700.  
3.3.2 Prevalence by sex and year 
The prevalence of a diagnosis of HHT was strongly related to sex, with a higher 
prevalence rate in females compared to males for all years between 2000 and 
2010 (Figure 3.1 and Table 3.3). In 2010 the point prevalence in women was 
1.29 per 10,000 person years (95% CI: 1.12-1.46) and for men was 0.82 per 
10,000 person years (95% CI: 0.69-96). After adjusting for age, deprivation 
status and geographical location, the prevalence rate ratio (PRR) in 2010 for 
HHT was higher in women compared with men (PRR 1.59, 95% CI: 1.30-1.94, 
p<0.0001). The prevalence rate for both men and women has remained 
relatively constant over the last 10 years. 
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Figure 3.1. Standardised UK prevalence of HHT by year and sex (2000-2010) 
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Table 3.3. Total prevalent cases of HHT by year (2000-2010) 
Year Total prevalent 
cases 
2000 336 
2001 351 
2002 364 
2003 374 
2004 383 
2005 397 
2006 399 
2007 405 
2008 405 
2009 394 
2010 365 
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3.3.3 Prevalence by sex and age group 
Prevalent cases from 2010 were grouped into 3 different age categories (<15 
years, 15-49 years and 50 years and over) and stratified by sex (Figure 3.2 and 
Table 3.4). The unadjusted prevalence rate in both sexes was lowest in those 
aged <15 years and highest in the 50+ age group and the adjusted prevalence 
rate ratios across the age groups differed significantly (p test for trend <0.0001) 
(Table 3.5). 
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Figure 3.2. UK prevalence of HHT by age group in 2010  
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Table 3.4. Prevalent HHT cases by age group and sex in 2010 
Age group Male cases Female cases 
<15 15 20 
15-49 51 90 
50+ 75 114 
Total 141 224 
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Table 3.5. Crude prevalence rates and prevalence rate ratios of HHT derived 
from Poisson regression modelling using The Health Improvement Network 
dataset in 2010 
 Crude prevalence 
rates (95% CI) 
per 10,000 
person-years 
Crude 
prevalence rate 
ratios (95% CI) 
Mutually adjusted 
prevalence rate 
ratios 
(95% CI)a 
Sex    
Male 0.84 (0.70-0.98) 1.00 1.00 
Female 1.28 (1.11-1.44) 1.56 (1.25-1.95) 1.53 (1.24-1.88) 
   p=0.0001 
Age group (years)    
<15 years 0.61 (1.15-1.77) 1.00 1.00 
15-50 years 0.84 (0.71-0.98) 1.39 (0.88-2.19) 1.39 (0.96-2.02) 
>50 years 1.58 (1.35-1.81) 2.62 (1.69-4.07) 2.53 (1.76-3.63) 
   p<0.0001  
p=<0.0001
b 
Townsend Score    
1 (Least deprived) 1.31 (1.07-1.55) 1.93 (1.29-2.89) 1.74 (1.14-2.64) 
2 1.05 (0.81-1.29) 1.55 (1.701-2.38) 1.36 (0.88-2.11) 
3 1.10 (0.85-1.35) 1.62 (1.03-2.55) 1.50 (0.97-2.31) 
4 0.87 (0.63-1.10) 1.28 (0.79-2.08)  1.23 (0.78-1.94) 
5 (Most deprived) 0.68 (0.43-0.93) 1.00 1.00 
9 (Missing values) 1.34 (0.77-1.91) 1.98 (1.12-3.52) 2.20 (1.25-3.88) 
   p=0.026 
p=0.60b 
aAdjusted for sex, age group, Townsend score and UK health authority 
b
p-trend across categories  
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3.3.4 Prevalence by deprivation status 
The prevalence of HHT was inversely associated with socioeconomic deprivation 
(Figure 3.3). The crude prevalence rate in the most deprived group (Townsend 
score: quintile 5) was 0.68 per 10,000 (95% CI: 0.43-0.93) and was 1.31 per 
10,000 in the least deprived quintile (95% CI: 1.07-1.55).  After adjusting for 
the effects of age, gender and geographical location, the prevalence rate ratio 
was higher in those in least deprived socioeconomic group when compared to 
those in the most deprived group (PRR 1.74, 95% CI: 1.14-2.64, p<0.0001).  
 
Figure 3.3. Standardised UK prevalence of HHT by Townsend score  
(2000-2010)*  
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3.3.5 Prevalence by health authority 
There was substantial variation in estimates of HHT prevalence across the UK 
when stratified by health authority over the 10 year period 2000-2010 (Figure 
3.4 and Table 3.6). The adjusted prevalence rate ratio varied almost twofold 
across the different UK health authority boundaries with the lowest adjusted 
prevalence in the West Midlands and the highest prevalence in the South West 
(PRR 1.86, 95% CI: 1.61-2.15, p<0.0001, comparing West Midlands and South 
West regions). 
 
Figure 3.4. The crude prevalence of hereditary haemorrhagic telangiectasia 
(per 10,000) by UK health authority area (2000-2010) 
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Table 3.6. Standardised prevalence of hereditary haemorrhagic telangiectasia by 
UK health authority area (2000-2010) 
Health Authority Crude 
prevalence 
rates (95% CI) 
per 10,000 
person-years 
Crude 
prevalence 
rate ratios 
(95% CI) 
Mutually 
adjusted 
prevalence 
rate ratios 
(95% CI)* 
West Midlands 0.78 (0.69-0.88) 1.00 1.00 
East Midlands 0.85 (0.71-1.00) 2.08 (1.11-3.90) 1.08 (0.88-1.33) 
London 0.78 (0.69-0.87) 0.93 (0.54-1.62) 1.13 (0.95-1.34) 
South East Coast 1.02 (0.92-1.13) 1.09 (0.64-1.87) 1.30 (1.11-1.52) 
Northern Ireland 0.93 (0.77-1.09) 1.10 (0.53-2.29) 1.30 (1.05-1.61) 
East of England 1.07 (0.95-1.18) 1.45 (0.83-2.50) 1.35 (1.15-1.59) 
Scotland 1.07 (0.97-1.17) 1.50 (0.92-2.43) 1.45 (1.25-1.69) 
North West 1.14 (1.03-1.25) 1.29 (0.77-2.16) 1.48 (1.27-1.72) 
South Central 1.23 (1.13-1.33) 1.34 (0.82-2.18) 1.54 (1.33-1.77) 
Yorkshire & Humber 1.37 (1.18-1.55) 2.19 (1.15-4.15) 1.76 (1.46-2.11) 
Wales 1.35 (1.20-1.51) 1.46 (0.83-2.55) 1.77 (1.50-2.09) 
North East 1.35 (1.14-1.55) 1.74 (0.91-3.36) 1.80 (1.48-2.19) 
South West 1.51 (1.39-1.63) 2.09 (1.31-3.36) 1.86 (1.61-2.15) 
   p<0.0001 
*Adjusted for age group, sex and Townsend score 
 
3.3.6 Sensitivity analysis 
The above analyses were repeated to include all Read codes listed in Table 3.2, 
rather than those for HHT and Rendu-Osler-Weber disease alone and revealed 
no significant differences in the qualitative trends of our results nor significance 
values for these trends (Figure 3.5, Figure 3.6 and Figure 3.7; Table 3.7, Table 
3.8 and Table 3.9). There was a slight change in the prevalence rate ratios 
calculated for the different health authority areas in the sensitivity analysis, with 
HHT or PAVMs diagnosed least commonly in London rather than the West 
Midlands (Table 3.10).  
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Figure 3.5. Standardised UK prevalence of HHT/PAVMs by year and sex  
(2000-2010) 
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Table 3.7. Total prevalent cases of HHT/PAVMs by year (2000-2010) 
Year Total prevalent 
cases 
2000 363 
2001 380 
2002 401 
2003 418 
2004 427 
2005 438 
2006 436 
2007 441 
2008 440 
2009 429 
2010 396 
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Figure 3.6. UK prevalence of HHT/PAVMs by age group in 2010 
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Table 3.8. HHT/PAVM cases by age group and sex (2010) 
Age group Male cases Female cases 
<15 16 20 
15-49 59 93 
50+ 87 121 
Total 162 234 
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Table 3.9. Crude prevalence rates and prevalence rate ratios of HHT/PAVMs 
derived from Poisson regression modelling using The Health Improvement 
Network dataset in 2010 
 Crude prevalence 
rates (95% CI) 
per 10,000 
person-years 
Crude 
prevalence rate 
ratios (95% CI) 
Mutually adjusted 
prevalence rate 
ratios 
(95% CI)a 
Sex    
Male 0.96 (0.81-1.11) 1.00 1.00 
Female 1.33 (1.16-1.50) 1.42 (1.15-1.76) 1.39 (1.13-1.69) 
   p=0.001 
Age group (years)    
<15 years 0.63 (0.42-0.83) 1.00 1.00 
15-50 years 0.91 (0.76-1.05) 1.45 (0.93-2.27) 1.46 (1.02-2.10) 
>50 years 1.74 (1.50-1.98) 2.81 (1.83-4.32) 2.72 (1.91-3.88) 
   p<0.0001  
p<0.0001
b 
Townsend Score    
1 (Least deprived) 1.41 (1.34-1.49) 1.83 (1.26-2.66) 1.67 (1.13-2.48) 
2 1.09 (1.02-1.16) 1.43 (0.96-2.14) 1.28 (0.85-1.93) 
3 1.27 (1.18-1.35) 1.59 (1.05-2.42) 1.49 (0.99-2.24) 
4 1.23 (1.15-1.32) 1.23 (0.78-1.95)  1.20 (0.78-1.85) 
5 (Most deprived) 0.94 (0.85-1.04) 1.00 1.00 
9 (Missing values) 1.18 (1.01-1.34) 1.74 (1.00-3.03) 1.94 (1.12-3.36) 
   p=0.037 
p=0.40b 
aAdjusted for sex, age group, Townsend score and health authority 
b
p-trend across age categories 
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Figure 3.7. Standardised UK prevalence of HHT/PAVMs by Townsend score 
(2000-2010) 
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Table 3.10. Standardised prevalence of HHT/PAVMs by UK health authority area 
(2000-2010) 
Health Authority Crude 
prevalence 
rates (95% CI) 
per 10,000 
person-years 
Crude 
prevalence 
rate ratios 
(95% CI) 
Mutually 
adjusted 
prevalence 
rate ratios 
(95% CI)* 
London 0.89 (0.79-0.98) 1.02 (0.87-1.19) 1.00 
West Midlands 0.87 (0.77-0.97) 1.00 1.06 (0.90-1.24) 
East Midlands 0.92 (0.77-1.07) 1.06 (0.87-1.29) 1.14 (0.93-1.38) 
South East Coast 1.12 (1.01-1.23) 1.30 (1.12-1.50) 1.35 (1.17-1.57) 
South Central 1.26 (1.16-1.37) 1.45 (1.27-1.67) 1.46 (1.27-1.68) 
East of England 1.21 (1.09-1.34) 1.40 (1.20-1.63) 1.46 (1.25-1.70) 
Scotland 1.05 (1.15-1.26) 1.33 (1.15-1.43) 1.52 (1.32-1.75) 
North West 1.23 (1.12-1.34) 1.42 (1.23-1.64) 1.53 (1.33-1.77) 
Wales 1.43 (1.27-1.59) 1.64 (1.40-1.93) 1.69 (1.44-1.98) 
Northern Ireland 1.42 (1.22-1.62) 1.64 (1.37-1.97) 1.76 (1.47-2.10) 
North East 1.35 (1.14-1.55) 1.55 (1.28-1.88) 1.87 (1.54-2.26) 
Yorkshire & Humber 1.38 (1.58-1.79) 1.82 (1.54-2.16) 2.08 (1.75-2.46) 
South West 1.61 (1.48-1.73) 1.85 (1.61-2.12) 2.09 (1.83-2.40) 
   p<0.0001 
*Adjusted for age, sex and Townsend score 
 
 
3.4 Discussion 
3.4.1 Summary of results 
This chapter describes the use of a national primary care population-based 
database to estimate national prevalence figures for HHT in the UK and to 
explore age, sex, socioeconomic and regional differences in the diagnosed 
prevalence of the disease. The 2010 point prevalence for HHT in the UK is 1.06 
per 10,000 (or 1 per 9,400) which has remained relatively stable between 2000 
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and 2010. The prevalence estimate is higher when additional Read codes likely 
to be associated with HHT are included (1 per 8,700) and is higher still if the 
prevalence in females is considered to be more representative of the population 
as a whole (1 per 7,800). The prevalence increases with age. The diagnosed 
prevalence ratio of HHT was 59% higher in women than in men and 74% higher 
in those from the least deprived socioeconomic group when compared to those 
in the most deprived group. There is a substantial geographical variation in the 
diagnosed prevalence of HHT across the UK.  
3.4.2 Strengths and limitations 
This is the first population-based study of HHT using a primary care database in 
the UK. With a total of 365 HHT prevalent cases identified in 2010 our study is 
almost four times the sample size of the last UK estimate undertaken in 1992107, 
is nationally representative and comparable in size with epidemiological studies 
conducted in other countries110-112. We have been able to stratify our prevalence 
estimates by sex, age group, deprivation status and geographical location 
without the risk of bias that may occur either from low response rates (as have 
been observed in previous surveys of HHT prevalence in the UK107) or from case-
series in specialist centres which may lack a denominator population or 
represent cases referred for specialist care with potentially more severe disease. 
There are potential limitations to the study which should be addressed. The first 
is that of the validity of the HHT diagnoses, which are recorded by general 
practitioners in the THIN database whilst the clinical diagnosis is generally made 
in secondary care. In practice, we are reasonably confident that the vast 
majority of these diagnoses will be valid with the increasing involvement of 
clinical geneticists in the screening and diagnosis of HHT which should result in 
more reliable information being conveyed to the primary care practitioner, and 
hence entered into the database. It seems very unlikely that a primary care 
practitioner would enter a diagnosis of HHT into the database unless it was 
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supported by correspondence from secondary care. That our HHT prevalence 
estimate is consistent with other estimates from previous studies also supports 
the reliability of our findings. One further limitation that complicates all studies 
of HHT prevalence at present is the possibility of undiagnosed asymptomatic or 
symptomatic cases at large in the community. This may explain the higher 
prevalence of PAVMs as defined by radiological criteria (and by inference, HHT) 
in patients who were participating in a recent Japanese CT screening program 
for lung cancer20 than we observed in our dataset which did not use this 
radiological definition of the disease. Diagnosis is often confounded by the 
heterogeneous clinical presentation of HHT due to its variable genetic 
penetrance and expressivity118. Hence, our prevalence estimates represent those 
with diagnosed HHT, and are likely to be lower than the true prevalence defined 
as all individuals with a mutation compatible with the disease. Other studies 
have also recognised the issue of under-diagnosis in HHT30. The fact that our 
data show the prevalence of the disease has been stable in both sexes over the 
last decade would suggest that the consistency in coding practice over this 
period has been maintained.   
We used the Townsend score which is a deprivation index based on geographical 
area as it was not possible to access individual-level deprivation data. This score 
presumes that individuals within a geographical area have a similar deprivation 
status which may not be the case. However, there is evidence to suggest that 
the Townsend scores calculated at a district level are good proxy measures for 
individual levels of deprivation119.  
3.4.3 Interpretation of results 
Reasons for the marked sex difference between the diagnosed prevalence of 
HHT require careful consideration. One study from the Dutch Antilles showed a 
33% increased prevalence ratio of a ‘definite’ diagnosis of HHT in females 
compared with males (using the Curacao criteria)110, and a recent US paper 
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found a female:male ratio of 1.54, with HHT being diagnosed more commonly in 
females109. Other studies have reported a more balanced distribution between 
sexes111,118. Given HHT is an autosomal dominant disorder, the offspring of 
affected individuals will have a 50% chance of inheriting a mutation and this 
should not per se be associated with a sex bias. Our data show a significant 
difference in diagnosis of HHT in women compared with men which appears to 
be greatest between the ages of 15 and 49. One possible explanation for this 
observation is that the higher diagnosed prevalence of HHT in females we 
observed is due to a difference in access to healthcare resources. Women have 
significantly higher rates of consultation with primary care providers during the 
ages of 15 to 70 years with many consultations due to issues surrounding 
contraception, pregnancy and childcare, and this may explain an increased 
ascertainment of symptomatic females with HHT120,121.  A possible alternative 
explanation for the disparity between sexes may be that the expression of the 
HHT phenotype is more common in females with the gene mutation. Little is 
known about the role of other genetic factors (such as moderator genes) or 
environmental factors that may modify the HHT phenotype but there is limited 
evidence that symptoms such as epistaxis may be amenable to treatment via 
manipulation of oestrogen and progesterone levels62. During pregnancy there is 
an increased risk of developing complications of HHT122,123 and it has been 
suggested that this may represent a modification of the HHT vasculature by 
female hormones or be secondary to the haemodynamic changes of pregnancy.  
An interesting parallel can be drawn with a different disease of the pulmonary 
vasculature – pulmonary arterial hypertension (PAH). PAH encompasses both 
idiopathic and heritable forms, and can develop secondary to other systemic 
diseases or drug/toxin exposure. Nearly all subtypes of PAH show a significant 
sex bias, being more commonly diagnosed in females, with a female to male 
ratio of between 1.7:1 and 2.3:1 depending on the disease registry studied124-
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127. 
Though females develop PAH more commonly than males, they have a better 
survival – this has been termed the ‘oestrogen paradox’ following investigation 
into the potential cellular/hormonal mechanisms underpinning this 
observation128. Whilst acutely elevated levels of oestrogen have a protective 
vasodilatory effect on the pulmonary vasculature, murine models of PAH suggest 
that more chronic oestrogen exposure activates pulmonary artery smooth 
muscle proliferation and ultimately increases pulmonary arterial pressure. 17β-
oestradiol has been shown to upregulate serotonin signalling which has direct 
effects on pulmonary vasoconstriction and remodelling, leading to PAH129. The 
paradoxical improvement in survival may to be due to direct protective effects of 
higher circulating oestrogen levels which appear to improve systolic function of 
the right ventricle130. Whilst the exact role of oestrogens in the pathophysiology 
of PAH has yet to be conclusively determined, it is interesting to speculate that 
observations from this PAH cohort may be applicable to development of PAVMs 
in the HHT population and thus contribute to the sex bias also observed in HHT. 
Clarifying the relative contribution of behavioural factors (influencing disease 
ascertainment) versus biological/hormonal influences in the presentation and 
diagnosis of HHT is an important area for further research. 
The reduced prevalence of diagnosed HHT in those from lower socioeconomic 
groups has multiple potential explanations which encompass controversial issues 
such as the proximity and quality of healthcare services provided in more 
deprived areas, as well as differences in individuals’ thresholds for accessing 
these services across different socioeconomic groups. It is internationally 
recognised that health and healthcare access inequities vary along social 
gradients131 and one study looking at health-seeking behaviour in those from 
more deprived areas with asthma found that these populations reported a higher 
prevalence of respiratory symptoms but had lower consultation rates for those 
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symptoms132. Explanations such as varying access to health care, differing 
perceptions of symptom severity or less positive views of health care services 
were postulated to explain this disparity132,133. These issues may also be relevant 
to patients with HHT and their healthcare-seeking behaviours.   
Finally, we observed an almost two-fold difference in diagnosed prevalence 
throughout the UK; least common in the West Midlands and most common in the 
South West.  A pattern of geographical variability has been seen in in other 
studies, most notably in the landmark French paper which first identified a 
particularly high concentration of affected individuals in the Ain, Jura and Deux-
Sevres regions of the country115.  They attributed their findings to a local 
founder effect where an initial new mutation had given rise to a cluster of 
affected individuals that then gradually moved by diffusion to involve other 
nearby regions134. It is not possible to say whether our findings could represent 
genetic clusters of the disease in the UK or if they are the result of variations in 
local primary or secondary care recording practice or access to healthcare 
resources.  Further work should try to address this as there may be regions of 
the UK with a disproportionate under-diagnosis of HHT, thus exposing individuals 
to the avoidable risk of the complications of this disease. 
3.4.4 Comparison with existing literature 
Table 3.1 provides a summary of the HHT prevalence estimates of different 
studies conducted worldwide over the last 25 years. Each study has investigated 
different populations using different methodologies which, in part, explains the 
differing results. Certain areas such as the Dutch Antilles and the Ain 
department of France have shown particularly high prevalence of the disease.  
Elsewhere, most studies indicate a prevalence between 1 and 1.6 per 10,000 (or 
between 1 per 6,000 and 1 per 10,000) and our study estimate falls within this 
range, although data from individuals with health insurance in the USA provide 
estimates as low as 1 per 33,000109. Our findings with respect to age are 
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consistent with previous work with the prevalence of HHT being higher in older 
age groups, suggesting that the disease has an age-related penetrance118 or 
alternatively that the likelihood of diagnosis is related to longevity. No other 
studies have looked at the prevalence of diagnosis by deprivation status and 
most studies have been restricted to a small geographical area excepting the 
epidemiological data from France which also shows a wide variation in 
prevalence depending on geographical location115,116,135. Further research should 
consider the influence of disease severity on the diagnosed prevalence rate and 
its potentially confounding effect on our observations with respect to sex, 
socioeconomic status and geographical location.  
3.4.5 Implications  
This is the first contemporary study in a representative UK population to 
estimate the prevalence of HHT and suggests that it is much more common than 
the previously thought, and similar to the prevalence seen in other countries. 
Assuming that the prevalence of HHT in males is the same as for females, the 
“true” estimate of total prevalence would be closer to 1.28 per 10,000 or 1 per 
7800 (the figure calculated for females alone). A similar approach extrapolating 
the “true” prevalence from females living in the South West of the UK (the 
health authority with the highest crude prevalence of HHT) estimates a 
prevalence of 1.9 per 10,000 and would equate to at least 11,800 cases of HHT 
in a population of 62.3 million in 2010136. The lower diagnostic rate of HHT in 
males and those from less affluent social backgrounds suggests a sociological (or 
alternatively a biological role) in the presentation of HHT, while the previously 
unreported regional differences is an observation that requires validation in 
other datasets. Future research would ideally draw on a national rare disease 
database with integrated clinical information and genetic samples allowing 
greater understanding of the presentation of the disease, the genotype-
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phenotype relationship in HHT and the influences upon it of moderator genes 
and external environmental factors.  
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 CHAPTER 4: COMPLICATIONS AND COMORBIDITIES 
ASSOCIATED WITH HHT: A POPULATION-BASED STUDY 
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4.1 Introduction 
Several studies have attempted to quantify the risk of complications associated 
with HHT. Most complications of the disease are due to the development of 
AVMs, particularly those in the cerebral and pulmonary circulations. It is 
estimated that between 1-10% of patients with HHT have cerebral AVMs17,43,137, 
and between 15-45% develop pulmonary AVMs117,138. Neurological complications 
of HHT include embolic stroke, cerebral abscess, migraine, haemorrhagic stroke 
and seizures17,23,80,139,140. Haemorrhagic sequelae include epistaxis, haemoptysis, 
gastrointestinal bleeding and anaemia23,107,110,141,142.  
HHT complications causally related to AVMs are important because if the AVMs 
can be identified in high risk patients and treated in a safe and timely fashion 
then significant morbidity and mortality may be avoided. For example, 
embolization of pulmonary AVMs may be associated with a reduced risk of 
neurological sequelae80. No consensus currently exists as to the optimal 
management of cerebral AVMs81,82.  
Many studies of HHT-related complications are published from specialist centre 
cohorts and are potentially susceptible to selection bias as more severe cases 
may be more likely to be referred for specialist care, possibly leading to an 
overestimate of the frequency and severity of complications identified. Using a 
population-based UK primary care database (THIN) we undertook a matched 
case-control analysis to investigate the association of various complications with 
a diagnosis of HHT.  
In addition to complications directly related to HHT, very few studies have 
considered the association of common cardiovascular comorbidities and 
malignancy143 with the disease. The prevalence of comorbidities associated with 
HHT should be recognised in this patient group to allow a better understanding 
of the real burden of HHT and to encourage clinicians to identify potentially 
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treatable causes of additional morbidity and mortality in this patient group. 
Thus, in addition to looking at complications directly related to HHT as detailed 
above, we also looked for associations with common cardiovascular 
comorbidities and solid organ cancers.   
 
4.2  Methods 
The THIN primary care database was used as the data source for analysis (see 
Chapter 2). Whilst THIN was officially launched in 2003 many practices in the UK 
were already using computerised software to collect clinical information with 
some providing prospective data to THIN dating back as far as 1985. At the time 
of data extraction (September 2011), THIN covered 5% of the UK population 
with 3.5 million people contributing data across 550 primary care practices88.  
4.2.1  Case-control set 
Cases were defined as those with a diagnosis of hereditary haemorrhagic 
telangiectasia or Rendu-Osler-Weber disease coded in their THIN computerised 
records between January 1, 1985 and September 1, 2011. THIN collects most 
data contemporaneously, though in some cases historical data (from 
consultations prior to the start of a practice contributing prospectively to THIN) 
are available having been retrospectively added to the database. For the 
majority of patients an index date was set as the first recorded diagnosis of HHT 
appearing in their existing records and they were categorised as 
‘contemporaneous’ cases. If a diagnosis of HHT was made prior to a patients’ 
practice contributing to THIN, then the date the practice joined THIN and started 
to provide longitudinal data was set as the index date (these individuals were 
categorised as ‘historical’ cases). Each case had a stop date defined as either the 
last date of data collection within THIN or the date of death. Up to 10 control 
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subjects who were alive and contributing data on each case’s index date were 
matched to cases by age, sex and primary care practice.  
4.2.2  Data extraction and processing  
At the point of each case’s index date, data were extracted on age (grouped in 3 
categories: less than 15 years, 15-49 years and 50 years and over), sex, 
socioeconomic status (as defined by Townsend score in quintiles87, including a 
category for missing data), geographical location (defined by UK Health 
Authority), and smoking status (never smoker, ex-smoker, current smoker or 
unknown status). At any point during the time period that the case contributed 
data to THIN, we searched for any complications potentially related to HHT 
(anaemia, cerebral abscess, dyspnoea, epistaxis, gastrointestinal bleeding, 
haemoptysis, intracerebral haemorrhage, migraine, seizure, stroke and transient 
ischaemic attack), common cardiovascular comorbidities (ischaemic heart 
disease, myocardial infarction, cardiac failure and venous thromboembolism) 
and common solid organ cancers (breast, lung, prostate and bowel). The 
occurrence of any complication was counted only once for each HHT case or 
matched control. Tables of Read codes used to identify complications in the THIN 
database are included in Appendix 2. 
4.2.3 Data analysis 
Conditional logistic regression was used to quantify the association between a 
diagnosis of HHT and potential complications in HHT-affected cases compared to 
control subjects. THIN provided information on smoking status, diabetes and 
hypertension which were considered as possible confounding variables for some 
complications. Only smoking status differed significantly between the cases and 
control groups and as such we adjusted all crude odds ratios solely for smoking 
status. A sensitivity analysis compared complication rates in the 
contemporaneous HHT cases versus those from the historical HHT cohort to 
explore whether this variable had any significant impact on recorded 
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complications of the disease. Data analysis was carried out using Stata statistical 
software version 12.0 (Stata Corp, College Station, TX, USA).  
4.3 Results 
Six hundred and seventy five individuals with a diagnosis of HHT or Rendu-
Osler-Weber disease were identified, together with a total of 6696 controls. The 
mean age of cases was 53.8 years (SD 23.0 years) and 63% were female. Cases 
had a similar socioeconomic distribution and a lower proportion of never 
smokers (38.5% vs. 42.4%) when compared with controls (Table 4.1).  
Univariate analysis determined that odds ratios for several complications were 
significantly higher in cases with HHT than in matched controls, including 
bleeding complications (anaemia: OR 4.42, 95%CI 3.51-5.55; epistaxis: OR 
11.6, CI 9.10-14.7; haemoptysis: 2.13, 95%CI 1.23-3.70 and gastrointestinal 
haemorrhage: OR 6.08, 95%CI 2.75-13.4) and neurological sequelae (cerebral 
abscess: 30.0, 95%CI 3.12-288; migraine: OR 1.68, 95%CI 1.28-2.20 and 
ischaemic/embolic stroke: 1.81, 95%CI 1.25-2.66) (Table 4.2). We did not 
detect a significantly increased odds of seizures, intracerebral haemorrhage, 
transient ischaemic attack or venous thromboembolism in individuals with HHT. 
After adjustment for smoking as a confounder, most odds ratios did not change 
appreciably. The adjusted odds ratio for cardiac failure was higher in those with 
HHT (OR 2.36, 95%CI 1.52-3.67), though not that of ischaemic heart disease or 
myocardial infarction. The odds of colon cancer in HHT cases was higher than 
controls (OR 2.76, 95%CI 1.11-6.85) but there was no detectable difference in 
rates of other solid organ tumours (Table 4.2).  
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Table 4.1. Characteristics of cases and controls 
 Cases 
 (N=675) 
      n            (%) 
Controls 
(N=6696) 
     n           (%)     
Odds ratio* 
(95% CI) 
Age 
Mean age (years) 
 
53.8 (SD 23.0) 
 
53.9 (SD 22.8) 
 
Age group 
<15 
15-50 
50+ 
 
29 
256 
390 
 
4.3 
38.0 
58.0 
 
269 
2547 
3880 
 
4.0 
38.0 
58.0 
 
Matching 
variable 
Gender 
Males 
Females 
 
249 
426 
 
36.9 
63.1 
 
2469 
4227 
 
36.9 
63.1 
 
Matching 
variable 
Socioeconomic status 
1 (Least deprived) 
2 
3 
4 
5 (Most deprived) 
Missing 
 
182 
134 
133 
111 
67 
48 
 
27.0 
19.9 
19.7 
16.4 
9.9 
7.1 
 
1899 
1423 
1250 
1068 
671 
385 
 
28.4 
21.3 
18.7 
16.0 
10.0 
5.75 
 
Reference 
1.00 (0.79-1.28) 
1.14 (0.89-1.46) 
1.13 (0.86-1.48) 
1.10 (0.79-1.53) 
1.62 (1.03-2.55) 
Smoking Status 
Never smoker 
Ex-smoker 
Current smoker 
Unknown/Missing 
 
260 
161 
114 
140 
 
38.5 
23.9 
16.9 
20.7 
 
2841 
1231 
1078 
1546 
 
42.4 
18.4 
16.1 
23.1 
 
Reference 
1.47 (1.19-1.83) 
1.17 (0.92-1.48) 
0.93 (0.72-1.19) 
Diabetes 
Never coded as diabetic 
Ever coded as diabetic 
 
619 
56 
 
91.7 
8.3 
 
6233 
463 
 
93.1 
6.9 
 
Reference 
1.24 (0.92-1.67) 
Hypertension 
Never coded as hypertensive 
Ever coded as hypertensive 
 
531 
144 
 
78.7 
21.3 
 
5258 
1438 
 
78.5 
21.5 
 
Reference 
0.98 (0.78-1.23) 
SD = Standard deviation 
*Statistical analysis using conditional logistic regression 
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Table 4.2. Crude and adjusted odds ratios of complications in HHT cases versus 
controls 
Complications Cases 
(N=675) 
 n   (%) 
Controls 
(N=6696) 
n   (%) 
Crude Odds 
ratio  
(95% CI) 
P 
value 
Adjusted odds 
ratios* 
(95% CI) 
P 
value 
Neurological       
Stroke 37 (5.5) 212 (3.2) 1.81 (1.25-2.66) 0.002 1.76 (1.20-2.58) 0.004 
TIA 14 (2.1) 92 (1.4) 1.56 (0.87-2.82) 0.146 1.52 (0.84-2.76) 0.167 
Intracerebral 
Haemorrhage 
4 (0.6) 20 (0.3) 2.00 (0.68-5.85) 0.21 1.99 (0.68-5.84) 0.21 
Cerebral Abscess 3 (0.4) 1 (0.01) 30.0 (3.12-288.4) 0.003 29.3 (3.03-282.8) 0.004 
Migraine 71 (10.5) 448 (6.7) 1.68 (1.28-2.20) <0.001 1.67 (1.29-2.20) <0.001 
Seizure 8 (1.2) 62 (0.9) 1.29 (0.61-2.71) 0.50 1.26 (0.60-2.66) 0.54 
Haemorrhagic       
Anaemia 135 (20.0) 401 (6.0) 4.42 (3.51-5.55) <0.001 4.41 (3.50-5.56) <0.001 
Epistaxis 177 (26.2) 230 (3.4) 11.6 (9.10-14.7) <0.001 11.4 (8.99-14.5) <0.001 
Gastrointestinal  
haemorrhage 
10 (1.5) 16 (0.2) 6.08 (2.75-13.4) <0.001 6.13 (2.76-13.6) <0.001 
Haemoptysis 16 (2.4) 77 (1.2) 2.13 (1.23-3.70) 0.007 1.99 (1.14-3.46) 0.015 
Cardiovascular 
comorbidities 
      
Cardiac Failure 30 (4.4) 141 (2.1) 2.39 (1.53-3.71) <0.001 2.37 (1.53-3.70) <0.001 
Ischaemic Heart 
Disease 
53 (7.9) 429 (6.4) 1.25 (0.90-1.72) 0.184 1.19 (0.86-1.65) 0.289 
Myocardial 
Infarction 
33 (4.9) 217 (3.2) 1.53 (1.03-2.27) 0.034 1.46 (0.98-2.17) 0.06 
Venous 
thromboembolism 
18 (2.7) 154 (2.3) 1.18 (0.71-1.94) 0.527 1.12 (0.68-1.86) 0.643 
Malignancies       
Lung cancer 5 (0.7) 37 (0.6) 1.36 (0.53-3.49) 0.524 1.20 (0.46-3.08) 0.712 
Breast cancer 10 (1.5) 117 (1.8) 0.85 (0.44-1.63) 0.623 0.86 (0.45-1.65) 0.647 
Prostate cancer 3 (0.4) 56 (0.8) 0.50 (0.15-1.63) 0.25 0.49 (0.15-1.60) 0.235 
Colon cancer 6 (0.9) 22 (0.3) 2.76 (1.11-6.85) 0.029 2.76 (1.10-6.90) 0.03 
*Adjusted for smoking status using conditional logistic regression 
  
62 
 
4.3.1 Sensitivity Analysis 
373 cases of HHT had a contemporaneous diagnosis within THIN, with the 
remaining 302 coded as ‘historical’ HHT cases. Demographic breakdown of 
contemporaneous cases (Table 4.3) and historically diagnosed cases (Table 4.4) 
are presented and show that these two cohorts were similar in age, sex, 
socioeconomic status and prevalence of smoking, diabetes and hypertension. 
Odds ratios for complications in HHT were similar between contemporaneously 
(Table 4.5) and historically diagnosed patients (Table 4.6).  
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Table 4.3. Characteristics of cases and controls with contemporaneously 
diagnosed HHT 
 Cases  
(N=373) 
      n           (%)  
Controls 
(N=3712) 
     n          (%)    
Odds ratio 
(95% CI) 
Age 
Mean age (years) 
 
54.8 (SD 23.7) 
 
54.8 (SD 23.6) 
 
Age group 
<15 
15-50 
50+ 
 
22 
123 
230 
 
5.9 
32.7 
61.3 
 
220 
1220 
2292 
 
5.9 
32.7 
61.4 
 
Matching 
variable 
Gender 
Males 
Females 
 
133 
240 
 
35.7 
64.3 
 
1324 
2388 
 
35.7 
64.3 
 
Matching 
variable 
Socioeconomic status 
1 (Least deprived) 
2 
3 
4 
5 (Most deprived) 
Missing 
 
106 
72 
75 
75 
25 
20 
 
28.4 
19.3 
20.1 
20.1 
6.7 
5.4 
 
1052 
791 
715 
605 
367 
182 
 
28.3 
21.3 
19.3 
16.3 
9.9 
4.9 
 
Reference 
0.92 (0.67-1.27) 
1.05 (0.76-1.46) 
1.23 (0.88-1.74) 
0.66 (0.40-1.09) 
1.12 (0.57-2.22) 
Smoking Status 
Never smoker 
Ex-smoker 
Current smoker 
Unknown/Missing 
 
155 
78 
64 
76 
 
41.6 
20.9 
17.2 
20.4 
 
1577 
669 
568 
898 
 
42.5 
18.0 
15.3 
24.2 
 
Reference 
1.21 (0.90-1.63) 
1.15 (0.84-1.58) 
0.75 (0.53-1.06) 
Diabetes 
Never coded as diabetic 
Ever coded as diabetic 
 
343 
30 
 
92.0 
8.0 
 
3427 
285 
 
92.3 
7.7 
 
Reference 
1.05 (0.70-1.57) 
Hypertension 
Never coded as hypertensive 
Ever coded as hypertensive 
 
288 
85 
 
77.2 
22.8 
 
2839 
873 
 
76.5 
23.5 
 
Reference 
0.94 (0.70-1.26) 
SD = Standard deviation 
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Table 4.4. Characteristics of cases and controls with historically diagnosed HHT 
 Cases  
(N=302) 
      n         (%) 
Controls 
(N=2984) 
     n         (%)    
Odds ratio 
(95% CI) 
Age 
Mean age (years) 
 
52.6 (SD 22.0) 
 
52.9 (SD 21.6) 
 
Age group 
<15 
15-50 
50+ 
 
7 
135 
160 
 
2.3 
44.7 
53.2 
 
 49 
1347 
1588 
 
1.6 
45.1 
53.0 
 
Matching 
variable 
Gender 
Males 
Females 
 
116 
186 
 
38.4 
61.6 
 
1145 
1839 
 
38.4 
61.6 
 
Matching 
variable 
Socioeconomic status 
1 (Least deprived) 
2 
3 
4 
5 (Most deprived) 
Missing 
 
76 
62 
58 
36 
42 
28 
 
25.2 
20.5 
19.2 
11.9 
13.9 
9.3 
 
847 
632 
535 
463 
304 
203 
 
28.4 
21.2 
17.9 
15.5 
10.2 
6.8 
 
Reference 
1.11 (0.77-1.60) 
1.25 (0.86-1.83) 
0.93 (0.59-1.46) 
1.76 (1.10-2.80) 
2.24 (1.21-4.14) 
Smoking Status 
Never smoker 
Ex-smoker 
Current smoker 
Unknown/Missing 
 
105 
83 
50 
64 
 
34.8 
27.5 
16.7 
21.2 
 
1264 
562 
510 
648 
 
42.4 
18.8 
17.1 
21.7 
 
Reference 
1.88 (1.37-2.59) 
1.20 (0.84-1.73) 
1.20 (0.83-1.73) 
Diabetes 
Never coded as diabetic 
Ever coded as diabetic 
 
276 
26 
 
91.4 
8.6 
 
2806 
178 
 
94.0 
6.0 
 
Reference 
1.55 (0.99-2.44) 
Hypertension 
Never coded as hypertensive 
Ever coded as hypertensive 
 
243 
59 
 
80.5 
19.5 
 
2419 
565 
 
81.1 
18.9p 
 
Reference 
1.05 (0.74-1.48) 
SD = Standard deviation 
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Table 4.5. Crude and adjusted odds ratios of complications in HHT cases with 
contemporaneously diagnosed HHT versus controls 
Complications Cases 
(N=675) 
 n   (%) 
Controls 
(N=6696) 
n   (%) 
Crude Odds 
ratio (95% CI) 
P 
value 
Adjusted odds 
ratios* 
(95% CI) 
P 
value 
Neurological        
Stroke 21 (5.6) 130 (3.5) 1.69 (1.03-2.77) 0.037 1.70 (1.03-2.80) 0.037 
TIA 7 (1.9) 55 (1.5) 1.26 (0.55-2.89) 0.588 1.25 (0.54-2.88) 0.601 
Intracerebral 
haemorrhage 
2 (0.5) 11 (0.3) 1.82 (0.4-8.20) 0.437 1.87 (0.41-8.49) 0.417 
Cerebral Abscess 1 (0.3) 1 (0.03) 10 (0.63-159.9) 0.103 10.5 (0.65-167.9) 0.097 
Migraine 35 (9.4) 236 (6.4) 1.56 (1.06-2.28) 0.022 1.56 (1.07-2.29) 0.022 
Seizure 8 (2.1) 33 (0.9) 2.45 (1.12-5.36) 0.025 2.45 (1.12-5.37) 0.025 
Haemorrhagic       
Anaemia 82 (22.0) 236 (6.4) 4.71 (3.49-6.35) <0.001   
Epistaxis 103 (27.6) 128 (3.5) 12.4 (9.0-17.0) <0.001   
Gastrointestinal  
haemorrhage 
4 (1.1) 9 (0.2) 4.19 (1.28-13.7) 0.02   
Haemoptysis 9 (2.4) 46 (1.2) 2.01 (0.96-4.20) 0.063 1.88 (0.90-3.96) 0.092 
Cardiovascular 
comorbidities 
      
Cardiac Failure 13 (3.5) 82 (2.2) 1.64 (0.87-3.10) 0.129 1.64 (0.86-3.10) 0.130 
Ischaemic Heart 
Disease 
27 (7.2) 264 (7.1) 1.01 (0.65-1.58) 0.953 0.99 (0.63-1.55) 0.967 
Myocardial 
Infarction 
18 (4.8) 125 (3.4) 1.49 (0.88-2.52) 0.136 1.44 (0.85-2.46) 0.175 
Venous 
thromboembolism 
9 (2.4) 101 (2.7) 0.88 (0.744-1.78) 0.729 0.85 (0.42-1.71) 0.656 
Malignancies       
Lung cancer 4 (1.1) 21 (0.6) 1.92 (0.65-5.63) 0.236 1.74 (0.59-5.12) 0.316 
Breast cancer 4 (1.1) 75 (2.0) 0.52 (0.19-1.44) 0.211 0.53 (0.19-1.45) 0.647 
Prostate cancer 1 (0.3) 31 (0.8) 0.30 (0.04-2.27) 0.246 0.30 (0.04-2.23) 0.239 
Colon cancer 4 (1.1)  14 (0.4) 2.91 (0.94-8.97) 0.063 2.88 (0.93-8.96) 0.067 
*Adjusted for smoking status 
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Table 4.6. Crude and adjusted odds ratios of complications in HHT cases with 
historically diagnosed HHT versus controls 
Complications Cases 
(N=302) 
 n   (%) 
Controls 
(N=2984) 
n   (%) 
Crude Odds 
ratio (95% CI) 
P 
value 
Adjusted odds 
ratios* 
(95% CI) 
P 
value 
Neurological        
Stroke 16 (5.3) 82 (2.6) 2.03 (1.12-3.65) 0.019 1.89 (1.04-3.44) 0.037 
TIA 7 (2.3) 37 (1.2) 2.01 (0.85-4.75) 0.110 1.89 (0.79-4.50) 0.151 
Intracerebral 
haemorrhage 
2 (0.7) 9 (0.3) 2.22 (0.48-10.3) 0.31 2.22 (0.48-10.3) 0.307 
Cerebral Abscess 2 (0.7) 0 (0) -    
Migraine 36 (12.0) 212 (7.1) 1.82 (1.24-2.67) 0.002 1.82 (1.24-2.67) 0.002 
Seizure 0 (0) 29 (1.0) -    
Haemorrhagic       
Anaemia 53 (17.6) 165 (5.5) 4.04 (2.82-5.77) <0.001   
Epistaxis 74 (24.5) 102 (3.4) 10.7 (7.44-15.3) <0.001   
Gastrointestinal 
haemorrhage 
6 (2.0) 7 (0.2) 8.57 (2.88-25.5) <0.001   
Haemoptysis 7 (2.3) 31 (1.0) 2.30 (1.00-5.29) 0.05 2.20 (0.96-5.07) 0.064 
Cardiovascular 
comorbidities 
      
Cardiac Failure 17 (5.7) 59 (2.0) 3.66 (1.95-6.88) <0.001 3.60 (1.90-6.82) <0.001 
Ischaemic Heart 
Disease 
26 (8.6) 165 (5.5) 1.64 (1.01-2.66) 0.044 1.48 (0.90-2.41) 0.120 
Myocardial 
Infarction 
15 (5.0) 92 (3.1) 1.59 (0.87-2.88) 0.130 1.45 (0.79-2.66) 0.230 
Venous 
thromboembolism 
9 (3.0) 53 (1.8) 1.73 (0.84-3.55) 0.527 1.62 (0.78-3.34) 0.194 
Malignancies       
Lung cancer 1 (0.3) 16 (0.5) 0.62 (0.08-4.74) 0.645 0.53 (0.07-4.06) 0.539 
Breast cancer 6 (2.0) 42 (1.4) 1.45 (0.60-3.51) 0.404 1.48 (0.61-3.59) 0.381 
Prostate cancer 2 (0.7) 25 (0.8) 0.74 (0.16-3.35) 0.699 0.69 (0.15-3.07) 0.622 
Colon cancer 2 (0.7) 8 (0.3) 2.50 (0.53-11.8) 0.246 2.45 (0.51-11.7) 0.260 
*Adjusted for smoking status 
-Unable to calculate OR 
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4.4 Discussion 
4.4.1  Summary 
Using a representative primary care dataset comparing HHT cases with matched 
controls we have quantified the risk of developing HHT-related complications. 
We have identified several bleeding complications (anaemia, epistaxis, 
gastrointestinal bleeding) and neurological sequelae (migraine, cerebral abscess 
and stroke) that are more common in patients with HHT. Cardiac failure is 
commoner in patients with HHT, as is development of colon cancer. 
4.4.2  Complications 
We found a higher risk of bleeding (anaemia, epistaxis, haemoptysis and 
gastrointestinal haemorrhage) and neurological complications (cerebral abscess, 
stroke and migraine) in HHT cases. A recent study using US health insurance 
data for surveillance of HHT and its complications found the disease to be under-
recognised in this database109. We suggest this is partly due to the relatively 
high costs of US health insurance, meaning individuals unable to afford health 
insurance are likely to be under-represented in the dataset. The UK National 
Health Service has a much wider coverage, with close to 98% of the population 
registered with a general practitioner84. Most published work looking at 
complications in the disease are descriptive analyses in cohorts often recruited 
from specialist HHT centres. On comparing the prevalences of clinical 
complications, most of our estimates are lower than those cited in the existing 
literature (Table 4.7). This may be a consequence of the ascertainment of 
complications being lower in a primary care database than in a clinical study 
with access to detailed clinical data that is collected in secondary and tertiary 
medical care centres. Alternatively, previous studies may have overestimated 
the prevalences of complications due to a referral and selection bias if more 
complicated or severe cases are seen in the specialist centres from which the 
cohort is derived. It is widely acknowledged that many cases of HHT in the 
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general population remain undiagnosed. Whilst some symptomatic patients 
presenting to healthcare services elude diagnosis because clinicians do not have 
a sufficiently high index of suspicion for HHT, there are likely to be other HHT 
gene carriers who remain undiagnosed simply because they display a milder 
phenotype of the disease.  
We noted a higher odds of colonic carcinoma in our HHT cases (in approximately 
1%) which may be a true association or alternatively be the consequence of mis-
classification with juvenile polyposis syndrome (JPS), a disease known to be 
associated with the HHT phenotype via a shared mutation in the SMAD4 
gene35,144. JPS is associated with up to a 40% increased risk of colon cancer145, 
and this may explain the increase in bowel cancer risk we observed.  
Overall, our data from a population-based sample of HHT patients suggest that 
the risks of complications of HHT may not be as high as have been suggested by 
previous studies. Future work could help validate our findings further by 
accessing the primary and secondary care records of the individuals in the THIN 
database included in this study, although previous audit has shown a relatively 
high level of completeness of clinical diagnostic data89.   
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Table 4.7. Comparison of our prevalence estimates for complications of HHT with 
those made in other studies (excluding any that confirmed the presence of 
pulmonary arteriovenous malformations) 
Complications Our prevalence 
estimate 
 
 (%) 
Range of 
prevalence 
estimates from 
other literature 
(%) 
References 
Anaemia 20 29 141 
Cerebral Abscess 0.4 0.03-9.1 80,139,146-148 
Epistaxis 26.2 90-99 107,141,142 
Gastrointestinal  bleeding 1.5 13-30 107,149 
Intracerebral bleed 0.6 2.1 17 
Migraine 10.5 33-40 150,151 
Stroke 5.5 7.2-9 80,140,152 
TIA 2.1 4.1 152 
 
4.4.3  Strengths and limitations 
The strengths of this study are the combination of a relatively large number of 
participants (containing data from almost 700 patients with HHT) and the long 
period of follow up - in excess of 20 years for some - which would be more 
difficult to achieve in a prospectively designed clinical study. Our findings are 
population-based and hence provide representative estimates for complications, 
minimising certain biases that can arise as a consequence of case-series analysis 
from specialist centres. The case-control design allows comparative estimates of 
relative risk to be made against a matched control group providing new data in 
addition to that generated by previous studies which used mainly descriptive 
analyses of complication frequencies in HHT-only cohorts.  
The potential limitations of this study require consideration. We were only able 
to study individuals clinically diagnosed with HHT. However, we expect a 
diagnosis of HHT recorded in THIN to have a relatively high specificity as most 
diagnoses are made in secondary care and we consider it unlikely that a primary 
care physician would code a patient as having HHT unless supported by evidence 
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from a specialist centre. We did not detect an increased risk of certain 
complications (such as intracerebral haemorrhage) which are well documented 
possible sequelae of HHT17. This may reflect issues of ascertainment inherent in 
primary care databases resulting from the miscoding of complications (for 
example coding intracerebral haemorrhage as stroke). 
4.5 Conclusion 
In conclusion, we present evidence from a large, representative primary care 
database providing quantitative estimates of complication risks in HHT compared 
to matched controls. Whilst some patients undoubtedly suffer significant 
morbidity due to HHT, our study suggests complication rates amongst the 
diagnosed population may not be as high as previously thought. This may 
impact on the information given in the counselling of newly diagnosed patients 
when discussing the natural history of the disease. As many of these 
complications are amenable to intervention, early diagnosis and treatment 
should remain the priority for responsible clinicians.   
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 CHAPTER 5: MORTALITY IN PATIENTS WITH HHT: A CASE-
CONTROL STUDY 
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5.1 Introduction 
There are relatively few published studies that have looked at survival in 
patients with HHT112,153-155. The largest published epidemiological study includes 
113 individuals and thus provides survival estimates limited by sample size155. 
The limited published literature suggests a diagnosis of HHT is associated with a 
reduction in life expectancy, and some of this reduced life expectancy may be as 
a result of complications related to the disease itself.  Studies have not so far 
considered the association between age at diagnosis, sex, geographical area of 
residence nor socioeconomic status on survival of patients recorded with a 
diagnosis of HHT. This data may potentially be of use in identifying patients, via 
their demographic characteristics, who may be at a higher risk of death, either 
from the complications of HHT or related medical disease. Using the THIN 
database (see Chapter 2) we undertook a matched case-control analysis to 
provide a population-based estimate of survival in 675 HHT individuals 
compared to age, sex and general practice-matched controls.   
 
5.2 Methods 
Data were extracted from the THIN database in September 2011. The 
methodology used was similar to that detailed in Chapter 4, with the same 
definition of contemporaneous and historical cases, and of index and stop dates.  
Up to 10 control subjects who were alive and contributing data on each case’s 
index date were matched to cases by age, sex and primary care practice. This 
study used a later data extract (obtained in September 2012) from that 
presented in chapter 3 (extract from September 2011) and as such includes a 
slightly different number of HHT cases within its analysis.   
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5.2.1  Data extraction and processing  
Data were extracted on age (grouped in 3 categories: less than 15 years, 15-49 
years and 50 years and over), sex, socioeconomic status (as defined by 
Townsend score in quintiles87, including a category for missing data), 
geographical location (defined by UK Health Authority) and smoking status 
(never smoker, ex-smoker, current smoker or unknown status). Date of death 
was extracted for any case or control that died whilst contributing data to THIN.  
5.2.2  Data analysis 
Survival analysis was performed using Kaplan-Meier methods, comparing HHT 
cases with controls. Start date was set as the index date (see definition in 
chapter 4) and end date was date of death or loss to follow-up. Cox regression 
analysis was used to compare mortality rates between the two groups adjusting 
for smoking status. Rates of ischaemic heart disease, diabetes and hypertension 
did not differ substantially between the cases and the control group and thus 
were not adjusted for in the mortality analyses (see Table 4.1, Chapter 4). We 
looked at survival differences stratified by sex and socioeconomic group amongst 
the HHT cases and also explored survival of cases diagnosed at age under 60 
years versus those 60+ years at the time of inclusion to the database as a 
previous study had reported a survival paradox with a subset of younger HHT 
patients having a higher mortality112. The Cox proportional hazards assumption 
was tested using log-minus-log plots of survival and Schoenfeld residuals 
(Appendix 5).  A sensitivity analysis was undertaken to look at survival 
outcomes in the contemporaneous HHT cases and the historical HHT cases. Data 
analysis was carried out using Stata statistical software version 12.0 (Stata 
Corp, College Station, TX, USA).  
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5.3 Results 
Six hundred and seventy five individuals with a diagnosis of HHT or Rendu-
Osler-Weber disease were identified, together with a total of 6696 controls, 
matched by age, sex and general practice. The demographic details of cases and 
controls are the same as those listed in Table 4.1, Chapter 4.  
5.3.1  Survival analysis 
The median follow up time was 6.9 years for cases, 10.1 years for controls, 6.5 
years for ‘historical cases’ and 8.2 years for ‘contemporaneous cases’. A total of 
73 cases with HHT (10.8%) and 486 controls (7.3%) died. The overall crude 
mortality rate in HHT cases was 11.0 per 1000 patient-years (95% CI 8.8-13.9) 
and in their matched controls was 6.1 per 1000 patient-years (95% CI 5.5-6.6). 
We found a worse survival in patients with HHT compared to their age, sex and 
practice-matched controls with a hazard ratio for death of 2.03 (CI 1.59-2.60, 
p<0.0001) (Error! Reference source not found.). The proportional hazards 
assumption did not hold true for these data (Figure 5.2) and thus the adjusted 
hazard ratios were split into three time periods of follow-up demonstrating a 
higher hazard ratio for mortality in the time period closest to a recorded 
diagnosis of HHT which persisted, but tailed off, at all time periods; 0-3 years 
(HR 4.57, CI 2.56-8.18, p<0.001), 3-10 years (HR 2.07, CI 1.42-2.99, p<0.001) 
and 10 or more years (HR 1.45, CI 0.95-2.21, p<0.001).  
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Figure 5.1. Survival in HHT cases versus controls 
 
 
Figure 5.2 Log-minus-Log plot of survival in HHT cases compared to matched 
controls 
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Age at death was plotted using a histogram for cases with HHT (Figure 5.3) and 
their matched controls (Figure 5.4) and both showed a negatively skewed 
distribution. Median age at death was 77 years for HHT cases (Interquartile 
range (IQR) 67-85 years) and 80 years for controls (IQR 74-87 years). Survival 
in HHT cases did not differ between males and females (HR 1.06, CI 0.66-1.70, 
p=0.825) (Figure 5.5) but was higher in those from the most affluent 
socioeconomic group when compared to the least (HR 1.15, CI 1.04-1.27, 
p=0.007) (Figure 5.6). After stratification by age, mortality was increased for 
both those aged 60+ years on entry to the study (i.e. at the index date) (HR 
1.60, CI 1.17-2.21, p=0.004) and for those under 60 years compared to 
matched controls (HR 6.74, CI 4.2-10.8, p<0.0001). Survival differed between 
cases aged <60 years at diagnosis when compared to cases aged 60+ years on 
diagnosis (HR 2.93, CI 1.80-4.75, p<0.0001) and was higher in the latter group 
(Figure 5.7). Cases diagnosed between the years 1990-1999 (labelled pre-2000) 
did not have a significantly different survival to those cases diagnosed between 
2000-2010 (labelled post-2000) (HR 1.28, CI 0.72-2.28, p=0.41) (Figure 5.8). 
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Figure 5.3. Histogram detailing age of death in cases with HHT 
 
 
Figure 5.4. Histogram detailing age of death in matched controls without HHT 
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Figure 5.5. Kaplan-Meier plot of survival amongst HHT cases stratified by sex 
 
Figure 5.6. Kaplan-Meier plot of overall survival amongst all HHT cases stratified 
by Townsend score 
 
*HR comparing survival between highest and lowest socioeconomic groups (Townsend 1 versus 5) 
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Figure 5.7. Kaplan-Meier plot of survival amongst HHT cases aged under 60 
years at date of diagnosis versus those over 60 years at date of diagnosis.  
 
Figure 5.8. Kaplan-Meier plot of survival amongst HHT cases diagnosed pre-
2000 versus those diagnosed post-2000. 
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5.3.2  Sensitivity analysis 
373 (55%) cases of HHT had a contemporaneous diagnosis within THIN, with 
the remaining 302 (45%) coded as ‘historical’ HHT cases. Survival in 
contemporaneous cases was worse than in their matched controls (HR 1.61, CI 
1.13-2.30, p=0.008) and the same pattern was evident when looking at the 
survival of historical cases compared with controls (HR 2.57, CI 1.81-3.66, 
p<0.0001). Age-adjusted survival in historically diagnosed HHT cases was worse 
than that in those diagnosed contemporaneously (HR 2.93, CI 1.80-4.75, 
p<0.0001) (Figure 5.9). 
 
Figure 5.9. Kaplan-Meier plot of survival amongst contemporaneous cases of 
HHT versus historically diagnosed cases.  
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5.4 Discussion 
5.4.1  Summary 
Using a representative primary care dataset comparing HHT cases with matched 
controls we observed a two-fold increase in hazard ratio for death in patients 
with HHT and a median age of death 3 years earlier than in those without the 
disease. There was no discernable difference in survival in HHT cases with 
respect to sex or whether the diagnosis was made before or after the year 2000. 
HHT cases in the higher socioeconomic group, adjusted for smoking status, had 
a better survival than those from the lowest socioeconomic group. 
5.4.2  Data interpretation  
Our data demonstrate that HHT patients have a poorer survival compared to 
controls. Median age at death was 77 years in HHT cases compared with 80 
years in controls. The published literature of survival in HHT is relatively small 
consisting of three papers112,153,154 and an abstract155 studying a total of 283 
cases, compared to our analysis of 675 individuals with the disease. These 
studies have either compared survival in HHT cases compared to matched 
controls112,154 or have looked at the parents of HHT-affected offspring and 
compared the age of death of parents with HHT to that of parents without the 
disease153,155 (Table 5.1). Where studies have identified a younger mean/median 
age of death in HHT cases, their estimates have been of a similar size to our 
own. The hazard ratios for death were highest in the three years following initial 
diagnosis and tail off later which may reflect the nature in which some HHT 
patients are diagnosed, for example, after a potentially life-limiting complication 
such as stroke. 
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Table 5.1. A summary of studies of survival in HHT 
Year 
Publi
-shed 
Authors Study 
size 
(cases) 
Methodology Cases vs 
controls 
Mean 
Follow-up 
(years) 
Mean difference in 
age at death in 
cases vs controls 
(reduction in 
years) 
2015 Donaldson 
et al 
675 Prospective 
epidemiological 
study 
HHT cases vs age, 
sex and location-
matched controls 
11.8a 3b 
2010 Edwards et 
al155 
113 Cross-sectional 
questionnaire 
study of HHT 
offspring 
HHT-affected 
parents vs 
unaffected 
parents 
n/a 8.3 
2006 Sabba et 
al153 
40 Retrospective 
clinical study 
HHT-affected 
parents vs 
unaffected 
parents 
n/a  6.8b 
2005 Kjeldsen et 
al154 
73 Prospective 
clinical/epidemio
logical study 
HHT cases vs age, 
gender and 
location-matched 
controls 
7.5 0 
1999 Kjeldsen et 
al112 
57 Prospective 
clinical/epidemio
logical study 
HHT cases vs 
‘expected 
mortality’ 
calculated from 
life table analysis 
21 n/a 
amedian follow-up 
bmedian age at death 
n/a = not available 
 
 
Whilst HHT appears to be more commonly diagnosed in females (see chapter 3) 
it is interesting that the mortality associated with a diagnosis does not differ 
between the sexes. In contrast, those in a higher socioeconomic group have a 
better survival than those in lower socioeconomic groups when adjusted for 
smoking. The disparities in survival across different socioeconomic groups is an 
area that has been extensively researched. Papers suggest a variety of reasons 
why individuals from lower socioeconomic groups may have a higher mortality 
when compared to their more affluent peers156,157. Contributing factors may 
include; persons of lower socioeconomic status knowing less about healthy life 
styles, health problems, and when and where to seek medical care; more limited 
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ability to purchase health-promoting and life-prolonging goods and services such 
as medical care; a greater likelihood of working in contact with hazardous and 
unhealthy working conditions and the propensity of individuals to invest in their 
own health (by smoking cessation, healthy diet, regular exercise, avoiding 
excessive alcohol or drug use). Some, or all of these factors may influence the 
survival disparity between HHT patients from differing socioeconomic strata.  
It is interesting to note that the survival in those HHT cases diagnosed in the 
last decade (2000-2010) was not significantly different from those diagnosed in 
the decade prior (1990-2000). This perhaps suggests that our current 
interventions, though beneficial in reducing morbidity from HHT, are not having  
the same impact with regards to improving survival. Understanding in greater 
detail the cause of the higher mortality, whether it be due to complications of  
the disease itself, or an interaction with commoner comorbidities such as 
cardiovascular or respiratory disease is an important step in trying to improve 
mortality outcomes. 
Whilst one study appeared to identify a survival paradox within a subset of HHT 
patients, such that those that were younger at diagnosis had a higher mortality 
than those whom were older at diagnosis, we did not replicate this finding in our 
study. We found, perhaps more in line with expectations, that those diagnosed 
with HHT at an older age had a higher mortality, than those diagnosed when 
younger - their life expectancy being shorter as a result of their more advanced 
age. It is important to recognise that these groups of older HHT cases will partly 
have ‘self-selected’ in order to appear in the THIN database at the time of data 
collection and thus in general this older group of patients may represent the less 
severe end of the disease spectrum. 
A substantial number of the HHT cases included in THIN had a historical rather 
than contemporaneous date of diagnosis. Whilst both groups had worse survival 
than their matched controls, the hazard ratio for death was almost three times 
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as high in the historically diagnosed group of HHT cases compared to the 
contemporaneous cases. This may be explained by more severe or symptomatic 
disease in the historical cases as a consequence of presentation earlier in life 
compared to those who were diagnosed as incident cases during the course of 
our period of data collection. This is consistent with our clinical experience that 
developments such as the formulation of the diagnostic Curaḉao criteria25, the 
publication of international guidelines for the diagnosis and management of 
HHT27, the increasing use of genetic testing and, perhaps, an increased 
awareness of the disease56, have contributed to diagnosis of more patients 
before they are severely symptomatic.   
 
5.4.3  Strengths and limitations 
The strengths of this study are its size and the relatively long period of follow-up 
in which the ascertainment of deaths is likely to be higher than in a study 
conducted over a shorter timescale. Our survival analysis compares mortality 
between HHT cases and matched controls from the general population rather 
than relying on estimated life expectancies from life tables112 and includes a 
population over 10 times larger than the previous largest case-control study 
estimating survival154.  
The potential limitations of this study are partly addressed in chapter 4 (with the 
study on HHT complications that utilises the same data extract) and include the 
fact that we were only studying individuals with a clinical diagnosis of HHT and, 
whilst we expect a diagnosis of HHT recorded in THIN to have a relatively high 
specificity, there are likely to be a substantial minority of patients with 
undiagnosed HHT whose mortality would not be recorded in the THIN database 
in a way that could be linked to their disease. Furthermore, though our data 
show a higher mortality in HHT patients compared with controls, we are not able 
to comment on whether this poorer survival is related directly to complications 
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of HHT as we could not access patients’ clinical notes or death certification in 
order to confirm the cause of death. A previous study found that just over a 
third of deaths in HHT patients could be attributed directly to complications of 
the disease112.  
5.4.4  Conclusion 
In conclusion, we present evidence from a large, representative primary care 
database confirming that on average a diagnosis of HHT is associated with a 3 
year reduction in median age at death compared to matched controls. The 
reduction in median age of death in this patient cohort suggests that clinicians 
should strive harder to achieve early diagnosis in HHT and to offer timely and 
appropriate intervention in those with potentially life limiting disease if survival 
in HHT is to improve.  
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 CHAPTER 6: THE SAFETY AND SUCCESS RATES OF 
PERCUTANEOUS EMBOLISATION FOR PULMONARY 
ARTERIOVENOUS MALFORMATIONS: A SYSTEMATIC REVIEW 
AND META-ANALYSIS
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6.1 Introduction 
A recent study suggests that PAVMs in the general population are more common 
than previously appreciated20. Approximately 70% of individuals with PAVMs 
have the autosomal dominant genetic disorder hereditary haemorrhagic 
telangiectasia (HHT)117. PAVMs may also arise secondary to other conditions 
including chest trauma, thoracic surgery, longstanding hepatic cirrhosis and 
mitral stenosis11. Untreated PAVMs may be associated with increased morbidity 
from complications including stroke, cerebral abscess, and haemoptysis and may 
contribute to the reduced life expectancy noted in some patients with HHT153,154. 
There is some evidence that treatment of PAVMs is associated with a reduced 
rate of serious complications80,158. 
Initially, surgical resection was the only curative treatment available, though 
interventional radiological therapy has now superseded it. Percutaneous 
embolisation (PCE) involves catheterisation and embolisation of the PAVM 
lesions with metal coils, specifically designed devices (such as the Amplatzer 
device) and detachable balloons (now rarely used). The aim of PCE is threefold; 
reduce the risk of paradoxical emboli passing through the PAVM, reduce the size 
of any shunt (and thus improve hypoxia) and reduce the risk of PAVM 
haemorrhage. A recent Cochrane review was unable to identify any randomised 
controlled studies comparing PCE to conservative management159, and for 
ethical reasons such studies are unlikely to be conducted now. Thus, current 
evidence for the safety and effectiveness of PCE is derived solely from 
observational studies. We carried out a systematic review and meta-analysis of 
the literature to provide summary statistics of the procedural safety and 
effectiveness to allow better understanding of the risks and benefits of the 
procedure. We investigated several areas; 
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1) the clinical characteristics of patients considered for PCE, 
2) the frequency of peri-procedural complications associated with PCE, 
3) long-term complications following PCE (occurring after 30 days), 
4) the overall effectiveness of PCE as a treatment for PAVMs, 
5) reasons for failed PCE (mechanisms of reperfusion in treated lesions) 
 
6.2 Materials and Methods 
6.2.1  Data sources and searches 
We searched Medline from 1946 and EMBASE from 1974, both up until 1st 
February 2014 using electronic search terms for pulmonary arteriovenous 
malformations and for percutaneous embolisation. We included search terms for 
thoracic surgery in order to include studies where patients may have received 
mixed-modality therapy (i.e. surgery and embolisation). Our search was 
restricted to English language articles. The search strategy is reproduced below 
(Figure 6.1). 
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Figure 6.1. Literature search strategy 
1. exp Arteriovenous Malformations/ 
2. arteriovenous malformation$.mp. 
3. exp Arteriovenous Fistula/ 
4. arteriovenous fistula.mp. 
5. avm.mp. 
6. a-v malformation.mp. 
7. 1 or 2 or 3 or 4 or 5 or 6 
8. pulmonary.mp. 
9. 7 and 8 
10. PAVM.mp. 
11. 9 or 10 
12. Embolisation, Therapeutic/ 
13. emboli#ation.mp. 
14. 12 or 13 
15. 11 and 14 
16. Thoracic Surgery/ 
17. surgery.mp. 
18. surgical.mp. 
19. 16 or 17 or 18 
20. 11 and 19 
 
6.2.2  Study selection 
We included papers on patients with PAVMs with any of the following 
information; details of the clinical characteristics of those considered for PCE, 
information regarding the peri-procedural and long-term complications 
associated with PCE, data regarding the procedural success rate in studies with 
documented follow-up and, finally, details of the mechanism of reperfusion in 
studies where recurrent PAVMs were detected after PCE had been undertaken. 
We arbitrarily defined peri-procedural complications as those occurring within 30 
days of embolisation (as this was how they were defined in some of the studies 
we identified), but also included any later complications where there was a clear 
causal link with the procedure (for example, delayed sepsis following a 
pulmonary infarct). Procedural success rate was calculated as the percentage of 
patients (or of PAVMs) successfully treated by an initial course of embolisation 
as defined by the absence of reperfusion of treated lesions on subsequent 
radiological imaging. The denominator used was the total number of 
patients/PAVMs who underwent embolisation, except in the case of the 
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procedural success rate and reperfusion meta-analyses, when the denominator 
was the total number of patients/PAVMs who underwent embolisation and had 
radiological follow-up available.  The concept of a ‘course of treatment’ was 
necessary as some patients required staged embolisation procedures, usually as 
a result of the number of PAVMs needing treatment or perceived detriment to 
undergoing a prolonged procedure. Papers contributing to the reperfusion meta-
analysis used the classification system for mechanisms of PAVM reperfusion 
described by Pollak et al160, namely; a) recanalisation of the embolised vessel, 
b) growth of a missed or previously small accessory artery (also described as a 
previously untreated feeder), c) bronchial or other systemic artery collateral flow 
(systemic-to-pulmonary reperfusion), d) pulmonary artery to pulmonary artery 
collateral flow around the occlusion (pulmonary-to-pulmonary reperfusion). We 
excluded case series reporting on fewer than 15 patients on the basis that these 
may derive from centres with limited experience of the procedure and may skew 
our estimates of risk and effectiveness. Also excluded were review articles, 
editorials, published letters and any studies looking specifically at embolisation 
of PAVMs developing as a consequence of treatment for congenital heart 
disease.  
6.2.3  Data extraction and quality assessment 
Two authors independently reviewed the literature in 3 rounds; first titles, then 
abstracts and finally full text of papers, excluding in each round studies not 
fitting our inclusion criteria. References of all full text papers were hand 
searched to identify any additional pertinent papers. Disagreements were 
resolved by face-to-face meetings between the two authors, with any unresolved 
issues referred to an independent third reviewer. Data extraction was performed 
by two authors using a structured extraction form collecting information on 
study design and location; year of publication; numbers recruited, treated or lost 
to follow-up; mean age of study population; sex ratio of participants and 
91 
 
proportion with diagnosed HHT. Study methodological quality was rated using a 
modified score based on a published checklist for assessment of case series 161 
(Table 6.1) with the mean quality score for all studies used as a threshold for 
defining higher or lower methodological quality. Data on clinical characteristics, 
peri-procedural and longer-term complications, procedural success rate 
(expressed both by numbers of successfully treated patients and PAVMs) and 
reasons for persistent PAVMs post-treatment were collected. Where possible, we 
defined a successful procedure as one in which subsequent radiological imaging 
did not identify persistence/reperfusion of previously treated lesions. We 
documented the mean follow-up periods for each study post-embolisation and 
the imaging protocol used. When multiple publications arose from the same 
cohort (as determined by overlapping recruitment time periods), we included the 
largest cohort only. When analysing papers that looked at reasons for the 
reperfusion of previously embolised PAVMs we did exclude one paper162, not on 
the basis of its sample size, but because it looked mainly at the use of 
detachable silicon balloons which are now rarely used in clinical practice by 
interventional radiologists. For the meta-analysis considering the causes of PAVM 
reperfusion we included, in preference, those papers that had treated the largest 
number of PAVM lesions rather than those that had treated the most patients 
(though often, as expected, the larger studies by patient number would also be 
the largest by PAVM number). 
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Table 6.1. Methodological quality assessment scale for case series 
Category 
 
Questions 
 
Response 
 
Score 
Yes No Unsure or 
N/A 
1.Diagnosis Are diagnostic criteria for pulmonary 
arteriovenous malformations clearly 
identified and met by patients? 
   1 
2.Informed    
Consent 
a) Has patient consent been 
documented? 
b) For prospective studies: is IRB/Ethics 
committee approval documented? 
 
 
 
 
 
 
1 
1 
3.Treatment  Is the treatment modality clearly stated? 
(e.g. coils vs balloons)? 
   1 
4.Follow-up Were patients followed up over time 
post-embolisation? 
   1 
5.Outcome 
Measures 
Are outcomes well defined and clinically 
relevant? Are they subjective, objective 
or standardised? 
   1 
6.Patient 
Perception 
Is there any documentation of the 
patient’s perception of outcome and of 
the intervention? 
   1 
7.Safety Do the authors describe known risks 
associated with the intervention (i.e. 
their own complication rate)? 
   1 
8.Author’s 
Conclusions 
Do the authors abstain from unfounded 
claims about safety or efficacy? 
   1 
9.Inclusion/ 
Exclusion 
Criteria 
Are inclusion and exclusion criteria 
clearly stated? 
   1 
10. 
Consecutive 
Cases 
Are all treated patients; 
Consecutive? 
Treated by one physician or at one 
institution? 
 
              
 
 

 
 
 
 
 
1 
1 
     TOTAL 12 
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6.2.4  Data synthesis and analysis 
With respect to the meta-analysis of clinical characteristics of patients 
undergoing embolisation, we deliberately excluded any paper from the particular 
meta-analysis that did not document at least one patient with PAVMs who had 
described said clinical characteristic. For example, if a paper did not include 
mention of at least one patient describing a reduced exercise tolerance prior to 
consideration for PCE, then this paper would not be included in the clinical 
characteristics meta-analysis for that particular symptom. The rationale was to 
reduce underestimation of symptom prevalences by excluding studies that might 
have a calculated 0% prevalence of a particular clinical characteristic by virtue of 
the fact that said study did not ask specifically about it or measure it as part of 
the protocol.  
We grouped peri-procedural complications into ‘major’ and ‘minor’ based on 
criteria in the quality improvement guideline published by the Society of 
Interventional Radiology79. In practice, major clinical complications included 
death, stroke, haemopericardium secondary to myocardial puncture and venous 
thromboembolic events.  Separate proportions meta-analyses were conducted to 
look at the weighted frequency of certain clinical characteristics, peri-procedural 
and longer-term complications and to look at estimates of procedural success 
rate and mechanisms of reperfusion. All prevalence estimates are presented, 
weighted by study size. Confidence intervals at the 95% level were determined 
with a random effects model using the DerSimonian and Laird method to 
calculate weights163. Study heterogeneity was assessed using I2 scores. If 
substantial heterogeneity was detected (defined as I2 value > 50%) subgroup 
analysis was undertaken, stratified for study methodological quality and whether 
or not the study pertained to a select patient group.  Select patient groups were 
defined as those in the following categories; diffuse PAVMs only, large PAVMs 
only (defined as diameter >=8mm) and idiopathic PAVMs only (PAVMs lesions 
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not associated with a confirmed diagnosis of HHT). Funnel plots were assessed 
visually for asymmetry to look for evidence of publication bias. The study 
protocol is listed on the website of the International Prospective Register of 
Systematic Reviews (PROSPERO)164. The presentation of the meta-analyses 
adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) guidelines165. All analyses were performed using the StatsDirect 
statistical software package version 2.7.9. 
 
6.3 Results 
The literature search identified 2,104 articles by title, from which 96 full text 
papers were obtained (Figure 6.2). A further 9 full text papers were included 
after manually searching the references of the aforementioned 96 papers. A 
total of 27 papers contributed to the meta-analyses23,160,166-190, though not all 
papers contributed data to each meta-analysis (Table 6.2). Papers excluded due 
to potential recruitment overlap are listed (Table 6.3). One study was 
prospective in design160 whilst all other studies were retrospective case series. 
No randomised controlled trials were identified. The mean age of study 
participants across all included papers ranged from 34-56 years and there was a 
60% female preponderance (95% CI 55-64%, I2 56.1%). The mean value for 
quality score was 8 (range 5-12, from a possible total score of 12), with 10 of 
the 23 studies (44%) ranked in the higher methodological quality group (quality 
score >8). Lower quality scores were due to unclear inclusion/exclusion criteria, 
absence of well-defined objectives/standardised outcome measures, absence of 
documented consent/ethical approval and a lack of clarity over whether 
embolised patients represented a consecutive series treated consistently by one 
operator or at one institution. Four of 27 studies (15%) were in selected patient 
groups: 2 studies including only diffuse PAVMs191,192, one including large PAVMs 
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only193, one looking solely at idiopathic PAVMs189. Visual analysis of funnel plots 
for publication bias did not display noticeable asymmetry (see Appendix 3).  
 
 
Figure 6.2. PRISMA flowchart for identifying studies included in meta-analysis 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Identified from 
searches, 
duplicates removed 
N=2104 
Excluded after title 
and abstract 
review 
N=2008 
Full text reviewed 
N=96 
Total papers 
included in all 
meta-analyses 
N=27 
Procedural success 
rate meta-analysis 
N=17 
Peri-procedural 
complications 
meta-analysis 
N=19 
Clinical 
characteristics 
meta-analysis 
N=16 
Excluded N=78 
*Recruitment overlap (N=8) 
*Not fitting inclusion criteria 
(N=70) 
*Too few cases  = 25 
*Not original research = 28 
*Method not relevant = 15 
*Unable to extract data = 2  
Included after 
reference search 
N=9 
Long-term 
complications 
meta-analysis 
N=8 
Reperfusion meta-
analysis  
N=7 
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Table 6.2. Study characteristics of all papers included in the separate meta-analyses 
Ref* Author Year Recruiting Institutions Study size Mean 
Age 
(years) 
Female 
(%) 
Quality 
score 
Selected 
patient 
group?** 
Meta-analyses 
Patients / 
PAVMs 
Clinical 
features 
Peri-
procedural  
Long- 
term  
Success 
rate 
Reperfusi
on 
166 Allison 1990 Hammersmith Hospital, UK 19 / -   †  √     
167 Andersen 2006 Odense Hospital, Denmark 35 / 106 49 60 9  √ √ √ √  
23 Cottin 2007 Multicentre (6 French hospitals) 126 / - 43.1 62.7 †  √     
168 Dutton 1995 Hammersmith Hospital, UK 53 / 102 41 57.1 7   √ √ √  
169 Grosso 2008 S.Croce e Carle Hospital, Cuneo, Italy 30 / 60 47.8 53.3 5  √ √  √  
170 Gupta 2002 Hammersmith Hospital, UK 66 / 225 44.4 31.8 9  √ √ √ √  
171 Haitjema 1995 St Antonius Hospital, Netherlands 32 / 92 36 71.9 6   √    
172 Hart 2010 Hammersmith Hospital, UK 69 / 161 44.6 59.4 8  √ √  √  
173 Hayashi 2012 Kagoshima University, Japan 21 / 37 43 81 10   √  √ √ 
174 Lacombe 2009 Hopital Ambroise Pare, France 39 / 681 35 79.5 12 a √ √ √ √  
175 Lee 1997 New Haven Hospital, Yale, USA 
Johns Hopkins Hospital 
45 / 45 41.6 48.9 8 b     √ 
176 Letourneau-
Guillon 
2010 St Michael’s, Toronto, Canada 
St Justine, Montreal, Quebec, Canada 
24 / 35 50 70.8 10  √ √ √ √ √ 
177 Liu 2010 Chinese People’s Liberation Army 
General Hospital, Beijing, China 
23 / - - 52.2 7  √ √ √ √  
178 Mager 2004 St Antonius, Nieuwegein 
UMC, Utrecht, Netherlands 
112 / 349 45 60.7 9  √ √ √ √  
179 Pierucci 2008 Yale University, USA 36 / - 35.4 58.3 9 a  √    
180 Pollak 1994 New Haven Hospital, Yale, USA 35 / 96 - - 8   √ √   
160 Pollak 2006 New Haven Hospital, Yale, USA 155 / 415 45 58.1 10  √ √  √ √ 
181 Prasad 2004 St Michaels’ Hospital, Toronto, Canada 54 / 306 39.2 - 10   √  √ √ 
182 Puskas 1993 Massachusetts General Hospital, USA 21 / - 37.5 61.9 †  √     
183 Remy-Jardin 2006 Calmette Hospital, Lille, France 38 / 64 34.3 55.3 7     √ √ 
184 Saluja 1999 Yale University, USA 82 / 238 40 62.2 8     √  
185 Swanson 1999 Mayo Clinic, USA 48 / 200 40 52.7 7  √ √  √  
186 Tapping 2011 Hull Royal Infirmary, UK 15 / 19 56 73 8  √ √  √  
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187 Trerotola 2009 University of Pennsylvania, USA 51 / 154 44 72.5 9  √ √    
180 White 1988 Johns Hopkins, USA 76 / 276 36 59.2 7  √ √    
189 Wong 2011 St Michaels Hospital, Toronto, Canada 17 / 28 47 65 9 c    √  
190 Woodward 2013 University of Pennsylvania, USA 23 / 162 44 56.5 10      √ 
*Reference numbers in table refer to those listed in the main manuscript 
**a) diffuse PAVMs only, b) large PAVMs only, c) idiopathic PAVMs only 
†Quality score not applicable, as not all patients studied underwent embolisation thus could not reasonably have fulfilled some of the criteria of the quality score 
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Table 6.3. Papers excluded from the meta-analyses due to potential overlap in 
patient recruitment 
Ref Author Publication 
Year 
Institution Location(s) 
194 Andersen 1999 Odense Hospital, Denmark 
195 Brillet 2006 Calmette Hospital, Lille, France 
196 Chilvers 1990 Hammersmith Hospital, UK 
197 Faughnan 2004 St Michael’s Hospital, Toronto, Canada 
Hospital for Sick Children, Toronto, 
Canada 
Sunnybrook and Women’s Centre, 
Toronto, Canada 
Yale Medical School, New Haven, USA 
Good Samaritan Medical Centre, Phoenix, 
Arizona, USA 
198 Jackson 1990 Hammersmith Hospital, UK 
49 Remy 1992 Lille Hospital, France 
199 White 1983 Johns Hopkins, USA 
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6.3.1  Results: meta-analysis of clinical characteristics 
The prevalence of a diagnosis of HHT in patients with PAVMs considered for 
treatment was 86% (95% CI 76-93, I2 93%, estimates from 16 studies including 
1122 patients) (Figure 6.3). The commonest prior symptoms were a reduction in 
exercise tolerance in 68% (95% CI 49-84%, I2 86.7%), epistaxis in 63% (95% 
CI 45-79%, I2 90.4%) and dyspnoea in 58% (95% CI 49-67%, I2 80.7%). 
Neurological complications occurred in over 40% of patients, with a previous 
stroke or TIA in 26.3% (95% CI 17.4-36.4%, I2 92.1%) and previous cerebral 
abscess in 12.6% (95% CI 9-16.8%, I2 67.6%) (Table 6.4, Figure 6.3 to Figure 
6.9). For all clinical characteristics except haemothorax and seizure there were 
high levels of heterogeneity between studies. Additional clinical characteristics 
were reported in studies but not included in the meta-analysis calculations due 
to a limited quantitative data – they include; fatigue, anaemia, undefined chest 
pain, cardiac murmur, cardiac dysfunction, cerebral AVM, non-cerebral abscess, 
hepatic AVM and gastrointestinal bleeding. 
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Table 6.4. Meta-analysis of clinical characteristics of patients with pulmonary 
arteriovenous malformations considered for embolisation 
Clinical 
Characteristic 
Prevalence 
(%)  
 
95% CI Heterogeneity 
(I2) (%) 
Contributing 
population 
Figure 
Studies / 
Patients 
 
Hypoxaemia* 98.2 95.7-100 ** 1 / 112  
Epistaxis 61 39-81 92 6 / 291 6.4 
Telangiectasia 60 26-89 93.7 3 / 177 6.5 
Reduced exercise 
tolerance* 
 
58.7 
 
50.9-66.5 
 
** 
 
1 / 155 
 
Dyspnoea 54 42-66 89.4 12 / 628 6.6 
Cyanosis 36 18-55 83.5 4 / 205 6.7 
Migraine 33 21-47 86.4 5 / 387 6.8 
Clubbing 30 15-47 80.9 3 / 211 6.9 
Stroke or TIA 27 17-39 92.7 16 / 952 6.10 
Transient ischaemic 
attack 
 
18 
 
12-24 
 
79.2 
 
13 / 787 
6.11 
Stroke 12.7 10-15.7 28.3 13 / 795 6.12 
Haemoptysis 11 7-15.8 75 13 / 860 6.13 
Cerebral abscess 10.8 7.2-15 66.2 13 / 798 6.14 
Seizure 6.9 3.8-10.9 0 3 / 190 6.15 
Haemothorax 4.4 2.6-6.7 8.1 5 / 415 6.16 
Intracranial 
haemorrhage* 
 
2.4 
 
0.3-5.0 
 
** 
 
1 / 126 
 
*Confidence intervals calculated manually around the prevalence in one paper 
**No heterogeneity value calculated as <3 studies contribute to estimate 
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Figure 6.3. Proportion of patients evaluated for embolisation diagnosed with HHT 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 77.2% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.86 (0.76, 0.93)
White (1988) 0.88 (0.79, 0.94)
Trerotola (2009) 0.92 (0.81, 0.98)
Tapping (2011) 1.00 (0.78, 1.00)
Swanson (1999) 0.56 (0.45, 0.66)
Puskas (1993) 0.57 (0.34, 0.78)
Pollak (2006) 0.95 (0.91, 0.98)
Mager (2004) 0.96 (0.91, 0.99)
Liu (2010) 0.30 (0.13, 0.53)
Letourneau-Guillon (2010) 0.86 (0.65, 0.97)
Lacombe (2009) 1.00 (0.91, 1.00)
Hart (2010) 0.75 (0.64, 0.85)
Gupta (2002) 0.83 (0.72, 0.91)
Grosso (2008) 1.00 (0.88, 1.00)
Cottin (2007) 1.00 (0.97, 1.00)
Andersen (2006) 0.91 (0.77, 0.98)
Allison (1990) 0.58 (0.33, 0.80)
proportion (95% confidence interval)
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Figure 6.4. Proportion of patients evaluated for embolisation with a history of 
epistaxis 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 92% 
 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.61 (0.39, 0.81)
White (1988) 0.79 (0.68, 0.87)
Tapping (2011) 0.53 (0.27, 0.79)
Puskas (1993) 0.29 (0.11, 0.52)
Liu (2010) 0.30 (0.13, 0.53)
Grosso (2008) 0.70 (0.51, 0.85)
Cottin (2007) 0.90 (0.83, 0.94)
proportion (95% confidence interval)
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Figure 6.5. Proportion of patients evaluated for embolisation with a history of 
telangiectasia 
 
Study and Year               Proportion (95% CI)  
 
 
Heterogeneity (I2) = 93.7% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.60 (0.26, 0.89)
Puskas (1993) 0.48 (0.26, 0.70)
Grosso (2008) 0.40 (0.23, 0.59)
Cottin (2007) 0.86 (0.78, 0.91)
proportion (95% confidence interval)
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Figure 6.6. Proportion of patients evaluated for embolization with a history of  
dyspnoea 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 89.4% 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.54 (0.42, 0.66)
White (1988) 0.71 (0.60, 0.81)
Trerotola (2009) 0.12 (0.04, 0.24)
Tapping (2011) 0.53 (0.27, 0.79)
Swanson (1999) 0.57 (0.46, 0.67)
Puskas (1993) 0.67 (0.43, 0.85)
Liu (2010) 0.65 (0.43, 0.84)
Lacombe (2009) 0.90 (0.76, 0.97)
Hart (2010) 0.41 (0.29, 0.53)
Gupta (2002) 0.56 (0.43, 0.68)
Grosso (2008) 0.20 (0.08, 0.39)
Cottin (2007) 0.56 (0.46, 0.64)
Allison (1990) 0.63 (0.38, 0.84)
proportion (95% confidence interval)
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Figure 6.7. Proportion of patients evaluated for embolisation with a history of 
cyanosis 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 83.5% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8
combined 0.36 (0.18, 0.55)
Puskas (1993) 0.29 (0.11, 0.52)
Lacombe (2009) 0.44 (0.28, 0.60)
Cottin (2007) 0.18 (0.12, 0.26)
All ison (1990) 0.58 (0.33, 0.80)
proportion (95% confidence interval)
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Figure 6.8. Proportion of patients evaluated for 106mbolization with a history of 
migraine 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 86.1% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8
combined 0.33 (0.21, 0.47)
White (1988) 0.43 (0.32, 0.55)
Puskas (1993) 0.24 (0.08, 0.47)
Pollak (2006) 0.46 (0.38, 0.54)
Hart (2010) 0.13 (0.06, 0.23)
Gupta (2002) 0.38 (0.26, 0.51)
proportion (95% confidence interval)
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Figure 6.9. Proportion of patients evaluated for embolisation with a history of 
clubbing 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 80.9% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8
combined 0.30 (0.15, 0.47)
Gupta (2002) 0.20 (0.11, 0.31)
Cottin (2007) 0.22 (0.15, 0.30)
All ison (1990) 0.58 (0.33, 0.80)
proportion (95% confidence interval)
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Figure 6.10. Proportion of patients evaluated for embolisation with a history of 
stroke or transient ischaemic attack 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 92.7% 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8
combined 0.27 (0.17, 0.39)
White (1988) 0.55 (0.43, 0.67)
Trerotola (2009) 0.27 (0.16, 0.42)
Tapping (2011) 0.13 (0.02, 0.40)
Swanson (1999) 0.30 (0.21, 0.40)
Puskas (1993) 0.19 (0.05, 0.42)
Pollak (2006) 0.72 (0.65, 0.79)
Mager (2004) 0.14 (0.08, 0.22)
Liu (2010) 0.13 (0.03, 0.34)
Letourneau-Guillon (2010) 0.27 (0.11, 0.50)
Lacombe (2009) 0.21 (0.09, 0.36)
Hart (2010) 0.14 (0.07, 0.25)
Gupta (2002) 0.48 (0.36, 0.61)
Grosso (2008) 0.13 (0.04, 0.31)
Cottin (2007) 0.16 (0.10, 0.23)
Andersen (2006) 0.11 (0.03, 0.27)
Allison (1990) 0.42 (0.20, 0.67)
proportion (95% confidence interval)
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Figure 6.11. Proportion of patients evaluated for embolisation with a history of 
transient ischaemic attack 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 79.2% 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8
combined 0.18 (0.12, 0.24)
White (1988) 0.37 (0.26, 0.49)
Trerotola (2009) 0.18 (0.08, 0.31)
Tapping (2011) 0.13 (0.02, 0.40)
Swanson (1999) 0.12 (0.06, 0.20)
Puskas (1993) 0.14 (0.03, 0.36)
Pollak (2006) 0.23 (0.16, 0.30)
Letourneau-Guillon (2010) 0.14 (0.03, 0.35)
Lacombe (2009) 0.10 (0.03, 0.24)
Hart (2010) 0.07 (0.02, 0.16)
Gupta (2002) 0.33 (0.22, 0.46)
Cottin (2007) 0.06 (0.03, 0.12)
Andersen (2006) 0.09 (0.02, 0.23)
Allison (1990) 0.37 (0.16, 0.62)
proportion (95% confidence interval)
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Figure 6.12. Proportion of patients evaluated for embolisation with a history of 
stroke 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 28.3% 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.1 0.2 0.3 0.4
combined 0.1273 (0.1003, 0.1572)
White (1988) 0.1842 (0.1045, 0.2897)
Trerotola (2009) 0.0980 (0.0326, 0.2141)
Swanson (1999) 0.1828 (0.1102, 0.2765)
Puskas (1993) 0.0476 (0.0012, 0.2382)
Pollak (2006) 0.1742 (0.1180, 0.2432)
Liu (2010) 0.1304 (0.0278, 0.3359)
Letourneau-Guillon (2010) 0.1364 (0.0291, 0.3491)
Lacombe (2009) 0.1026 (0.0287, 0.2422)
Hart (2010) 0.0725 (0.0239, 0.1611)
Gupta (2002) 0.1515 (0.0751, 0.2610)
Cottin (2007) 0.0952 (0.0502, 0.1605)
Andersen (2006) 0.0286 (0.0007, 0.1492)
Allison (1990) 0.0526 (0.0013, 0.2603)
proportion (95% confidence interval)
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Figure 6.13. Proportion of patients evaluated for embolisation with a history of 
haemoptysis 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 75% 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8
combined 0.1101 (0.0701, 0.1577)
White (1988) 0.1316 (0.0649, 0.2287)
Tapping (2011) 0.1333 (0.0166, 0.4046)
Swanson (1999) 0.1505 (0.0848, 0.2397)
Puskas (1993) 0.0476 (0.0012, 0.2382)
Pollak (2006) 0.0323 (0.0106, 0.0737)
Mager (2004) 0.0089 (0.0002, 0.0487)
Liu (2010) 0.3478 (0.1638, 0.5727)
Lacombe (2009) 0.1795 (0.0754, 0.3353)
Hart (2010) 0.1304 (0.0614, 0.2332)
Gupta (2002) 0.0909 (0.0341, 0.1874)
Grosso (2008) 0.1000 (0.0211, 0.2653)
Cottin (2007) 0.1190 (0.0682, 0.1887)
Andersen (2006) 0.0857 (0.0180, 0.2306)
proportion (95% confidence interval)
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Figure 6.14. Proportion of patients evaluated for embolisation with a history of 
cerebral abscess 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 66.2% 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6
combined 0.1081 (0.0723, 0.1501)
White (1988) 0.0921 (0.0378, 0.1806)
Trerotola (2009) 0.0196 (0.0005, 0.1045)
Tapping (2011) 0.0667 (0.0017, 0.3195)
Swanson (1999) 0.0538 (0.0177, 0.1210)
Puskas (1993) 0.0476 (0.0012, 0.2382)
Pollak (2006) 0.0903 (0.0503, 0.1469)
Letourneau-Guillon (2010) 0.0455 (0.0012, 0.2284)
Lacombe (2009) 0.2308 (0.1113, 0.3933)
Hart (2010) 0.0290 (0.0035, 0.1008)
Gupta (2002) 0.1667 (0.0862, 0.2787)
Grosso (2008) 0.2333 (0.0993, 0.4228)
Cottin (2007) 0.1905 (0.1260, 0.2700)
Andersen (2006) 0.1429 (0.0481, 0.3026)
proportion (95% confidence interval)
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Figure 6.15. Proportion of patients evaluated for embolisation with a history of 
seizure 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 0% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.1 0.2 0.3
combined 0.069 (0.038, 0.109)
White (1988) 0.079 (0.030, 0.164)
Swanson (1999) 0.054 (0.018, 0.121)
Puskas (1993) 0.048 (0.001, 0.238)
proportion (95% confidence interval)
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Figure 6.16. Proportion of patients evaluated for embolisation with a history of 
haemothorax 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 8.1% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20
combined 0.0441 (0.0258, 0.0670)
White (1988) 0.0921 (0.0378, 0.1806)
Mager (2004) 0.0268 (0.0056, 0.0763)
Gupta (2002) 0.0303 (0.0037, 0.1052)
Cottin (2007) 0.0317 (0.0087, 0.0793)
Andersen (2006) 0.0286 (0.0007, 0.1492)
proportion (95% confidence interval)
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6.3.2  Results: meta-analysis of peri-procedural complications  
A total of 1,111 patients had embolotherapy across all the studies included in 
the meta-analyses of peri-procedural complications and of success rate (with at 
least 3644 PAVMs treated). Amongst 974 patients (3314 treated lesions) in the 
peri-procedural complications meta-analysis, major complications included one 
death (due to pyogenic infection secondary to pulmonary infarction) (prevalence 
0.5%, 95% CI 0.2-1.0, I2 0%), 6 strokes (prevalence 1.0%, 95% CI 0.5-1.7%, 
I2 0%), 2 venous thromboembolic events (prevalence 0.7%, 95% CI 0.2-1.2%, 
I2 0%), and one patient with a haemopericardium secondary to probable cardiac 
perforation following attempted retrieval of a dislocated coil from the left 
ventricle (prevalence 0.6%, 95% CI 0.2-1.2%, I2 0%) (Table 6.5). We 
calculated a procedural rate of 1.0% for major clinical complications (10/974). 
Commoner complications included pleuritic chest pain/pleurisy in 9.4% (95% CI 
5.8-13.6, I2 77.2%) and ischaemic chest pain in 2.2% (95% CI 1.2-3.4, I2 
25.8%). There were no documented episodes of myocardial infarction. Box plots 
for each complication are available (Figure 6.17 - Figure 6.33). Heterogeneity 
between studies existed in prevalence estimates for some complications (for 
example, pleuritic chest pain/pleurisy) but this was not explained methodological 
quality nor whether included studies contained or omitted selected populations 
(as defined above) (Table 6.6). 
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Table 6.5. Meta-analysis of peri-procedural complications of percutaneous 
embolisation for pulmonary arteriovenous malformations in 19 studies with 974 
patients 
Complications Prevalence 
(%)  
 
95% CI Heterogeneity 
(I2) 
(%) 
Figure 
 
Pleuritic chest pain/Pleurisy 9.4 5.8-13.6 77.2 6.17 
Ischaemic chest pain 2.2 1.2-3.4 25.8 6.18 
Other* 1.8 0.6-3.6 67.4 6.19 
Haemoptysis 1.7 0.8-3.0 41.1 6.20 
Pulmonary infarct 1.4 0.6-2.6 44.8 6.21 
Uncatheterisable/ 
Unoccludable PAVM 
1.4 
 
0.5-2.7 51.8 6.22 
Device embolism 1.1 0.6-1.9 0 6.23 
Device migration 1.0 0.5-1.8 0 6.24 
Stroke 1.0 0.5-1.7 0 6.25 
Arrhythmia** 0.9 0.4-1.6 0 6.26 
Transient ischaemic attack 0.8 0.4-1.5 0 6.27 
Groin haematoma 0.8 0.4-1.5 0 6.28 
Air embolism 0.8 0.3-1.4 0 6.29 
Venous thromboembolism† 0.7 0.2-1.2 0 6.30 
Haemopericardium 0.6 0.2-1.2 0 6.31 
Ectopic device deposition 0.5 0.2-1.1 0 6.32 
Death 0.5 0.2-1 0 6.33 
Myocardial infarction 0 0 0  
* These include; transient confusion (n=1), perioral pain (n=1), intra-procedure leg pain 
(n=1), transient brachial plexus injury (n=1), episode of transient deafness (n=1), delayed 
lung abscess (n=1), pleural effusion (n=9) and mild contrast reaction (n=1) 
**Bradycardia or atrial fibrillation 
† Deep venous thrombosis or pulmonary embolus 
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Figure 6.17. Proportion of embolised patients experiencing pleuritic chest 
pain/pleurisy 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 77.2% 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6
combined 0.094 (0.058, 0.136)
White (1988) 0.105 (0.047, 0.197)
Trerotola (2009) 0.000 (0.000, 0.070)
Tapping (2011) 0.067 (0.002, 0.319)
Swanson (1999) 0.000 (0.000, 0.074)
Prasad (2004) 0.222 (0.120, 0.356)
Pollak (2006) 0.123 (0.075, 0.185)
Pollak (1994) 0.114 (0.032, 0.267)
Pierrucci (2008) 0.306 (0.163, 0.481)
Mager (2004) 0.125 (0.070, 0.201)
Liu (2010) 0.000 (0.000, 0.148)
Letourneau-Guillon (2010) 0.167 (0.047, 0.374)
Lacombe (2009) 0.000 (0.000, 0.090)
Hayashi (2012) 0.190 (0.054, 0.419)
Hart (2010) 0.058 (0.016, 0.142)
Haitjema (1995) 0.125 (0.035, 0.290)
Gupta (2002) 0.045 (0.009, 0.127)
Grosso (2008) 0.000 (0.000, 0.116)
Dutton (1995) 0.170 (0.081, 0.298)
Andersen (2006) 0.200 (0.084, 0.369)
proportion (95% confidence interval)
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Figure 6.18. Proportion of embolised patients experiencing ischaemic chest pain 
 
Study and Year              Proportion (95% CI) 
 
Heterogeneity (I2) = 25.8% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.1 0.2 0.3
combined 0.0219 (0.0123, 0.0342)
White (1988) 0.0395 (0.0082, 0.1111)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0185 (0.0005, 0.0989)
Pollak (2006) 0.0194 (0.0040, 0.0555)
Pollak (1994) 0.1143 (0.0320, 0.2674)
Pierrucci (2008) 0.0278 (0.0007, 0.1453)
Mager (2004) 0.0089 (0.0002, 0.0487)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0000 (0.0000, 0.0903)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0000 (0.0000, 0.1089)
Gupta (2002) 0.0758 (0.0251, 0.1680)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0566 (0.0118, 0.1566)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.19. Proportion of embolised patients with ‘other’ complications 
 
Study and Year               Proportion (95% CI) 
 
Heterogeneity (I2) = 67.4% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6
combined 0.0178 (0.0059, 0.0359)
White (1988) 0.0000 (0.0000, 0.0474)
Trerotola (2009) 0.0196 (0.0005, 0.1045)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0185 (0.0005, 0.0989)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0000 (0.0000, 0.0324)
Liu (2010) 0.2174 (0.0746, 0.4370)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.2564 (0.1304, 0.4213)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0000 (0.0000, 0.1089)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0377 (0.0046, 0.1298)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.20. Proportion of embolised patients developing haemoptysis 
 
Study and Year              Proportion (95% CI) 
 
Heterogeneity (I2) = 41.1% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.1 0.2 0.3 0.4
combined 0.0171 (0.0079, 0.0299)
White (1988) 0.0000 (0.0000, 0.0474)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0741 (0.0206, 0.1789)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.1667 (0.0637, 0.3281)
Mager (2004) 0.0179 (0.0022, 0.0630)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0256 (0.0006, 0.1348)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0145 (0.0004, 0.0781)
Haitjema (1995) 0.0000 (0.0000, 0.1089)
Gupta (2002) 0.0152 (0.0004, 0.0816)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0286 (0.0007, 0.1492)
proportion (95% confidence interval)
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Figure 6.21. Proportion of embolised patients developing pulmonary infarcts 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 44.8% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.1 0.2 0.3 0.4
combined 0.0142 (0.0057, 0.0264)
White (1988) 0.0132 (0.0003, 0.0711)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0926 (0.0308, 0.2030)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0089 (0.0002, 0.0487)
Liu (2010) 0.0435 (0.0011, 0.2195)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.1538 (0.0586, 0.3053)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0000 (0.0000, 0.1089)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.22. Proportion of embolised patients with uncatheterisable/unoccludable 
pulmonary arteriovenous malformations 
 
Study and Year              Proportion (95% CI) 
 
Heterogeneity (I2) = 51.9% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.1 0.2 0.3 0.4
combined 0.0137 (0.0050, 0.0268)
White (1988) 0.0000 (0.0000, 0.0474)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.1667 (0.0748, 0.3022)
Prasad (2004) 0.0556 (0.0116, 0.1539)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0000 (0.0000, 0.0324)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0256 (0.0006, 0.1348)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0625 (0.0077, 0.2081)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.23. Proportion of embolised patients with device embolism 
 
Study and Year              Proportion (95% CI)   
 
Heterogeneity (I2) = 0% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.0114 (0.0057, 0.0189)
White (1988) 0.0263 (0.0032, 0.0918)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0185 (0.0005, 0.0989)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0179 (0.0022, 0.0630)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0000 (0.0000, 0.0903)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0000 (0.0000, 0.1089)
Gupta (2002) 0.0152 (0.0004, 0.0816)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0377 (0.0046, 0.1298)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.24. Proportion of embolised patients with device migration 
 
Study and Year              Proportion (95% CI) 
 
 
Heterogeneity (I2) = 0% 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.0104 (0.0051, 0.0177)
White (1988) 0.0000 (0.0000, 0.0474)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0556 (0.0116, 0.1539)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0286 (0.0007, 0.1492)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0268 (0.0056, 0.0763)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0000 (0.0000, 0.0903)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0625 (0.0077, 0.2081)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.25. Proportion of embolised patients developing stroke 
 
Study and Year              Proportion (95% CI) 
 
 
Heterogeneity (I2) = 0% 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.0098 (0.0046, 0.0168)
White (1988) 0.0000 (0.0000, 0.0474)
Trerotola (2009) 0.0196 (0.0005, 0.1045)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0208 (0.0005, 0.1107)
Prasad (2004) 0.0185 (0.0005, 0.0989)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0089 (0.0002, 0.0487)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0000 (0.0000, 0.0903)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0000 (0.0000, 0.1089)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Grosso (2008) 0.0333 (0.0008, 0.1722)
Dutton (1995) 0.0189 (0.0005, 0.1007)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.26. Proportion of embolised patients developing arrhythmia 
 
Study and Year             Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.0088 (0.0039, 0.0155)
White (1988) 0.0000 (0.0000, 0.0474)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0185 (0.0005, 0.0989)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0089 (0.0002, 0.0487)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0000 (0.0000, 0.0903)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0145 (0.0004, 0.0781)
Haitjema (1995) 0.0313 (0.0008, 0.1622)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0286 (0.0007, 0.1492)
proportion (95% confidence interval)
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Figure 6.27. Proportion of embolised patients developing transient ischaemic 
attack 
 
Study and Year              Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.0084 (0.0037, 0.0150)
White (1988) 0.0000 (0.0000, 0.0474)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0000 (0.0000, 0.0660)
Pollak (2006) 0.0065 (0.0002, 0.0354)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0179 (0.0022, 0.0630)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0256 (0.0006, 0.1348)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0000 (0.0000, 0.1089)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.28. Proportion of embolised patients developing a groin haematoma 
 
Study and Year              Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.0084 (0.0037, 0.0150)
White (1988) 0.0000 (0.0000, 0.0474)
Trerotola (2009) 0.0196 (0.0005, 0.1045)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0370 (0.0045, 0.1275)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0089 (0.0002, 0.0487)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0000 (0.0000, 0.0903)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0000 (0.0000, 0.1089)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0286 (0.0007, 0.1492)
proportion (95% confidence interval)
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Figure 6.29. Proportion of embolised patients developing symptoms of air 
embolism 
 
Study and Year             Proportion (95% CI) 
 
Heterogeneity (I2) = 41.4% 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.008 (0.003, 0.014)
White (1988) 0.039 (0.008, 0.111)
Trerotola (2009) 0.000 (0.000, 0.070)
Tapping (2011) 0.000 (0.000, 0.218)
Swanson (1999) 0.000 (0.000, 0.074)
Prasad (2004) 0.056 (0.012, 0.154)
Pollak (2006) 0.000 (0.000, 0.024)
Pollak (1994) 0.000 (0.000, 0.100)
Pierrucci (2008) 0.000 (0.000, 0.097)
Mager (2004) 0.000 (0.000, 0.032)
Liu (2010) 0.000 (0.000, 0.148)
Letourneau-Guillon (2010) 0.000 (0.000, 0.142)
Lacombe (2009) 0.000 (0.000, 0.090)
Hayashi (2012) 0.000 (0.000, 0.161)
Hart (2010) 0.000 (0.000, 0.052)
Haitjema (1995) 0.000 (0.000, 0.109)
Gupta (2002) 0.000 (0.000, 0.054)
Grosso (2008) 0.000 (0.000, 0.116)
Dutton (1995) 0.000 (0.000, 0.067)
Andersen (2006) 0.000 (0.000, 0.100)
proportion (95% confidence interval)
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Figure 6.30. Proportion of embolised patients developing a venous 
thromboembolic event 
 
Study and Year             Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.0065 (0.0024, 0.0124)
White (1988) 0.0132 (0.0003, 0.0711)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0000 (0.0000, 0.0660)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0089 (0.0002, 0.0487)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0000 (0.0000, 0.0903)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0000 (0.0000, 0.1089)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.31. Proportion of embolised patients developing haemopericardium 
 
Study and Year       Proportion (95% CI)  
 
Heterogeneity (I2) = 0% 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.0059 (0.0021, 0.0115)
White (1988) 0.0000 (0.0000, 0.0474)
Trerotola (2009) 0.0000 (0.0000, 0.0698)
Tapping (2011) 0.0000 (0.0000, 0.2180)
Swanson (1999) 0.0000 (0.0000, 0.0740)
Prasad (2004) 0.0000 (0.0000, 0.0660)
Pollak (2006) 0.0000 (0.0000, 0.0235)
Pollak (1994) 0.0000 (0.0000, 0.1000)
Pierrucci (2008) 0.0000 (0.0000, 0.0974)
Mager (2004) 0.0000 (0.0000, 0.0324)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau-Guillon (2010) 0.0000 (0.0000, 0.1425)
Lacombe (2009) 0.0000 (0.0000, 0.0903)
Hayashi (2012) 0.0000 (0.0000, 0.1611)
Hart (2010) 0.0000 (0.0000, 0.0521)
Haitjema (1995) 0.0313 (0.0008, 0.1622)
Gupta (2002) 0.0152 (0.0004, 0.0816)
Grosso (2008) 0.0000 (0.0000, 0.1157)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.32. Proportion of embolised patients with ectopic device deposition 
 
Study and Year               Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.005 (0.002, 0.011)
White (1988) 0.000 (0.000, 0.047)
Trerotola (2009) 0.000 (0.000, 0.070)
Tapping (2011) 0.000 (0.000, 0.218)
Swanson (1999) 0.000 (0.000, 0.074)
Prasad (2004) 0.000 (0.000, 0.066)
Pollak (2006) 0.000 (0.000, 0.024)
Pollak (1994) 0.000 (0.000, 0.100)
Pierrucci (2008) 0.000 (0.000, 0.097)
Mager (2004) 0.000 (0.000, 0.032)
Liu (2010) 0.000 (0.000, 0.148)
Letourneau-Guillon (2010) 0.000 (0.000, 0.142)
Lacombe (2009) 0.051 (0.006, 0.173)
Hayashi (2012) 0.000 (0.000, 0.161)
Hart (2010) 0.000 (0.000, 0.052)
Haitjema (1995) 0.000 (0.000, 0.109)
Gupta (2002) 0.000 (0.000, 0.054)
Grosso (2008) 0.000 (0.000, 0.116)
Dutton (1995) 0.000 (0.000, 0.067)
Andersen (2006) 0.000 (0.000, 0.100)
proportion (95% confidence interval)
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Figure 6.33. Proportion of deaths in embolised patients 
 
Study and Year               Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15 0.20 0.25
combined 0.005 (0.002, 0.010)
White (1988) 0.000 (0.000, 0.047)
Trerotola (2009) 0.000 (0.000, 0.070)
Tapping (2011) 0.000 (0.000, 0.218)
Swanson (1999) 0.000 (0.000, 0.074)
Prasad (2004) 0.000 (0.000, 0.066)
Pollak (2006) 0.000 (0.000, 0.024)
Pollak (1994) 0.000 (0.000, 0.100)
Pierrucci (2008) 0.000 (0.000, 0.097)
Mager (2004) 0.000 (0.000, 0.032)
Liu (2010) 0.043 (0.001, 0.219)
Letourneau-Guillon (2010) 0.000 (0.000, 0.142)
Lacombe (2009) 0.000 (0.000, 0.090)
Hayashi (2012) 0.000 (0.000, 0.161)
Hart (2010) 0.000 (0.000, 0.052)
Haitjema (1995) 0.000 (0.000, 0.109)
Gupta (2002) 0.000 (0.000, 0.054)
Grosso (2008) 0.000 (0.000, 0.116)
Dutton (1995) 0.000 (0.000, 0.067)
Andersen (2006) 0.000 (0.000, 0.100)
proportion (95% confidence interval)
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Table 6.6. Sensitivity analysis: peri-procedural complications 
 ALL PAPERS HIGHER QUALITY SCOREa LOWER QUALITY SCOREb NON-SELECTED PATIENT 
GROUPS ONLYc 
Complications Prevalence 
 
95% CI Heterogeneity 
(I2) 
Prevalence 
 
95% CI Heterogeneity 
(I2) 
Prevalence 
 
95% CI Heterogeneity 
(I2) 
Prevalence 
 
95% CI Heterogeneity 
(I2) 
Pleuritic pain/Pleurisy 9.4 5.3-
13.6 
77.2 11.9 6.3-
19.0 
81.9 6.8 3.0-12 67.2 9.2 5.8-13.3 72.7 
Ischaemic chest pain 2.2 
 
1.2-3.4 25.8 2.1 1.1-3.4 3.9 2.4 0.7-5.0 45.7 2.2 1.2-3.6   30.8 
Other† 1.8 0.6-3.6 67.4 1.8 0.3-4.7 75.2 1.7 0.3-4.4 57.6 1.1 0.4-2.2 36.5 
Haemoptysis 1.7 0.8-3.0 41.1 2.8 0.9-5.7 65.4 0.8 0.2-1.9 0 1.2 0.6-2.0 0 
Pulmonary Infarct 1.4 0.6-2.6 44.8 1.9 0.4-4.4 68.7 1.0 0.3-2.2 0 1.0 0.4-1.8 7.4 
Uncatheterisable/ 
Unoccludable PAVM 
1.4 0.5-2.7 51.8 0.8 0.2-1.8 12.8 2.0 0.3-5.3 67.8 1.3 0.4-2.8 55.7 
Device Embolism 1.2 0.6-1.9 0 1.0 0.4-1.9 0 1.4 0.5-2.8 0 1.2 0.6-2.0 0 
Device Migration 0.8 0.5-1.8 0 1.1 0.4-2.2 17.1 1.0 0.3-2.3 0 1.1 0.5-2.0 10.3 
Stroke 0.9 0.5-1.7 0 0.8 0.3-1.7 0 1.2 0.4-2.6 0 1.0 0.5-1.8 0 
Arrhythmia 0.9 0.4-1.6 0 0.8 0.3-1.7 0 1.0 0.3-2.2 0 0.9 0.4-1.6 0 
Transient Ischaemic 
Attack 
0.8 0.4-1.5 0 1.1 0.4-2.0 0 0 0 0 0.8 0.3-1.4 0 
Groin Hematoma 0.8 0.4-1.5 0 1.1 0.4-2.0 0 0 0 0 0.9 0.4-1.6 0 
Air Embolism 0.8 0.3-1.4 0 0.6 0.1-1.4 0 1.1 0.3-2.4 0 0.8 0.3-1.5 0 
Venous  
Thromboembolism 
0.6 0.2-1.2 0 0.6 0.1-1.3 0 0.8 0.2-1.9 0 0.7 0.2-1.3 0 
Haemopericardium 0.6 0.2-1.2 0 0 0 0 0.7 0.1-1.8 0 0.6 0.2-1.2 0 
Ectopic Device 
Deposition 
0.6 0.2-1.1 0 0.5 0.1-1.3 0 0 0 0 0 0 0 
Death 0.5 0.2-1.0 0 0 0 0 0.7 0.1-1.8 0 0.5 0.1-1.0 0 
Prevalence estimates, Confidence intervals (CI) and heterogeneity estimates are all expressed as percentages 
*See Table 1 (main manuscript) for a list of ‘other’ complications 
aQuality score >8 
bQuality score <=8 
cPapers considering diffuse, large or idiopathic PAVMs excluded from analysis 
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6.3.3 Results: meta-analysis of long-term complications  
Over a median period of follow-up of 39 months in 8 studies including 494 
patients there were a total of 2 deaths, neither of which were attributed by the 
original authors to the complications of HHT or its treatment. One patient had a 
cardiorespiratory arrest after appendix surgery the second patient was found, at 
post-mortem examination, to have died of pneumonia. One death was a 
complication of intrahepatic shunt insertion for liver telangiectases. The 
commonest long-term complications in patients embolised for PAVMs were TIA 
(prevalence 2.5%, 95% CI 0.9-4.9%, I2 54.4%), cerebral abscess (prevalence 
2.1%, 95% CI 1.1-3.3%, I2 0%) and haemoptysis (prevalence 1.1%, 95% CI 
0.3-2.6%, I2 41.5%).  (Table 6.7, Figure 6.34 - Figure 6.38). There was no 
evidence of significant heterogeneity between prevalence estimates of long-term 
complications and thus a sensitivity analysis was not undertaken for this 
variable.  
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Table 6.7. Meta-analysis of long-term complications occurring in patients with 
pulmonary arteriovenous malformations post-embolisation 
Long-term Complications Prevalence 
(%) 
95% CI Heterogeneity 
(I2) (%) 
Figure 
 
Transient ischaemic attack 2.4 0.9-4.6 41.4 6.34 
Cerebral abscess 2.1 1.1-3.3 0 6.35 
Haemoptysis 1.1 0.3-2.5 35.9 6.36 
Stroke 0.5 0.06-1.3 0 6.37 
Total deaths 0.6 0.1-1.5 0 6.38 
Total deaths attributable to HHT* 0 0 0  
Death directly due to HHT disease* 0 0 0  
Death due to intervention for PAVM* 0 0 0  
Haemothorax* 0 0 0  
Venous thromboembolism* 0 0 0  
Pulmonary Hypertension* 0 0 0  
*No cases recorded in the examined literature and thus box plots of prevalence not 
reproduced below 
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Figure 6.34. Proportion of patients experiencing a transient ischaemic attack 
over long-term follow-up post-embolisation 
 
Study and Year                Proportion (95% CI) 
 
Heterogeneity (I2) = 41.4% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.1 0.2 0.3
combined 0.024 (0.009, 0.046)
Pollak (2006) 0.028 (0.008, 0.070)
Mager (2004) 0.027 (0.006, 0.076)
Liu (2010) 0.000 (0.000, 0.148)
Letourneau (2010) 0.045 (0.001, 0.228)
Lacombe (2009) 0.103 (0.029, 0.242)
Gupta (2002) 0.000 (0.000, 0.054)
Dutton (1995) 0.000 (0.000, 0.067)
Andersen (2006) 0.000 (0.000, 0.100)
proportion (95% confidence interval)
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Figure 6.35. Proportion of patients with cerebral abscess diagnosed over long-
term follow-up post-embolisation 
 
Study and Year                Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.04 0.08 0.12 0.16
combined 0.0214 (0.0106, 0.0359)
Pollak (2006) 0.0347 (0.0114, 0.0792)
Mager (2004) 0.0179 (0.0022, 0.0630)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau (2010) 0.0000 (0.0000, 0.1544)
Lacombe (2009) 0.0256 (0.0006, 0.1348)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Dutton (1995) 0.0189 (0.0005, 0.1007)
Andersen (2006) 0.0000 (0.0000, 0.1000)
proportion (95% confidence interval)
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Figure 6.36. Proportion of patients experiencing haemoptysis over long-term 
follow-up post-embolisation 
 
Study and Year                Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.04 0.08 0.12 0.16
combined 0.009 (0.002, 0.019)
Pollak (2006) 0.021 (0.004, 0.060)
Mager (2004) 0.000 (0.000, 0.032)
Liu (2010) 0.000 (0.000, 0.148)
Letourneau (2010) 0.000 (0.000, 0.154)
Lacombe (2009) 0.000 (0.000, 0.090)
Gupta (2002) 0.000 (0.000, 0.054)
Dutton (1995) 0.000 (0.000, 0.067)
Andersen (2006) 0.000 (0.000, 0.100)
proportion (95% confidence interval)
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Figure 6.37. Proportion of patients developing stroke over long-term follow-up 
post-embolisation 
 
Study and Year                Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.04 0.08 0.12 0.16
combined 0.0047 (0.0006, 0.0126)
Pollak (2006) 0.0000 (0.0000, 0.0253)
Mager (2004) 0.0000 (0.0000, 0.0324)
Liu (2010) 0.0000 (0.0000, 0.1482)
Letourneau (2010) 0.0000 (0.0000, 0.1544)
Lacombe (2009) 0.0000 (0.0000, 0.0903)
Gupta (2002) 0.0000 (0.0000, 0.0544)
Dutton (1995) 0.0000 (0.0000, 0.0672)
Andersen (2006) 0.0286 (0.0007, 0.1492)
proportion (95% confidence interval)
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Figure 6.38. Proportion of total deaths over long-term follow-up post-
embolisation 
 
Study and Year               Proportion (95% CI)  
 
Heterogeneity (I2) = 0% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.04 0.08 0.12 0.16
combined 0.006 (0.001, 0.015)
Pollak (2006) 0.000 (0.000, 0.025)
Mager (2004) 0.000 (0.000, 0.032)
Liu (2010) 0.000 (0.000, 0.148)
Letourneau (2010) 0.000 (0.000, 0.154)
Lacombe (2009) 0.000 (0.000, 0.090)
Gupta (2002) 0.030 (0.004, 0.105)
Dutton (1995) 0.000 (0.000, 0.067)
Andersen (2006) 0.000 (0.000, 0.100)
proportion (95% confidence interval)
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6.3.4  Results: meta-analysis of embolisation success rate  
The overall procedural success rate for individual patients was 84% (95% CI 75-
92%, I2 87%, 13 studies, 561 patients) over a median follow-up period of 41 
months. The overall success rate of embolisation for individual PAVMs was 90% 
(95% CI 83-95%, I2 93%, 10 studies, 1444 PAVMs) (Table 6.8 and Figure 6.39 - 
Figure 6.43). When only studies with at least 12 months follow-up using either 
thoracic CT or pulmonary angiography, and with < 20% loss to follow-up, were 
analysed the success rate by patient was 82% (95% CI 67-93%, I2 87%, 7 
studies, 294 patients) and by PAVM was 88% (95% CI 79-95%, I2 95%, 6 
studies, 825 PAVMs) (Figure 6.42). Studies where coils alone (steel, platinum, or 
both) were used had a success rate of 80% by patient (95% CI 58-95%, I2 
91%, 5 studies, 243 patients). Studies using coils in combination with the 
Amplatzer device had a success rate of 86% by patient (95% CI 74-95%, I2 
86%, 7 studies, 251 patients). It was not possible to calculate success rates for 
balloon embolisation alone or use of the Amplatzer device alone. Heterogeneity 
existed but was not attributable to study methodological quality nor whether 
included studies focussed solely on non-selected populations (see definition 
above) (Table 6.9). We calculate a post-embolisation recanalisation rate of 5.9% 
(across all embolised PAVMs, not solely those reperfused) (95% CI 3.3-9.4, I2 
80, from 9 studies and 1394 PAVMs embolised).   
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Table 6.8. Meta-analysis of procedural success rate of percutaneous embolisation for pulmonary arteriovenous malformations (by patient 
and by PAVM) 
 Patients Population Figure Pulmonary AVMs Population Figure 
Prevalence  
(%) 
 
95% CI  Heterogeneity  
(I2) (%) 
Studies /  
Patients 
 Prevalence 
(%)  
 
95% CI Heterogeneity  
(I2) (%) 
Studies /  
PAVMs 
 
Overall success rate 84 
 
75-92 87 13 / 561 6.39 0 83-95 93 10 / 1444 6.40 
By Device used*           
Coils alone 80 58-95 91 5 / 243  87 70-97 97 5 / 880 6.41 
Mixed (Coils and Amplatzer) 86 74-95 86 7 / 251  -** - - -  
Follow-up           
CT or angiography follow-up for  
> 12 months  
and < 20% loss to follow-up 
82 67-93 87 7 / 294  88 79-95 90 6 / 825 6.42 
Recanalisation rate 5.1 1.2-11.4 83 10 / 493  5.9 3.3-9.4 80 9 / 1394 6.43 
*Insufficient studies published to look at success rate for either balloon embolisation alone or Amplatzer alone 
** only one study using a combination of coils and Amplatzer devices 
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Figure 6.39. Overall embolisation success rate (by patient) 
 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 86.6% 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.84 (0.75, 0.92)
Wong (2011) 0.71 (0.44, 0.90)
Tapping (2011) 0.92 (0.62, 1.00)
Swanson (1999) 0.79 (0.65, 0.90)
Pollak (2006) 0.94 (0.88, 0.97)
Mager (2004) 0.72 (0.63, 0.80)
Liu (2010) 1.00 (0.85, 1.00)
Letourneau (2010) 0.91 (0.71, 0.99)
Lacombe (2009) 0.53 (0.36, 0.69)
Hayashi (2012) 0.67 (0.43, 0.85)
Hart (2010) 1.00 (0.48, 1.00)
Gupta (2002) 1.00 (0.94, 1.00)
Grosso (2008) 0.87 (0.69, 0.96)
Andersen (2006) 0.74 (0.55, 0.88)
proportion (95% confidence interval)
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Figure 6.40. Overall embolisation success rate (by PAVM) 
 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 83.1% 
 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.5 0.6 0.7 0.8 0.9 1.0
combined 0.94 (0.90, 0.97)
Tapping (2011) 0.95 (0.74, 1.00)
Saluja (1999) 0.96 (0.93, 0.98)
Remy-Jardin (2006) 0.75 (0.63, 0.85)
Prasad (2004) 0.92 (0.89, 0.95)
Pollak (2006) 0.97 (0.95, 0.99)
Mager (2004) 0.92 (0.88, 0.94)
Letourneau (2010) 0.93 (0.76, 0.99)
Hayashi (2012) 0.97 (0.86, 1.00)
Dutton (1995) 1.00 (0.96, 1.00)
Andersen (2006) 0.92 (0.86, 0.97)
proportion (95% confidence interval)
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Figure 6.41. Embolisation success rate (by PAVM) when coils alone were used 
 
Study and Year       Proportion (95% CI) 
 
      Heterogeneity (I2) = 96.9% 
 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.87 (0.70, 0.97)
Remy-Jardin (2006) 0.47 (0.34, 0.60)
Prasad (2004) 0.92 (0.89, 0.95)
Pollak (2006) 0.97 (0.95, 0.99)
Hayashi (2012) 0.70 (0.53, 0.84)
Dutton (1995) 1.00 (0.96, 1.00)
proportion (95% confidence interval)
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Figure 6.42. Embolisation success rate (by PAVM) when follow-up protocol 
included CT thorax or pulmonary angiography, follow-up exceeded 12 months, 
and < 20% of patients were lost to follow-up 
 
Study and Year       Proportion (95% CI) 
 
      Heterogeneity (I2) = 89.5% 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.5 0.7 0.9 1.1
combined 0.88 (0.79, 0.95)
Tapping (2011) 0.95 (0.74, 1.00)
Remy-Jardin (2006) 0.75 (0.63, 0.85)
Prasad (2004) 0.92 (0.89, 0.95)
Pollak (2006) 0.97 (0.95, 0.99)
Letourneau (2010) 0.93 (0.76, 0.99)
Hayashi (2012) 0.70 (0.53, 0.84)
proportion (95% confidence interval)
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Figure 6.43. Overall recanalisation rate (by PAVM) 
 
Study and Year       Proportion (95% CI) 
 
      Heterogeneity (I2) = 79.8% 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6
combined 0.059 (0.033, 0.094)
Trerotola (2009) 0.054 (0.022, 0.109)
Tapping (2011) 0.053 (0.001, 0.260)
Prasad (2004) 0.042 (0.022, 0.073)
Pollak (2006) 0.028 (0.014, 0.050)
Mager (2004) 0.084 (0.055, 0.122)
Letourneau (2010) 0.071 (0.009, 0.235)
Hayashi (2012) 0.243 (0.118, 0.412)
Dutton (1995) 0.000 (0.000, 0.036)
Andersen (2006) 0.075 (0.033, 0.143)
proportion (95% confidence interval)
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Table 6.9. Sensitivity analysis: procedural success rate 
 ALL PAPERS HIGHER QUALITY SCOREa LOWER QUALITY SCOREb NON-SELECTED PATIENT 
GROUPS ONLYc 
Success rates Prevalence 
 
95% CI Heterogeneity 
(I2) 
Prevalence 
 
95% CI Heterogeneity 
(I2) 
Prevalence 
 
95% CI Heterogeneity 
(I2) 
Prevalence 
 
95% CI Heterogeneity 
(I2) 
Success expressed by 
pulmonary AVMs 
embolised 
            
Overall success rate 90 84-94 83 91 86-95 84.1 91 86-95 84.1 87 73-96 80.5 
By device used             
Coils alone 87 70-97 97 90 79-97 92.7 90 79-97 92.7 90 79-97 92.7 
Mixed (Coils and 
Amplatzer) 
91 79-99 * 91 79-99 * 91 79-99 * 91 79-99 * 
By follow-up             
CT or angiography 
follow-up for > 12 
months  
and < 20% loss to 
follow-up 
88 79-95 90 90 81-97 89.2 
 
90 81-97 89.2 
 
90 81-97 89.2 
 
Recanalisation rate 5.9 3.3-9.4 80 7.4 4-11.8 80.6 7.4 4-11.8 80.6 7.4 4-11.8 80.6 
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Table 6.10 (continued). Sensitivity analysis: procedural success rate 
 
 ALL PAPERS HIGHER QUALITY SCOREa LOWER QUALITY SCOREb NON-SELECTED PATIENT 
GROUPS ONLYc 
Success rates Prevalence 
 
95% CI Heterogeneity 
(I2) 
Prevalence 
 
95% CI Heterogeneity 
(I2) 
Prevalence 
 
95% CI Heterogeneity 
(I2) 
Prevalence 
 
95% CI Heterogeneity 
(I2) 
Success expressed by 
patients embolised 
            
Overall success rate 83 75-91 88 91 81-98 89.6 95 90-98 0 29 85-97 85 
By device used             
Coils alone 80 58-95 91 93 77-100 90.3 99 91-99 * 94 70-99 92.3 
Mixed (Coils and 
Amplatzer) 
86 74-95 86 88 70-98 * 93 82-99 * 91 83-97 0 
By follow-up             
CT or angiography 
follow-up for > 12 
months  
and < 20% loss to 
follow-up 
82 67-93 87 90 72-99 90.9 86 72-95 68.6 
 
92 82-98 83.1 
Recanalisation rate 5.1 1.2-
11.4 
83 5.4 0.5-
15.2 
90.2 4.3 1.2-9.4 0 94 87-99 84.6 
Prevalence estimates, Confidence intervals (CI) and heterogeneity estimates are all expressed as percentages 
*No heterogeneity estimate as <3 studies contribute to the meta-analysis 
†See Table 1 (main manuscript) for a list of ‘other’ complications 
aQuality score >8, bQuality score <=8 
cPapers considering diffuse, large or idiopathic PAVMs excluded from analysis 
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6.3.5 Results: meta-analysis of reperfusion mechanism   
Of the studies that considered the reasons for the reperfusion/persistence of 
previously embolised PAVMs we present the following data.  The overall rate of 
reperfusion (by PAVM) was 13.2% (95% CI 6-22.8, I2 90.4%, from 6 studies 
and 841 PAVMs embolised). Analysis of mechanisms of reperfusion is presented 
in Table 6.11 and Table 6.12 with the prevalences in Table 6.11 presented with a 
denominator of all PAVMs embolised, and the prevalences in Table 6.12 
presented with a denominator of all reperfused PAVMs. The commonest cause of 
a persistent PAVM was recanalisation of a previously embolised lesion 
(prevalence 9.7%, 95% CI 4.1-17.3, I2 88%, from 6 studies and 841 PAVMs 
embolised) (Table 6.11, Figure 6.44 - Figure 6.48). If studies that only included 
reperfused PAVMs (rather than all PAVMs embolised) are considered, 
recanalisation remains the dominant mechanism of persistent PAVM lesions 
(prevalence 75%, 95% CI 61-86, I2 54%, from 7 studies and 123 reperfused 
PAVMs included) (Table 6.12, Figure 6.49 - Figure 6.52). 
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Table 6.11. Meta-analysis of causes for reperfusion of previously embolised 
pulmonary arteriovenous malformations (denominator as total number of 
embolised PAVMs). 
Recurrence 
marker 
Prevalence 
(%)  
 
95% CI Heterogeneity 
(I2) (%) 
Number of 
PAVMs/studies 
Figure 
  
Reperfusion 13.2 6-22.8 90.4 841 / 6 6.44 
Recanalisation 9.7 4.1-17.3 88 841 / 6 6.45 
Previously 
untreated feeder 
1.9 0.5-4.2 65.7 841 / 6 6.46 
Systemic-to-
pulmonary 
reperfusion 
1.6 0.3-3.8 66.7 841 / 6 6.47 
Pulmonary-to-
pulmonary 
reperfusion 
0.3 0.04-0.8 0 841 / 6 6.48 
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Figure 6.44. Reperfusion rate (by PAVM) 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 90.4% 
 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6
combined 0.132 (0.060, 0.228)
Remy-Jardin (2006) 0.250 (0.150, 0.374)
Prasad (2004) 0.082 (0.052, 0.122)
Pollak (2006) 0.028 (0.014, 0.050)
Letourneau (2010) 0.071 (0.009, 0.235)
Lee (1997) 0.154 (0.069, 0.281)
Hayashi (2012) 0.297 (0.159, 0.470)
proportion (95% confidence interval)
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Figure 6.45. Recanalisation rate (by PAVM) 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 88% 
 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6
combined 0.097 (0.041, 0.173)
Remy-Jardin (2006) 0.188 (0.101, 0.305)
Prasad (2004) 0.049 (0.026, 0.082)
Pollak (2006) 0.018 (0.007, 0.036)
Letourneau (2010) 0.071 (0.009, 0.235)
Lee (1997) 0.096 (0.032, 0.210)
Hayashi (2012) 0.243 (0.118, 0.412)
proportion (95% confidence interval)
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Figure 6.46. Untreated feeder vessel (by PAVM) 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 65.7% 
 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.04 0.08 0.12 0.16
combined 0.0186 (0.0046, 0.0418)
Remy-Jardin (2006) 0.0469 (0.0098, 0.1309)
Prasad (2004) 0.0037 (9.48E-05, 0.0207)
Pollak (2006) 0.0025 (6.44E-05, 0.0141)
Letourneau (2010) 0.0000 (0.0000, 0.1234)
Lee (1997) 0.0577 (0.0121, 0.1595)
Hayashi (2012) 0.0270 (0.0007, 0.1416)
proportion (95% confidence interval)
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Figure 6.47. Systemic-to-pulmonary reperfusion (by PAVM) 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 66.7% 
 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.1 0.2 0.3
combined 0.0155 (0.0030, 0.0375)
Remy-Jardin (2006) 0.0156 (0.0004, 0.0840)
Prasad (2004) 0.0037 (9.48E-05, 0.0207)
Pollak (2006) 0.0051 (0.0006, 0.0183)
Letourneau (2010) 0.0000 (0.0000, 0.1234)
Lee (1997) 0.0000 (0.0000, 0.0685)
Hayashi (2012) 0.1351 (0.0454, 0.2877)
proportion (95% confidence interval)
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Figure 6.48. Pulmonary-to-pulmonary reperfusion (by PAVM) 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.00 0.05 0.10 0.15
combined 0.0029 (0.0004, 0.0077)
Remy-Jardin (2006) 0.0000 (0.0000, 0.0560)
Prasad (2004) 0.0000 (0.0000, 0.0137)
Pollak (2006) 0.0025 (6.44E-05, 0.0141)
Letourneau (2010) 0.0000 (0.0000, 0.1234)
Lee (1997) 0.0000 (0.0000, 0.0685)
Hayashi (2012) 0.0000 (0.0000, 0.0949)
proportion (95% confidence interval)
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Table 6.12. Meta-analysis of causes for reperfusion of previously embolised 
pulmonary arteriovenous malformations (denominator as total number of 
reperfused PAVMs). 
Recurrence 
marker 
Prevalence 
(%)  
 
95% CI Heterogeneity 
(I2) (%) 
Number of 
AVMs/studies 
Figure 
  
Recanalisation 75 61-86 54 933 / 7 6.49 
Previously untreated 
feeder 
14.8 9.3-21.4 0 933 / 7 6.50 
Systemic-to-
pulmonary 
reperfusion 
8.0 1.9-17.8 58.8 933 / 7 6.51 
Pulmonary-to-
pulmonary 
reperfusion 
6.3 0.8-16.7 67 933 / 7 6.52 
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Figure 6.49. Recanalisation (by PAVM) 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 54% 
 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.75 (0.61, 0.86)
Woodw ard (2013) 0.91 (0.79, 0.97)
Remy-Jardin (2006) 0.75 (0.48, 0.93)
Prasad (2004) 0.59 (0.36, 0.79)
Pollak (2006) 0.64 (0.31, 0.89)
Letourneau (2010) 1.00 (0.16, 1.00)
Lee (1997) 0.63 (0.24, 0.91)
Hayashi (2012) 0.82 (0.48, 0.98)
proportion (95% confidence interval)
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Figure 6.50. Untreated feeder vessel (by PAVM) 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 0% 
Proportion meta-analysis plot [random effects]
0.0 0.3 0.6 0.9
combined 0.148 (0.093, 0.214)
Woodw ard (2013) 0.151 (0.067, 0.276)
Remy-Jardin (2006) 0.188 (0.040, 0.456)
Prasad (2004) 0.045 (0.001, 0.228)
Pollak (2006) 0.091 (0.002, 0.413)
Letourneau (2010) 0.000 (0.000, 0.842)
Lee (1997) 0.375 (0.085, 0.755)
Hayashi (2012) 0.091 (0.002, 0.413)
proportion (95% confidence interval)
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Figure 6.51. Systemic-to-pulmonary reperfusion (by PAVM) 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 58.8% 
 
 
 
 
 
 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.3 0.6 0.9
combined 0.080 (0.019, 0.178)
Woodw ard (2013) 0.000 (0.000, 0.067)
Remy-Jardin (2006) 0.063 (0.002, 0.302)
Prasad (2004) 0.045 (0.001, 0.228)
Pollak (2006) 0.182 (0.023, 0.518)
Letourneau (2010) 0.000 (0.000, 0.842)
Lee (1997) 0.000 (0.000, 0.369)
Hayashi (2012) 0.273 (0.060, 0.610)
proportion (95% confidence interval)
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Figure 6.52. Pulmonary-to-pulmonary reperfusion (by PAVM) 
Study and Year       Proportion (95% CI) 
 
Heterogeneity (I2) = 67% 
 
 
 
Proportion meta-analysis plot [random effects]
0.0 0.3 0.6 0.9
combined 0.063 (0.008, 0.167)
Woodw ard (2013) 0.245 (0.138, 0.383)
Remy-Jardin (2006) 0.000 (0.000, 0.206)
Prasad (2004) 0.000 (0.000, 0.154)
Pollak (2006) 0.091 (0.002, 0.413)
Letourneau (2010) 0.000 (0.000, 0.842)
Lee (1997) 0.000 (0.000, 0.369)
Hayashi (2012) 0.000 (0.000, 0.285)
proportion (95% confidence interval)
163 
 
6.4 Discussion 
6.4.1  Summary 
This is the first meta-analysis undertaken of the observational literature 
concerning percutaneous embolisation as a treatment for pulmonary 
arteriovenous malformations and provides summary estimates of procedural 
safety and procedural success rate. A major clinical complication occurred in 1% 
of PCE procedures undertaken.  Our calculated procedural success rate is 84% 
per patient, or 90% per PAVM over a median follow-up period of 41 months. We 
conclude, on the basis of the current published literature, that PCE is effective 
for obliterating PAVMs in the majority of patients and that it is associated with a 
low rate of clinically significant complications.  
6.4.2  Interpretation of results 
Clinical characteristics of patients considered for embolisation  
Patients considered for embolisation showed a high prevalence of complications 
related to HHT and when these prevalences are compared directly with those 
derived from the case-control study described in chapter 4 the former group had 
a higher burden of complications (Table 6.13). This is due to the fact that the 
former group is highly selected and includes patients with known pulmonary 
AVMs, whilst the latter patient population is a more representative sample of 
those with diagnosed HHT, not all of whom will have evidence of PAVMs. In 
addition, there is the issue of recall bias in the patient group included in the 
meta-analysis as most studies relied on patients answering questions from 
memory regarding whether they had experienced particular complications that 
could have been attributable to PAVMs in HHT. In addition, the way we analysed 
our meta-analysis data may have contributed to skewing the prevalence 
estimates. We deliberately omitted any papers that failed to mention a certain 
complication from being counted as a denominator to prevalence for that specific 
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complication. In other words, a paper would have to specifically mention in the 
text or table what the prevalence of a specific complication was for that 
complication to be included in the meta-analysis – i.e. no assumptions were 
made. Thus, studies in which no patients had developed haemoptysis, for 
example, would only be included if they specifically mentioned haemoptysis was 
asked about and documented that its prevalence was zero.  
 
Table 6.13. Comparison of prevalences of complications in HHT patients from 
meta-analysis versus those from case-control study 
Clinical 
Characteristic 
Prevalence 
from meta-
analysis 
Prevalence from 
case-control 
study 
(%)  (%) 
Epistaxis 61 26.2 
Migraine 33 10.5 
Stroke or TIA 27 7.6 
Transient ischaemic 
attack 
 
18 
 
2.1 
Stroke 12.7 5.5 
Haemoptysis 11 2.4 
Cerebral abscess 10.8 0.4 
Seizure 6.9 1.2 
Intracranial 
haemorrhage 
 
2.4 
 
0.6 
 
Peri-procedural complications associated with embolisation  
Percutaneous embolisation is now the procedure of choice in patients with 
PAVMs of a size amenable to intervention and is graded as a strong 
recommendation in the international guidelines on the management of patients 
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with PAVMs and HHT27. According to our data, major complications associated 
with PCE are rare, and this should be of reassurance to patients undergoing this 
intervention. Counselling patients in advance of the likelihood of developing the 
commoner symptoms (such as pleuritic chest pain) should be undertaken so that 
patient expectations prior to the procedure are appropriate and timely 
management is achievable in the event of symptoms. 
Longer-term complications following embolisation  
Over the longer term, there is little data collected in patients following PCE, but 
the commonest recorded complications are neurological (TIA, stroke and 
cerebral abscess).  These complications could have occurred due to a failed 
initial procedure, a reperfusion following an initially successful procedure, or 
could be unrelated to PAVMs, being as they are also complications that are 
common in the general population and can arise due to, for example, 
atherosclerotic cardiovascular disease. Studies did not investigate these patients 
in sufficient detail over the longer term to allow us to discern the reason for any 
complications that occurred.  
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Effectiveness of embolisation in managing pulmonary AVMs  
Initial technical success rates for PCE approach 100% 160,170,178,181,188,193,196,197,200, 
but after follow-up with appropriate imaging embolisation fails to treat PAVM 
lesions in around 15% of individuals. These patients are at risk of significant 
embolic complications via their reperfused lesions and must be screened on a 
regular basis post-treatment to ensure recurrent lesions are identified. Whilst 
the evidence base for a consequent reduction in PAVM-related complications 
post-embolisation is not extensive, there are studies suggesting a reduction in 
shunt and breathlessness 201 and a decreased ischaemic stroke rate 80. Current 
guidelines recommend screening follow-up at 6-12 months post procedure (with 
multidetector CT) and thereafter, every 3-5 years 27. A recent study suggests 
that the radiation burden inherent in screening and treating PAVMs in some 
patients may be unacceptably high55 and has prompted calls for a rethink about 
safer screening and follow-up strategies post-embolisation56.  
Mechanisms of reperfusion in treated lesions (failed embolisation) 
Recanalisation is by far the commonest method of reperfusion. It occurs when 
the nest of coils or the Amplatzer device blocking the feeding vessels to the 
PAVM fails to stem the flow completely through the PAVM. This may be due to a 
technical failure early on or during device deployment or may reflect a more 
chronic process of organisation and recanalisation of clot established in the 
PAVM that allows subsequent reperfusion. Few studies a have looked at the 
methods of reperfusion but given that recanalisation is so common, better 
strategies to treat PAVMs, better embolisation materials and devices, and more 
experienced operators will be required to bring reperfusion rates down further.  
6.4.3 Strengths and limitations 
The major strength of this review is its ability to provide summary estimates of 
the literature, based on a sample of patients undergoing PCE that is over six 
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times larger than that of individual studies. This permits a more representative 
estimate of peri-procedural complication rates which will inform clinicians and 
interventional radiologists, allowing them to counsel patients with more accurate 
information on the risks and benefits of the procedure. We are able to present 
figures for overall success rate, stratified by method of embolisation and method 
of follow-up. There are several potential limitations in this meta-analysis. First is 
the level of observational evidence available for inclusion (mainly retrospective 
case series). This partly reflects the ethical problems inherent in designing a 
study with a conservatively managed comparator group of patients with PAVMs 
who would be deprived of a procedure perceived to be effective in preventing 
significant complications, including stroke.    
A second limitation is the possibility of bias in the included studies. Language 
bias may exist as we included only studies published in English. Asymmetry was 
not detected on visual analysis of funnel plots which reduces the likelihood of 
significant publication bias though does not rule it out completely.  Selection bias 
could exist as we excluded case reports and small case series from our analysis 
in a bid to limit skewing of our effectiveness estimates. We accept that small 
published studies may describe mortality or a rare complication of PCE that 
would not be included in our meta-analysis. One example of this is the 
suggestion that PAVM sacs that persist post-embolisation and acquire a systemic 
arterial collateral blood supply could pose a risk of subsequent massive 
haemoptysis202. This particular paper was not identified in our literature search 
for the meta-analysis and therefore there could be other evidence that remains 
unidentified or has been specifically excluded from our study that would, in fact, 
offer useful insight into complications post embolisation for PAVMs.  
Third, heterogeneity was relatively high in estimates of success rates, as would 
be expected from a synthesis of procedures from different centres. Much 
heterogeneity arose as a result of the differing methodology employed in each 
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study and, as a result of this, and to aid reporting, we suggest that future 
studies included certain important information about the study design (Table 
6.14). 
. 
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Table 6.14. Methodological suggestions for future studies looking at 
percutaneous embolisation as a treatment for pulmonary arteriovenous 
malformations 
Study Design 
Consecutive patients should be included – with reasons explained if this did not occur 
Clearly state when studies contain overlapping patient populations 
Clear inclusion and exclusion criteria stated 
Record details of all patients with PAVMs a) initially evaluated, b) subsequently embolised and c) 
any lost during follow-up.  
Clearly state the definition of a peri-procedural complication. We arbitrarily suggest 30 days, with 
any complications occurring later able to be defined as peri-procedural if there is a clear causal 
link with the procedure 
Follow-up both embolisation patients and if possible any patients ineligible for embolisation or 
refusing the procedure in order to better define the history of untreated PAVMs.  
Be specific about follow-up criteria; 
 Aim for follow-up of at least 36 months 
 Follow-up protocol should preferably include either CT or angiography as oximetry, shunt 
studies, chest radiograph and cardiac bubble echo are less sensitive means of detecting 
recurrent PAVMs 
 State the details of the follow-up protocol used  
 State, if different, the time periods of clinical and radiological follow-up obtained. 
Use a clear definition of a ‘successful procedure’. One example from a recent study(36);  
 Success – marked reduction (>30%) or disappearance of aneurysmal sac, with no 
pulmonary or systemic perfusion 
 Partial success - <30% reduction in the size of the aneurysmal sac with persistent 
pulmonary perfusion and patent feeding artery beyond the level of the embolisation 
device too small for a re-embolisation (<2-3mm) 
 Partial failure – Substantial reduction in the size of the aneurysmal sac, persistent 
pulmonary perfusion and a patent feeding artery/arteries beyond the level of the 
embolisation device larger than 2-3mm which was an indication for re-embolisation 
 Failure – An unchanged or enlarged aneurysmal sac with persistent pulmonary perfusion 
In patients with reperfused PAVMs, where possible, specify the mechanism according to these 
criteria(9); 
 recanalisation of an embolised vessel,  
 growth of a missed or previously small accessory artery (previously untreated feeder),  
 bronchial or other systemic artery collateral flow (systemic-to-pulmonary reperfusion), 
 pulmonary artery to pulmonary artery collateral flow around the occlusion (pulmonary-to-
pulmonary reperfusion). 
Consider documenting any  symptomatic improvements post embolisation with use of structured 
patient questionnaires/symptom scales 
*Reference numbers in table refer to those listed in the main manuscript 
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Fourth, we acknowledge that the evidence base reflects publications from a 
limited number of specialist centres who likely perform a relatively high number 
of PCEs annually in comparison with smaller centres. PCE is an operator-
dependent procedure and, whilst most studies published consecutive cases from 
one or two centres where the operator remained the same over time, we were 
not able to adjust our results for operator experience. For this reason it is 
important that all interventional radiologists undertaking PCE are aware of their 
own local safety estimates and success rates.   
Despite its limitations, our study provides pooled estimates from a population 
over six-fold larger than previously published studies, and allows more 
representative estimates of procedural risk and success rate. These estimates 
may guide clinicians in providing more informed consent to patients with PAVMs 
when discussing the risks and benefits of undergoing PCE as well as providing a 
benchmark for less experienced centres offering the procedure. We emphasize 
the need for all centres to have a structured approach to screening patients for 
the recurrence of lesions post-treatment. The summary of published evidence 
from observational studies suggests that serious complications of PCE are 
infrequent and that embolisation is an effective intervention for PAVMs.  
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7.1 Introduction 
Percutaneous embolisation (PCE) as a treatment for pulmonary AVMs is now the 
‘gold standard’ management for identified lesions in which the procedure is 
technically feasible160,170,178. In this thesis we have previously shown (see 
chapter 6), based on published evidence, that PCE is associated with a relatively 
low risk of mortality or major complications. However, the published evidence 
derives mainly from specialist centres with a declared interest in the procedure 
that may have a relatively high volume of activity and hence may not be 
representative of the safety profile of the procedure nationally. Likewise, local 
audit of the procedure from individual hospital trusts, presuming it is even 
regularly undertaken, would miss mortality or complications associated with PCE 
which had occurred in other geographical regions. We used a national database 
collecting inpatient data from all hospitals in England over a 15 year period to 
describe geographic and temporal trends and mortality associated with 
embolisation of pulmonary arteriovenous malformations. 
 
7.2 Methods 
7.2.1  Study design, setting and source of data 
We conducted a retrospective national study using data obtained from the 
Health Episodes Statistics (HES) database (see chapter 2). We were provided 
with a pseudonymised extract of data between years 1997/98 and 2010/11. The 
domains under which data were requested are listed in Table 7.1. 2011 data was 
considered provisional as it was supplied before the end of the calendar year, 
but these data were included where appropriate for completeness. Filters were 
applied to search for relevant patients by both procedural code and diagnostic 
code. A procedure filter was applied using OPCS-4203 codes (version 4.6, April 
2011) to identify procedures likely to correspond to embolisation therapy for 
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pulmonary AVMs. The diagnosis filter was then applied by searching for both the 
ICD-9 and ICD-10204 codes for “arteriovenous fistulae of pulmonary vessels” 
(417.0 and I28.0, respectively) and hereditary haemorrhagic telangiectasia 
 
Table 7.1. Data extraction domains for inpatient data from HES and for mortality 
data from ONS. 
Inpatient data 
 
ONS mortality data 
Demographic data 
 
All data 
Month and year of birth Date of death 
Sex Date of registration of death 
Ethnic category Sex 
Postcode district of residence Date of death 
Lower Super Output Area Original underlying cause of death 
Middle Super Output Area Death record used (HES or ONS) 
Rural/Urban indicator  
Admission data 
 
Date of admission 
Date of decision to admit 
Method of admission 
Waiting time 
Date of discharge 
Method of discharge 
Duration of spell 
Duration of episode 
Clinical data 
 
Diagnosis codes 
Operative procedure codes 
Main admitting speciality 
Treatment speciality 
Socioeconomic status 
Lower Super Output Area 
Middle Super Output Area 
Rural/Urban indicator 
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 (448.0 and I78.0 in ICD-9 and ICD-10, respectively) as over 70% of patients 
with pulmonary AVMs have underlying HHT117. Thus three extracts were 
provided for patients who had undergone embolisation; those coded with an 
“arteriovenous fistulae of pulmonary vessels” only, those coded as HHT only and 
those coded as both. These data were linked to ONS mortality records to detect 
any patients that subsequently died.  
7.2.2  Data management and analysis 
We combined the three extracts described above to produce the final dataset for 
analysis. A unique HES-assigned identification number is provided to identify 
individuals (generated by an algorithm that may combine information including 
sex, date of birth, NHS number, postcode of residence and provider code)205 and 
thus allows distinction between multiple procedures undertaken in the same 
patient or the appearance of the same patient in different extracts and prevents 
inadvertent double counting. 
The data extract provided contained records on 540 procedures. 12 records were 
dropped from analysis as they were coded as having been admitted under the 
specialties of neurology or neurosurgery (likely to be treatment of cerebral 
AVMs). 55 records were excluded from analysis as the procedure code did not 
specify embolisation in the lung and the diagnosis code contained only HHT (with 
no code specifying pulmonary AVMs) thus, again, we could not safely assume 
the procedure was specific to the pulmonary circulation. 
We undertook a descriptive analysis looking at the age and sex distribution of 
procedures undertaken, numbers of procedures by year, by admitting speciality 
and by geographical location (postcode area of patient residence). We calculated 
the median length of stay (by looking at the surrogate of ‘duration of episode’ 
which is the difference between date of admission and date of discharge) and 
analysed any deaths occurring in patients after the procedure (looking at cause 
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of death and time of death relative to admission date for the procedure) to help 
determine whether they could have been as a result of the intervention. 
 
7.3 Results 
7.3.1  Procedure demographics 
Data were available on a total of 473 procedures undertaken in 340 individuals 
over the period between 1997–2011. Of those 340 individuals, 62% were 
female. Table 7.2 shows the procedure codes searched for, with by far the 
majority coded as “Percutaneous transluminal embolisation of pulmonary 
artery”. The annual number of procedures (Figure 7.1) shows a gradual increase 
in the number of embolisations undertaken up to a peak in 2003 and then for 
following years the numbers vary between 23 to 44 per year. There was a wide 
age range of individuals undergoing embolisation (from 2 to 78 years) with the 
most procedures undertaken in the age group 40 to 49 years (Figure 7.2). A 
geographical map of the postcode area of residence of patients undergoing the 
procedure (Figure 7.3) showed variation across the UK, with the most embolised 
patients residing in postcode areas of; Portsmouth, Bristol, Newcastle and 
Northwest London. The median length of stay was 2 nights (interquartile range 
(IQR) 2-2) and 6% of embolisations had an episode duration of zero days 
suggesting they were day case procedures. Respiratory medicine is the 
admitting specialty for the vast majority of embolisations undertaken with many 
fewer admissions coded under cardiology, general medicine and radiology (Table 
7.3). The median number of procedures undertaken per patient was one (range 
1-7) with 25% needing at least one repeat procedure (Table 7.4). 
 
 
176 
 
Table 7.2. Codes identified in the health episode statistics database considered 
pertinent to embolisation of pulmonary arteriovenous malformations and 
included in the subsequent analysis. 
 
Procedure type Procedure 
code 
Number of  
procedures 
% 
Percutaneous transluminal embolisation of pulmonary 
artery 
L132 443 93.7 
Embolisation of arteriovenous abnormality not elsewhere 
classified (NEC) 
L753 24 5.1 
Percutaneous transluminal embolisation of arteriovenous 
malformation (NEC) 
L754 5 1.1 
Percutaneous transluminal venous embolisation of 
arteriovenous malformation 
L755 1 0.2 
Total  473  
 
 
 
 
Figure 7.1. Annual number of percutaneous embolisation procedures 
performed between 1997 and 2010 in England
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Figure 7.2. Patient age at first embolisation procedure 
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Figure 7.3. Geographical map by postcode area of patient residence of those 
undergoing percutaneous embolisation (by number of patients). 
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Table 7.3. Number of procedures performed stratified by admitting speciality 
 
Specialty Procedure number % 
 
Respiratory Medicine 417 88.2 
General Medicine 15 3.2 
Cardiology 15 3.2 
Radiology 15 3.2 
Cardiothoracic surgery 4 0.9 
A+E 2 0.4 
Other* 5 1.1 
Total 473  
  *General surgery, ENT, Gastroenterology, Infectious Diseases, Paediatrics 
 
 
 
 
 
Table 7.4. Number of patients undergoing multiple procedures. 
 
Procedure number Number of patients % 
 
1 253 74.4 
2 61 17.9 
3 16 4.7 
4 5 1.5 
5 2 0.6 
6 1 0.3 
7 2 0.6 
Total 340  
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7.3.2  Mortality 
No patients died within 7 days of any individual procedure, though two died 
within 30 days. Of those two deaths, one was due to bronchiectasis and the 
second was attributed to a pulmonary AVM. 35 patients were recorded as having 
died at some time point following their embolisation. In those patients that 
subsequently died, most did so several years after their admission for 
embolisation (median time interval 3.3 years (IQR = 1.8-5.9). The commonest 
causes of subsequent death were malignancy (N=11) or HHT itself (N=5) (Table 
7.5). 
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Table 7.5. Mortality data citing cause of death in all patients (coded as PAVM, HHT or both) who underwent an interventional procedure. 
Extract 
filter (HHT, 
PAVM, 
Both) 
Cause of death  Procedure 
code 
n Death 
within 7 
days of 
admission 
Death 
within 30 
days of 
admission 
Comments 
HHT Acute  MI 410 1 N N  
PAVM Intracerebral haemorrhage 431 1 N N  
HHT Acute anaemia due to blood loss 4480 1 N N  
PAVM Progressive spinal ataxia 7473 1 N N  
PAVM Malignant neoplasm of stomach, unspecified C169 1 N N  
PAVM 
PAVM  
Malignant neoplasm of unspecified part of 
bronchus or lung  
C349 2 N N  
PAVM  Malignant neoplasm of breast of unspecified site C509 1 N N  
PAVM Malignant neoplasm of kidney, except renal pelvis C64 1 N N  
PAVM Malignant neoplasm without specified site C80 1 N N  
PAVM Acute myeloblastic leukaemia C920 1 N N  
HHT Acute promyelocytic leukaemia C924 1 N N  
PAVM Chronic ischaemic heart disease, unspecified I259 1 N N  
Both Primary pulmonary hypertension I270 1 N N  
PAVM 
HHT 
HHT 
Both 
Hereditary haemorrhagic telangiectasia I780 4 N 
N 
N 
N 
N 
N 
N 
N 
 
Both Bronchopneumonia, unspecified organism J180 1 N N  
PAVM Pneumonia, unspecified organism J189 1 N N  
HHT COPD with acute LRTI J440 1 Y N Died day 7 
HHT COPD J449 1 N N  
PAVM Bronchiectasis J47 1 N Y Death within 10d  
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HHT Pneumonitis due to inhalation of food and vomit J690 1 N N  
Both Biliary cirrhosis, unspecified K745 1 N N  
HHT Other and unspecified cirrhosis of liver K746 1 N N  
PAVM Car driver injured in collision with car, pick-up 
truck or van in traffic accident 
V435 1 N N  
PAVM Unspecified fall W190 1 N N  
 Total  29    
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7.4 Discussion 
7.4.1 Summary 
This is the first nationally representative study in England to investigate the 
geographical and temporal trends and mortality after radiological embolisation of 
pulmonary arteriovenous malformations. The annual number of procedures 
increased until 2003 and then plateaued while the mortality associated with 
pulmonary embolisation is low. 
 
7.4.2 Strengths and limitations 
One particular strength of our analysis is that the HES data allows us to consider 
a relatively large number of procedures undertaken over a long time period, with 
linkage to ONS cause of death statistics. These data are representative of all 
eligible procedures undertaken in England over this time period, and this 
approach provides a national audit of the mortality after this procedure. 
 
This study has a number of limitations to consider. Firstly, the majority of 
procedures included were coded as “percutaneous transluminal embolisation of 
pulmonary artery” rather than a code that was specific for embolisation of a 
pulmonary arteriovenous malformation. Given that the second data filter 
searched specifically for individuals with codes for pulmonary AVMs and/or HHT, 
we believe that we are identifying relevant embolisation procedures in the 
correct patient group. Secondly, though we were provided with data related to 
procedural mortality, we did not have any reliable data concerning complication 
rates associated with the procedure. Thirdly, we did not have information related 
to the centre where the patient was treated so we are unable to map procedure 
activity across England stratified by treating centre. Finally, while there were two 
deaths within 30 days of a procedure (due to bronchiectasis and a pulmonary 
AVM), the relation of these events to the intervention is not clear, and hence we 
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are unable to distinguish between mortality as result of emergency interventions 
to prevent haemoptysis as opposed to direct complications of the procedure in 
previously stable patients with these diseases. As a consequence, a mortality 
rate of 0.4% per procedure can be considered the upper limit of mortality rate 
attributable to the intervention, with a lower limit of 0%.  
 
7.4.3 Interpretation of results 
The number of procedures undertaken for those patients coded with PAVMs or 
HHT increased over the time period from 1997 to 2003 which may reflect an 
increased ascertainment of PAVMs considered treatable by vascular embolisation 
or a move away from surgical intervention as an alternative treatment option. 
Since 2004 there have been approximately 25 to 40 procedures annually. Most 
procedures are undertaken in those aged 40 to 49 years which corresponds with 
the mean age of diagnosis of PAVMs at 43 years23. Two-thirds of treated patients 
were female, which is consistent with observations that there is a higher 
diagnostic rate of both HHT and PAVMs in women108,206. The wide variation 
across England in embolisation rates when stratified by geographical area may 
partly be due to differences in the diagnosed prevalence of HHT across 
England108 as it may exist in clusters of affected family members given its 
autosomal dominant pattern of inheritance. That the vast majority of patients 
are under the care of respiratory medicine is unsurprising as most patients with 
HHT are referred to the speciality for screening to detect potential PAVMs. Just 
over a quarter (26%) of patients had multiple episodes associated with 
embolisation on different dates which we assumed to be due to multiple 
interventions. There are several possible explanations as to why patient may 
have undergone repeated procedures; some patients may have required ‘staged’ 
embolisation procedures, usually as a result of the number of PAVMs needing 
treatment; some patients may have experienced a reperfusion of previously 
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treated lesions, development of a new lesion or growth of previously small 
untreatable lesions that became sizeable enough to require a further 
embolisation. Our data did not allow us to distinguish between these different 
indications for a repeat intervention.  
 
7.4.4 Conclusion 
Our analysis of a representative database of embolisation procedures for 
pulmonary AVMs undertaken across England suggests the procedure is 
associated with a low mortality (0.4% at most). Establishing a national database 
of patients undergoing the procedure, would allow the identification of any 
significant mortality or morbidity related to embolisation. These data are of 
importance for both physicians and radiologists when counselling patients with 
pulmonary AVMs who are considered potentially suitable for embolotherapy. 
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 CHAPTER 8: CONCLUSIONS AND FUTURE RESEARCH  
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8.1 Summary 
During my period of research as demonstrated by this thesis I have been able to 
more clearly describe the epidemiology of hereditary haemorrhagic 
telangiectasia in the UK, including its complications and associated mortality and 
have demonstrated the relative safety and effectiveness of percutaneous 
embolisation as a treatment for pulmonary arteriovenous malformations (a 
common complication of the disease). This work has culminated in the 
publication of two papers in peer-reviewed journals, with a further two currently 
under consideration by editors, and several abstracts presented at international 
conferences.  
The main findings are; 
 
1. Trends in prevalence of HHT across the UK 
The diagnosed prevalence of HHT within the UK is at least 1.06 per 10,000 (95% 
CI: 0.95-1.17) (or 1 per 9,400 individuals), has been stable over the decade 
2000-2010 and is in line with estimates from other countries worldwide. The 
true UK prevalence is likely to be higher than our diagnosed prevalence as many 
cases remain clinically undetected. A diagnosis of HHT is more commonly made 
in females (PRR 1.59, 95% CI: 1.30-1.94), and those from higher socioeconomic 
groups (PRR 1.74, 95% CI: 1.14-2.64). This pattern may partly reflect an 
ascertainment bias associated with an increased attendance of females to 
primary care (due, for example, to consultation for contraception and child 
health issues) though may also be a reflection of the role of oestrogens (and/or 
genetic influences) on the manifestation of disease complications. Differences in 
usage of primary care services across socioeconomic groups may partly explain 
the different prevalences of the disease when stratified for markers of social 
deprivation.  HHT prevalence varies twofold throughout different geographical 
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regions as defined by UK health authority, which may be as a result of 
ascertainment bias or clustering of affected cases due to the pattern of 
inheritance of HHT.  
 
2. Complications associated with HHT.  
We characterised the risk of developing certain complications of HHT in a 
representative population of patients from the UK when compared with 
unaffected controls. Bleeding complications, including anaemia, epistaxis, 
haemoptysis and gastrointestinal haemorrhage were commoner in those with 
HHT, as were several significant neurological sequelae including 
ischaemic/embolic stroke, cerebral abscess and migraine. Of the cardiovascular 
comorbidities analysed, only cardiac failure was found to more common in those 
with HHT, though not the prevalence of ischaemic heart disease or myocardial 
infarction. Bowel cancer was commoner in HHT cases (OR 2.76, 95%CI 1.11-
6.85) likely as a consequence of the overlap between HHT and juvenile polyposis 
syndrome (with the latters’ association with increased risk of gastrointestinal 
malignancy) linked to the gene SMAD 4, common to both. There was no 
discernable difference in rates of other solid organ tumours.   
 
3. Mortality associated with HHT.   
Mortality in patients with HHT compared to their age, sex and general practice-
matched controls was significantly higher with a hazard ratio for death of 2.03 
(95% CI 1.59-2.60). Median age at death was decreased by 3 years in those 
with HHT compared to controls. Whilst our data do not allow us to investigate 
the cause of death for these patients, it is likely that the disease itself confers 
some of the increased mortality by virtue of the significant complications that 
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are associated with it such as stroke, cerebral abscess and significant 
haemorrhage112. Survival in HHT did not differ by sex but was higher in those 
from the most affluent socioeconomic group when compared to the least (HR 
1.15, CI 1.04-1.27, p=0.007). The survival advantage associated with higher 
socioeconomic status has been demonstrated in a variety of other diseases207-
209. 
 
4. Evidence for safety and effectiveness of embolotherapy for pulmonary 
arteriovenous malformations.  
The commonest minor complications associated with percutaneous embolisation 
were pleuritic and ischaemic chest pain. There was a major complication rate of 
1% associated with procedures (these were due to a death (sepsis following 
pulmonary infarct), stroke, venous thromboembolism and haemopericardium 
due to cardiac perforation). Overall, there is a very low mortality associated with 
embolisation in the published literature. 
Our calculated procedural success rate is 84% per patient, or 90% per PAVM 
over a median follow-up period of 41 months. Thus, approximately 15% of 
patients potentially require a repeat embolisation procedure for persistent 
lesions at follow-up. Recanalisation is the commonest mechanism for persistence 
of a previously embolised PAVM lesion (occurring in 75% of persistent lesions 
identified). It is suggested that improved embolisation strategies, better 
operator experience and updated embolisation materials and devices will be 
required to reduce recanalisation, and persistence rates further. 
Overall we conclude that embolisation is a safe and effective procedure for the 
management of pulmonary AVMs, though caution that smaller, less experienced 
centres should be aware of their own success and complication rates when 
counselling patients undergoing embolisation.  
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5. Mortality of embolisation undertaken for pulmonary arteriovenous 
malformations in England.  
Since 2004 there have been approximately 25 to 40 embolisation procedures 
annually within England. A quarter of all those embolised require a subsequent 
procedure. There is a geographical variation in the region of residence of those 
undergoing the procedure which may be related to genetic clustering of the 
disease HHT. Mortality associated with the procedure is, at most, 0.4% but may 
be as low as zero. It should be of reassurance to patients and interventional 
radiologists that our representative sample of embolisations has a low 
procedural mortality that is comparable to that suggested by the worldwide 
literature included in our meta-analysis study described above. 
 
8.2 Ongoing work 
In parallel with the epidemiological research undertaken we have also been 
collecting samples for a genetic study into HHT. The aim of this part of research 
is to obtain a cross sectional sample of salivary DNA from both HHT patients and 
unaffected related controls to allow analysis using novel high throughput genetic 
sequencing techniques to better characterise the genetic basis of HHT.  
Our specific objectives are; 
 Identify new polymorphisms associated with disease causing mutations in 
patients with HHT.  
 Discover new gene loci potentially associated with the disease and in 
particular with the development of the pulmonary arterio-venous 
malformation phenotype 
 Attempt to more closely correlate disease-causing genetic mutations with 
specific complications of the disease (analysis of the genotype-phenotype 
interaction). 
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 Discover moderator genes that may influence the expression of disease 
causing genes in hereditary haemorrhagic telangiectasia. 
 
A significant minority of patients with clinically suspected or confirmed HHT do 
not test positive for known mutations. This has implications for screening in their 
families. Given the significant clinical variability between sufferers of HHT it 
remains possible that rare, low frequency alleles, so far unrecognised, may have 
major roles to play in the phenotype of this variable disease.  
To search for new polymorphisms associated with known HHT genes involves 
sequencing the exomes of  HHT patients and identifying sequences of interest 
that appear in multiple HHT patients in the region of known HHT loci. These 
sequences can then be compared to a database of already discovered 
polymorphisms210. If the polymorphisms have not been previously identified they 
are then compared to the 1000 Genome project database (a database of the 
complete genetic sequence of 1000 ‘healthy’ individuals) to see if they are 
‘normal variants’ in the human population211. If not, they could represent 
candidate polymorphisms involved in the HHT phenotype. 
To search for novel gene loci associated with the disease requires a case-control 
design. Patients with HHT (cases) are subject to whole exome sequencing 
alongside their unaffected first-degree relatives (controls). We will use a 
combination of the most relevant sequencing approaches including targeted 
sequencing, whole exome sequencing and the recently developed whole exome 
chip. Targeted sequencing, as the name implies, relies on sequencing a pre-
selected area of the genome thought to be relevant to the disease. When looking 
for novel mutations this approach can lead to investigators ‘missing’ an area of 
importance in the genome. The advantage of whole exome sequencing is that it 
allows all the exons of an individual to be sequenced thus covering significantly 
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larger areas of potential interest without the selection bias212. However, this 
comes at a substantially increased cost, so complimentary sequencing 
approaches will be employed.  
We have currently collected a total of 67 salivary DNA samples, 37 from possible 
HHT cases and 30 from their relatives (presumed to be unaffected based on a 
questionnaire sent to all participants in the study asking about specific 
symptoms of the disease and whether they had ever received a formal diagnosis 
of HHT or were followed-up by a specialist clinic). We looked to see whether any 
of the cases or controls had undergone specific genetic testing for HHT 
mutations and if so whether any common mutations were identified (ENG, 
ACVRL 1 and SMAD 4). After excluding patients with known mutations or without 
comparable samples from first-degree relatives, we identified a total of 7 paired 
samples in for further testing. These salivary DNA samples are currently stored 
awaiting initially to be tested first for the three common mutations, and if 
negative for all, will proceed to high throughput gene sequencing. Further 
research publications from this data will depend on any pertinent findings as a 
result of this genetic sequencing.  
 
8.3 Recommendations for future research 
Suggestions for potential further research projects are divided into those that 
arise as an extension of the epidemiological findings in this thesis, and those 
that may be explored in the context of UK-wide advances in genetics and 
genomics research.   
Some of the limitations of the research described in this thesis could form the 
basis for further study.  
Validation study of HHT diagnoses 
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Whilst several studies have attempted to validate the diagnoses coded within 
THIN in patients with commoner pathologies such as chronic kidney disease or 
cardiovascular disease, none has been published in HHT. Such a validation study 
would require a sample of patient notes to be reviewed to confirm that a 
diagnosis of HHT in the notes was accurately coded in THIN by practice 
administrators. This may strengthen the validity of our prevalence estimates for 
HHT within THIN. In addition, it was not possible to determine by what criteria 
patients within THIN were diagnosed as having HHT. We do not know what 
proportion of patients were diagnosed based on clinical criteria alone compared 
with those that had a positive gene test. This information may be available from 
patient notes/genetic databases and could further strengthen the validity of a 
diagnosis coded in THIN, particularly if the proportion of diagnoses made using 
gene testing (the current ‘gold standard’ in those patients with mutations 
amenable to detection) was relatively high. This data may also provide insight 
into UK trends in the use of gene testing as part of the diagnostic pathway.  
 
Investigation into the sex bias in diagnosed rates of HHT 
We identified a significantly larger proportion of females diagnosed with HHT 
which may be as a result of ascertainment bias due to females consulting 
behaviours in primary care but could also potentially be due to biological or 
genetic factors that influence the presentation of the HHT phenotype. Published 
literature offers conflicting observations on the existence of a bias in sex. A 
study in a larger patient cohort, derived, for example, from the USA may provide 
more statistical power to confirm a difference. In addition, a larger patient 
cohort may also allow exploration of the relationship between pregnancy and the 
use of hormonal treatments, including the oral contraceptive, on diagnosed rates 
of HHT which may support a role for biological factors in the disease phenotype. 
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We were unable to look at this specifically in our THIN cohort due to low 
statistical power from small numbers and missing data.  
 
Complications associated with HHT 
Our recorded complication rates for patients with diagnosed HHT appeared to be 
lower than those in the published literature worldwide, mainly derived from non-
epidemiological studies. This may be due to lower ascertainment of 
complications from an epidemiological database or may actually be more 
accurate as a result of discerning a more representative sample. We do not 
know what proportion of our patients coded in THIN were diagnosed as ‘possible’ 
or ‘definite’ HHT clinically by use of the Curacao criteria which has variable 
sensitivity and specificity for the diagnosis of HHT depending on the number of 
criteria fulfilled. It may be that we had a higher rate of ‘possible’ HHT diagnoses 
within our cohort and that lower complication rates reflected a proportion of 
patients included in the cohort who had a milder phenotype of disease or did 
not, in fact, have HHT. A prospective study recruiting a large number of patients 
from a representative sample and collecting regular data on complications would 
be the ideal way to study the natural history of the HHT phenotype and 
complication rates in both treated and untreated individuals.   
 
Mortality associated with HHT 
Whilst we demonstrate a two-fold increase in the hazard ratio for death in 
patients with HHT compared to age and sex matched control subjects we were 
not able to attribute this mortality directly to complications associated with HHT. 
Linkage to ONS data regarding death certification or direct review of a sample of 
patients’ clinical records would allow us to be more explicit about whether HHT 
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or its complications confer a higher mortality in this patient population or 
whether death was attributable to other factors not directly linked to the disease 
itself. This is important, as if the former, it would strengthen the argument for 
more proactive approaches to patient screening/diagnosis and the offering of 
evidence-based therapeutic interventions (such as treatment for PAVMs and 
possibly CAVMs) in this population.  
 
Validation study of codes for embolisation of PAVMs 
The majority of the patients in our study described in chapter 7 were coded as 
having undergone “Percutaneous transluminal embolisation of pulmonary artery 
” with the assumption made that, in the context of HHT, this meant a 
therapeutic intervention specifically for PAVMs. This assumption could be tested, 
again by a review of a sample of patient notes to ensure that the validity of 
coding of the procedure. 
 
Complication rates for embolisation and performing centres in England.  
It would be informative to use the HES data to characterise the complication 
rates associated with embolisation of PAVMs in England (given that we had 
access only to mortality data). We could further identify the centres where the 
procedures were actually undertaken, rather than the geographical areas from 
which the patients undergoing embolisation were referred from. This would allow 
us to look at procedural activity throughout England, and identify areas where 
the population were not served by a ‘local’ centre undertaking embolisation. This 
would offer an important insight into areas of the country where patients may 
have to travel significant distances for appropriate treatment.  With these data, 
we may also be able to comment on which performing centres had lower 
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complication rates for embolisation, both compared to published complication 
rates from ‘HHT Centres of Excellence’ and with other centres in England. Whilst 
these findings may be contentious, they could potentially be used facilitate the 
linking of more experienced centres with those who perform fewer procedures, 
or have less good outcomes in a bid to improve standards of patient care. 
We did submit a request for these data from the Health and Social Care 
Information Centre (the guardians of HES data) but experienced significant 
delays in the response to our data extract request and had to complete this 
thesis in the absence of this additional data.  
 
Follow-up screening protocols for patients with diagnosed and/or treated 
pulmonary AVMs 
Current guidelines recommend screening follow-up at 6-12 months post 
embolisation (with multi-detector CT) in patients with treated pulmonary AVMs 
and thereafter, every 3 years 27. These guidelines are based on expert opinion 
rather than evidence. Recently concerns have been raised that patients screened 
and treated for pulmonary AVMs may be exposed to an unacceptably high risk of 
radiation213. Radiation exposure is greatest in those undergoing interventional 
therapy for PAVMs but is also associated with repeated thoracic CT screening 
protocols. This is especially pertinent in those patients who are relatively young 
and may need long-term follow-up, or are female or pregnant, given the 
radiation exposure risk to the breast or foetus. In the cited study, 11% (26 
patients) received a cumulative effective dose of in excess of 100 millisieverts 
(mSv) which is the level at which there is considered to be good evidence for a 
significant risk of harm and an excess lifetime cancer risk of 1%. Whilst TTCE 
can be used as a repeat screening tool in those previously negative for PAVMs, 
given that it can remain positive214 (due to collateral microcirculation) in patients 
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following treatment for PAVMs it is not considered a useful follow-up imaging 
method in this patient cohort, and as such, ‘radiation heavy’ screening methods 
such as thoracic CT are more commonly considered. Future studies should look 
at cumulative radiation exposure stratified by number and type of PAVMs 
(embolised or unembolised) and may suggest safer, more effective or at least 
more evidence-based screening protocols for these patients.  
 
Future research using clinical databases and genetic techniques 
The UK government published, in 2012, its strategy for rare diseases215 which 
places research high on the agenda and recognises specifically that using genetic 
databases and next generation sequencing techniques is key to advancing our 
knowledge base. Many outstanding questions regarding HHT, its clinical 
presentation, diagnosis, complications and appropriate management could 
usefully be addressed by the development of a UK-wide or indeed worldwide 
registry of HHT patients with data collected on patient demographics, disease 
phenotype and genetic mutations. Such a comprehensive database does not 
currently exist. Genetic mutations are collected worldwide and are available 
online at the HHT mutation database36, but this does not link directly with 
individual patient demographics or clinical data. Several recent UK-based 
initiatives, described below, may provide useful data in the medium to long-
term.    
A) RD-Connect 
This initiative led by the University of Newcastle Upon Tyne, is developing a 
unique global infrastructure that links up databases, registries, biobanks and 
clinical bioinformatics data used in rare disease216. 
B) UK Biobank 
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UK Biobank aims to investigate the respective contributions 
of genetic predisposition and environmental exposure (including nutrition, 
lifestyle, medications etc.) to the development of certain diseases217. Though the 
focus is predominantly on common and chronic diseases such as cancer, heart 
disease, stroke and diabetes, there may be useful data gleaned on those 
patients who develop rarer inherited diseases such as HHT. Between 2006-2010 
UK Biobank recruited 500,000 people aged between 40-69 from across the UK to 
provide demographic and clinical data, blood/urine/saliva samples for future 
analysis, and who agreed to have their health followed over the long-term. This 
has the potential to be a powerful resource for looking at the genotype-
phenotype correlation in any patients included who are diagnosed with HHT and 
also for investigating rare genetic variants associated with HHT in patients who 
do not test positive for an identifiable mutation (currently 15% of cases). 
However, given the size of the database and the prevalence of HHT we would 
not expect to have significant numbers of HHT cases included in UK Biobank 
archives until the database expands to recruit more of the UK population (for 
example, in a database of 500,000 and a minimum prevalence of HHT of 1 per 
9,400, we would expect just over 50 patients to be included). Most of the larger 
genetic studies in HHT worldwide report on cohorts of between 150-200 
patients.  
C) 100,000 Genomes project 
Launched in late 2012 with the aim to sequence 100,000 genomes by 2017, the 
main focus of this research project is on patients with rare disease and their 
families as well as patients with cancer211. A total of 3 million people in the UK 
are affected by a rare disease, which is 1 in 17 or 6-7% of the whole population. 
Samples will be obtained from 75,000 people, with 40,000 being patients with 
disease. About 15,000 patients in total will be included from those with a rare 
disease. This data, which will be obtained using cutting edge high throughput 
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gene sequencing techniques may help us to understand in more detail the role of 
genetics in moderating the phenotypic presentation of HHT cases.  
Ultimately, these genetic databases will take time to recruit and none are 
specifically focussed upon HHT. The priority should be to establish a national or 
international register of suspected or confirmed cases of HHT with the aim to 
facilitate further clinical studies in larger patient cohorts and encourage a 
collaboration between the relatively few specialist centres worldwide with a 
research interest in HHT.   
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 APPENDICES 
10.1 APPENDIX 1 - OPCS-4 codes for interventional procedures that may 
have been undertaken as treatment of pulmonary arteriovenous 
malformations. 
Procedure OPCS-4 code 
Percutaneous transluminal embolisation of pulmonary artery                                         L13.2 
Percutaneous transluminal embolisation of major systemic to pulmonary 
collateral artery            
L69.3 
Percutaneous transluminal embolisation of artery                                                         L71.3 
Embolisation of arteriovenous abnormality NEC                                                          L75.3 
Percutaneous transluminal embolisation of arteriovenous malformation NEC                L75.4 
Percutaneous transluminal venous embolisation of arteriovenous 
malformation            
L75.5 
Percutaneous transluminal arterial and venous embolisation of arteriovenous 
malformation  
L75.6 
Percutaneous transluminal coil embolisation of small aneurysm of artery                     O01.1 
Percutaneous transluminal coil embolisation of medium aneurysm of artery                  O01.2 
Percutaneous transluminal coil embolisation of large aneurysm of artery                      O01.3 
Percutaneous transluminal coil embolisation of giant aneurysm of artery                      O01.4 
Other specified transluminal coil embolisation of aneurysm of artery                             O01.8 
Unspecified transluminal coil embolisation of aneurysm of artery                                 O01.9 
Percutaneous transluminal balloon assisted coil embolisation of three or more 
aneurysms of artery 
O02.1 
Percutaneous transluminal balloon assisted coil embolisation of two 
aneurysms of artery  
O02.2 
Percutaneous transluminal balloon assisted coil embolisation of single 
aneurysm of artery 
O02.3 
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Other specified transluminal balloon assisted coil embolisation of three or 
more aneurysms of artery                                                                                                                           
O02.8 
Unspecified transluminal balloon assisted coil embolisation of three or more 
aneurysms of artery 
O02.9 
Percutaneous transluminal stent assisted coil embolisation of three or more 
aneurysms of artery 
O03.1 
Percutaneous transluminal stent assisted coil embolisation of two aneurysms 
of artery 
O03.2 
Percutaneous transluminal stent assisted coil embolisation of single aneurysm 
of artery 
O03.3 
Other specified transluminal stent assisted coil embolisation of aneurysm of 
artery    code  
O03.8 
Unspecified transluminal stent assisted coil embolisation of aneurysm of 
artery         
O03.9 
Percutaneous transluminal liquid polymer embolisation of aneurysm of artery            O04.1 
Percutaneous transluminal stent assisted liquid polymer embolisation of 
aneurysm of artery 
O04.2 
Other specified other transluminal embolisation of aneurysm of artery                        O04.8 
Unspecified other transluminal embolisation of aneurysm of artery                           O04.9 
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10.2 APPENDIX 2 - Read codes used to identify potential complications 
of HHT and associated cardiovascular comorbidities and 
malignancies 
 
Anaemia 
Description Medcode 
H/O: anaemia 145..11 
H/O: anaemia - iron deficient 1451.00 
Iron deficiency anaemias D00..00 
Hypochromic - microcytic anaemia D00..11 
Microcytic - hypochromic anaemia D00..12 
Iron deficiency anaemia due to chronic blood loss D000.00 
Normocytic anaemia due to chronic blood loss D000.11 
Iron deficiency anaemia due to blood loss D000.12 
Other specified iron deficiency anaemia D00y.00 
Microcytic hypochromic anaemia D00y100 
Other specified iron deficiency anaemia NOS D00yz00 
Unspecified iron deficiency anaemia D00z.00 
Iron deficiency anaemia NOS D00zz00 
[X]Other iron deficiency anaemias Dyu0000 
Acute posthaemorrhagic anaemia D211.00 
Normocytic anaemia following acute bleed D211.11 
Chronic anaemia D214.00 
 
 
 
 
 
227 
 
Arteriovenous Malformations 
Description Medcode 
Arteriovenous fistula of pulmonary vessels G420.00 
Arteriovenous malformation P76D.00 
Congenital cerebral arteriovenous aneurysm P7y0100 
Congenital arteriovenous fistula of brain P7y0111 
Pulmonary arterio-venous aneurysm P736.00 
Pulmonary arterio-venous fistula P736.11 
Pulmonary arterio-venous malformation P736.12 
Pulmonary artery aneurysm P737.00 
Percutaneous transluminal embolisation of arteriovenous 
malformation NEC 
7A61500 
Percutaneous transluminal venous embolisation of 
arteriovenous malformation 
7A61600 
Percutaneous transluminal arterial venous embolisation of 
arteriovenous malformation 
7A61700 
 
Breast Cancer 
Description Medcode 
Juvenile breast carcinoma BB94.00 
Secretory breast carcinoma BB94.11 
Malignant neoplasm of female breast B34..00 
Ca female breast B34..11 
Malignant neoplasm of nipple and areola of female breast B340.00 
Malignant neoplasm of nipple of female breast B340000 
Malignant neoplasm of areola of female breast B340100 
Malignant neoplasm of nipple or areola of female breast NOS B340z00 
Malignant neoplasm of central part of female breast B341.00 
Malignant neoplasm of upper-inner quadrant of female breast B342.00 
Malignant neoplasm of lower-inner quadrant of female breast B343.00 
Malignant neoplasm of upper-outer quadrant of female breast B344.00 
Malignant neoplasm of lower-outer quadrant of female breast B345.00 
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Malignant neoplasm of axillary tail of female breast B346.00 
Malignant neoplasm, overlapping lesion of breast B347.00 
Malignant neoplasm of other site of female breast B34y.00 
Malignant neoplasm of ectopic site of female breast B34y000 
Malignant neoplasm of other site of female breast NOS B34yz00 
Malignant neoplasm of female breast NOS B34z.00 
Carcinoma in situ of breast and genitourinary system B83..00 
Carcinoma in situ of breast B830.00 
Lobular carcinoma in situ of breast B830000 
Intraductal carcinoma in situ of breast B830100 
Paget's disease and infiltrating breast duct carcinoma BB9K.00 
Paget's disease and intraductal carcinoma of breast BB9K000 
Personal history of malignant neoplasm of breast ZV10300 
Lobular carcinoma in situ BB9E.00 
Intraductal carcinoma and lobular carcinoma in situ BB9E000 
Lobular carcinoma NOS BB9F.00 
Infiltrating ductular carcinoma BB9G.00 
 
Cardiac Failure 
Description Medcode 
Heart failure G58..00 
Cardiac failure G58..11 
Congestive heart failure G580.00 
Congestive cardiac failure G580.11 
Right heart failure G580.12 
Right ventricular failure G580.13 
Biventricular failure G580.14 
Acute congestive heart failure G580000 
Chronic congestive heart failure G580100 
Decompensated cardiac failure G580200 
Compensated cardiac failure G580300 
Congestive heart failure due to valvular disease G580400 
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Left ventricular failure G581.00 
Asthma - cardiac G581.11 
Pulmonary oedema - acute G581.12 
Impaired left ventricular function G581.13 
Acute left ventricular failure G581000 
Acute heart failure G582.00 
Heart failure with normal ejection fraction G583.00 
HFNEF - heart failure with normal ejection fraction G583.11 
Right ventricular failure G584.00 
Heart failure NOS G58z.00 
 
Cerebral Abscess 
Description Medcode 
Drainage of abscess of brain tissue 7004000 
Aspiration of abscess of brain tissue 7008100 
Intracranial abscess F040.00 
Brain abscess F040.11 
Cerebral intracranial abscess F040000 
Cerebral abscess F040011 
Cerebellar intracranial abscess F040100 
Cerebellar abscess F040111 
Intracranial abscess NOS F040z00 
 
Colonic Cancer 
Description Medcode 
Malignant neoplasm of colon B13..00 
Malignant neoplasm of hepatic flexure of colon B130.00 
Malignant neoplasm of transverse colon B131.00 
Malignant neoplasm of descending colon B132.00 
Malignant neoplasm of sigmoid colon B133.00 
Malignant neoplasm of caecum B134.00 
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Carcinoma of caecum B134.11 
Malignant neoplasm of appendix B135.00 
Malignant neoplasm of ascending colon B136.00 
Malignant neoplasm of splenic flexure of colon B137.00 
Malignant neoplasm, overlapping lesion of colon B138.00 
Dukes stage A 4M10.00 
Dukes stage B 4M11.00 
Dukes stage C1 4M12.00 
Dukes stage C2 4M13.00 
Dukes stage D 4M14.00 
Personal history of malignant neoplasm of large intestine ZV10014 
Personal history of malignant neoplasm of rectum ZV10017 
 
Dyspnoea 
Description Medcode 
Breathlessness 173..00 
Breathlessness symptom 173..11 
Dyspnoea - symptom 173..12 
Shortness of breath symptom 173..13 
Breathless - moderate exertion 1732.00 
Breathless - mild exertion 1733.00 
Breathless - at rest 1734.00 
Shortness of breath 1739.00 
Short of breath on exertion 173C.00 
Dyspnoea on exertion 173C.11 
SOBOE 173C.12 
Breathless - strenuous exertion 173G.00 
MRC Breathlessness Scale: grade 1 173H.00 
MRC Breathlessness Scale: grade 2 173I.00 
MRC Breathlessness Scale: grade 3 173J.00 
MRC Breathlessness Scale: grade 4 173K.00 
MRC Breathlessness Scale: grade 5 173L.00 
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Breathlessness NOS 173Z.00 
O/E - dyspnoea 2322.00 
Dyspnoea R060A00 
Breathlessness R060D00 
 
Epistaxis 
Description Medcode 
Epistaxis symptom 1C6..11 
O/E - epistaxis 2D25.00 
Epistaxis R047.00 
Nose bleed symptom 1C6..00 
Has nose bleeds - epistaxis 1C62.00 
Nose bleed symptom NOS 1C6Z.00 
Nosebleed R047.11 
 
Epilepsy 
Description Medcode 
H/O: epilepsy 1473.00 
Epilepsy confirmed 1O30.00 
Epilepsy monitoring 667..00 
Epilepsy drug side effects 6677.00 
Epilepsy treatment changed 6678.00 
Epilepsy treatment started 6679.00 
Epilepsy control good 667C.00 
Epilepsy control poor 667D.00 
Epilepsy management plan given 667M.00 
Epilepsy monitoring NOS 667Z.00 
Seen in epilepsy clinic 9N0r.00 
Epilepsy monitoring call first letter 9Of5.00 
Epilepsy monitoring call second letter 9Of6.00 
Epilepsy monitoring call third letter 9Of7.00 
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Epilepsy F25..00 
Generalised nonconvulsive epilepsy F250.00 
Petit mal (minor) epilepsy F250000 
Epileptic absences F250011 
Epileptic seizures - atonic F250200 
Epileptic seizures - akinetic F250300 
Juvenile absence epilepsy F250400 
Other specified generalised nonconvulsive epilepsy F250y00 
Generalised nonconvulsive epilepsy NOS F250z00 
Generalised convulsive epilepsy F251.00 
Grand mal (major) epilepsy F251000 
Tonic-clonic epilepsy F251011 
Epileptic seizures - clonic F251200 
Epileptic seizures - myoclonic F251300 
Epileptic seizures - tonic F251400 
Tonic-clonic epilepsy F251500 
Other specified generalised convulsive epilepsy F251y00 
 
Family history of Ischaemic heart disease 
Description Medcode 
No FH: Ischaemic heart disease 1226.00 
No relevant family history 122..00 
No relevant FH: family history 122..11 
No FH: Cardiovascular disease 1224.00 
FH: Cardiovascular disease 12C..00 
FH: Angina 12C..14 
FH: Ischaemic heart dis. <60 12C2.00 
FH: Myocardial infarction < 60 12C2.11 
FH: MI- Myocardial infarct <60 12C2.12 
FH: Angina < 60yrs 12C2.13 
FH: Ischaemic heart dis. >60 12C3.00 
FH: Myocardial infarction > 60 12C3.11 
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FH: MI- myocardial infarct >60 12C3.12 
FH: Angina > 60yrs 12C3.13 
FH: Myocardial infarction 12C5.00 
FH: Coronary thrombosis 12C5.11 
FH: Ischaemic heart disease 12C5.12 
FH: Atherosclerosis 12C6.00 
FH myocardial infarction male first degree age known 12CA.00 
FH myocardial infarction male first degree age unknown 12CB.00 
FH myocardial infarction female first degree age known 12CC.00 
FH myocardial infarction female first degree age unknown 12CD.00 
FH angina male first degree age known 12CE.00 
FH angina male first degree age unknown 12CF.00 
FH angina female first degree age known 12CG.00 
FH angina female first degree age unknown 12CH.00 
 
Gastrointestinal bleeding 
Description Medcode 
GIB - Gastrointestinal bleeding J68z.11 
Gastric haemorrhage NOS J68z000 
Intestinal haemorrhage NOS J68z100 
Gastrointestinal tract haemorrhage NOS J68zz00 
 
Haemoptysis 
Description Medcode 
Blood in sputum - haemoptysis 172..00 
Blood in sputum - symptom 172..11 
Haemoptysis - symptom 172..12 
Haemoptysis R063.00 
Haemoptysis NOS R063z00 
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Haemothorax 
Description Medcode 
Haemothorax H51y200 
 
Headache 
Description Medcode 
Headache 1B1G.00 
C/O - a headache 1B1G.11 
Cephalgia 1B1G.12 
Generalised headache 1BA2.00 
Unilateral headache 1BA3.00 
Bilateral headache 1BA4.00 
Frontal headache 1BA5.00 
Occipital headache 1BA6.00 
Parietal headache 1BA7.00 
Temporal headache 1BA8.00 
Headache site NOS 1BAZ.00 
Aching headache 1BB1.00 
Throbbing headache 1BB2.00 
Shooting headache 1BB3.00 
Headache character NOS 1BBZ.00 
Referral to headache special interest general practitioner 8H4c.00 
Seen by general practitioner with special interest headache 9Nl7.00 
Vascular headache, not elsewhere classified F2X..00 
Vascular headache, not elsewhere classified Fyu5A00 
Chronic headache disorder Fyu5E00 
Headache R040.00 
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Hypertension 
Description Medcode 
On treatment for hypertension 662O.00 
Hypertension monitoring 662..12 
Good hypertension control 6627.00 
Poor hypertension control 6628.00 
Hypertension:follow-up default 6629.00 
Moderate hypertension control 662b.00 
Hypertension six month review 662c.00 
Hypertension annual review 662d.00 
Hypertension treatment. started 662F.00 
Hypertensive treatment changed 662G.00 
Hypertension clinical management plan 8CR4.00 
Referral to hypertension clinic 8HT5.00 
Hypertension treatment refused 8I3N.00 
Seen in hypertension clinic 9N03.00 
Hypertension monitored 9OIA.11 
Hypertensive disease G2...00 
BP - hypertensive disease G2...11 
Essential hypertension G20..00 
High blood pressure G20..11 
Malignant essential hypertension G200.00 
Benign essential hypertension G201.00 
Systolic hypertension G202.00 
Diastolic hypertension G203.00 
Essential hypertension NOS G20z.00 
Hypertension NOS G20z.11 
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Hypoxaemia 
Description Medcode 
Hypoxaemia R2y0100 
 
Intracerebral bleed 
Description Medcode 
Haemorrhagic stroke monitoring 662o.00 
Stroke due to intracerebral haemorrhage G61..12 
Intracerebral haemorrhage G61..00 
CVA - cerebrovascular accid due to intracerebral 
haemorrhage 
G61..11 
Cortical haemorrhage G610.00 
Internal capsule haemorrhage G611.00 
Basal nucleus haemorrhage G612.00 
Cerebellar haemorrhage G613.00 
Pontine haemorrhage G614.00 
Bulbar haemorrhage G615.00 
External capsule haemorrhage G616.00 
Intracerebral haemorrhage, intraventricular G617.00 
Intracerebral haemorrhage, multiple localized G618.00 
Intracerebral haemorrhage in hemisphere, unspecified G61X.00 
Left sided intracerebral haemorrhage, unspecified G61X000 
Right sided intracerebral haemorrhage, unspecified G61X100 
Intracerebral haemorrhage NOS G61z.00 
Other and unspecified intracranial haemorrhage G62..00 
Intracranial haemorrhage NOS G62z.00 
Subarachnoid haemorrhage G60..00 
Subarachnoid haemorrhage NOS G60z.00 
Sequelae of subarachnoid haemorrhage G680.00 
Sequelae of intracerebral haemorrhage G681.00 
Sequelae of other nontraumatic intracranial haemorrhage G682.00 
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Ischaemic Heart Disease 
Description Medcode 
Ischaemic heart disease G3...00 
Arteriosclerotic heart disease G3...11 
Atherosclerotic heart disease G3...12 
IHD - Ischaemic heart disease G3...13 
Acute myocardial infarction G30..00 
Attack - heart G30..11 
Coronary thrombosis G30..12 
Cardiac rupture following myocardial infarction (MI) G30..13 
Heart attack G30..14 
MI - acute myocardial infarction G30..15 
Thrombosis - coronary G30..16 
Silent myocardial infarction G30..17 
Acute anterolateral infarction G300.00 
Other specified anterior myocardial infarction G301.00 
Acute anteroapical infarction G301000 
Acute anteroseptal infarction G301100 
Anterior myocardial infarction NOS G301z00 
Acute inferolateral infarction G302.00 
Acute inferoposterior infarction G303.00 
Posterior myocardial infarction NOS G304.00 
Lateral myocardial infarction NOS G305.00 
True posterior myocardial infarction G306.00 
Acute subendocardial infarction G307.00 
Acute non-Q wave infarction G307000 
Acute non-ST segment elevation myocardial infarction G307100 
Inferior myocardial infarction NOS G308.00 
Acute Q-wave infarct G309.00 
Mural thrombosis G30A.00 
Acute posterolateral myocardial infarction G30B.00 
Acute transmural myocardial infarction of unspecified site G30X.00 
Acute ST segment elevation myocardial infarction G30X000 
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Other acute myocardial infarction G30y.00 
Acute atrial infarction G30y000 
Acute papillary muscle infarction G30y100 
Acute septal infarction G30y200 
Other acute myocardial infarction NOS G30yz00 
Acute myocardial infarction NOS G30z.00 
Other acute and subacute ischaemic heart disease G31..00 
Postmyocardial infarction syndrome G310.00 
Dressler's syndrome G310.11 
Preinfarction syndrome G311.00 
Crescendo angina G311.11 
Impending infarction G311.12 
Unstable angina G311.13 
Angina at rest G311.14 
Myocardial infarction aborted G311000 
MI - myocardial infarction aborted G311011 
Unstable angina G311100 
Angina at rest G311200 
Refractory angina G311300 
Worsening angina G311400 
Acute coronary syndrome G311500 
Preinfarction syndrome NOS G311z00 
Coronary thrombosis not resulting in myocardial infarction G312.00 
Other acute and subacute ischaemic heart disease G31y.00 
Acute coronary insufficiency G31y000 
Microinfarction of heart G31y100 
Subendocardial ischaemia G31y200 
Transient myocardial ischaemia G31y300 
Other acute and subacute ischaemic heart disease NOS G31yz00 
Angina pectoris G33..00 
Angina decubitus G330.00 
Nocturnal angina G330000 
Angina decubitus NOS G330z00 
Prinzmetal's angina G331.00 
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Variant angina pectoris G331.11 
Coronary artery spasm G332.00 
Angina pectoris NOS G33z.00 
Status anginosus G33z000 
Stenocardia G33z100 
Syncope anginosa G33z200 
Angina on effort G33z300 
New onset angina G33z600 
Stable angina G33z700 
Angina pectoris NOS G33zz00 
Other chronic ischaemic heart disease G34..00 
Coronary atherosclerosis G340.00 
Triple vessel disease of the heart G340.11 
Coronary artery disease G340.12 
Single coronary vessel disease G340000 
Double coronary vessel disease G340100 
Atherosclerotic cardiovascular disease G342.00 
Ischaemic cardiomyopathy G343.00 
Silent myocardial ischaemia G344.00 
Other specified chronic ischaemic heart disease G34y.00 
Chronic myocardial ischaemia G34y100 
Other specified chronic ischaemic heart disease NOS G34yz00 
Other chronic ischaemic heart disease NOS G34z.00 
Asymptomatic coronary heart disease G34z000 
Subsequent myocardial infarction G35..00 
Subsequent myocardial infarction of anterior wall G350.00 
Subsequent myocardial infarction of inferior wall G351.00 
Subsequent myocardial infarction of other sites G353.00 
Subsequent myocardial infarction of unspecified site G35X.00 
Certain current complications following acute myocardial 
infarction 
G36..00 
Haemopericardium as current complication following acute 
myocardial infarction 
G360.00 
Atrial septal defect as current complication following acute G361.00 
240 
 
myocardial infarction 
Ventricular septal defect as current complication following 
acute myocardial infarction 
G362.00 
Rupture of cardiac wall without haemopericardium as 
current complication following acute myocardial infarction 
G363.00 
Rupture of chordae tendinae as current complication 
following acute myocardial infarction 
G364.00 
Rupture of papillary muscle as current complication 
following acute myocardial infarction 
G365.00 
Thrombosis of atrium, auricular appendage, and ventricle 
as current complications following acute myocardial 
infarction 
G366.00 
Cardiac syndrome X G37..00 
Coronary microvascular disease G39..00 
Other specified ischaemic heart disease G3y..00 
Ischaemic heart disease NOS G3z..00 
 
Lung Cancer 
Description Medcode 
Malignant neoplasm of trachea, bronchus and lung B22..00 
Malignant neoplasm of trachea B220.00 
Malignant neoplasm of cartilage of trachea B220000 
Malignant neoplasm of mucosa of trachea B220100 
Malignant neoplasm of trachea NOS B220z00 
Malignant neoplasm of main bronchus B221.00 
Malignant neoplasm of carina of bronchus B221000 
Malignant neoplasm of hilus of lung B221100 
Malignant neoplasm of main bronchus NOS B221z00 
Malignant neoplasm of upper lobe, bronchus or lung B222.00 
Pancoast's syndrome B222.11 
Malignant neoplasm of upper lobe bronchus B222000 
Malignant neoplasm of upper lobe of lung B222100 
Malignant neoplasm of upper lobe, bronchus or lung NOS B222z00 
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Malignant neoplasm of middle lobe, bronchus or lung B223.00 
Malignant neoplasm of middle lobe bronchus B223000 
Malignant neoplasm of middle lobe of lung B223100 
Malignant neoplasm of middle lobe, bronchus or lung NOS B223z00 
Malignant neoplasm of lower lobe, bronchus or lung B224.00 
Malignant neoplasm of lower lobe bronchus B224000 
Malignant neoplasm of lower lobe of lung B224100 
Malignant neoplasm of lower lobe, bronchus or lung NOS B224z00 
Malignant neoplasm of overlapping lesion of bronchus & 
lung 
B225.00 
Malignant neoplasm of other sites of bronchus or lung B22y.00 
Malignant neoplasm of bronchus or lung NOS B22z.00 
Lung cancer B22z.11 
Carcinoma in situ of trachea B811.00 
Carcinoma in situ of bronchus and lung B812.00 
Carcinoma in situ of carina of bronchus B812000 
Carcinoma in situ of main bronchus B812100 
Carcinoma in situ of upper lobe bronchus and lung B812200 
Carcinoma in situ of middle lobe bronchus and lung B812300 
Carcinoma in situ of lower lobe bronchus and lung B812400 
Carcinoma in situ of bronchus or lung NOS B812z00 
Bronchiolo-alveolar adenocarcinoma BB5S200 
Alveolar cell carcinoma BB5S211 
Personal history of malig neop of trachea/bronchus/lung ZV10100 
Personal history of malignant neoplasm of bronchus ZV10111 
Personal history of malignant neoplasm of lung ZV10112 
Personal history of malignant neoplasm of trachea ZV10113 
 
Migraine 
Description Medcode 
Migraine F26..00 
Classical migraine F260.00 
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Common migraine F261.00 
Atypical migraine F261000 
Common migraine NOS F261z00 
Migraine variants F262.00 
Basilar migraine F262300 
Ophthalmic migraine F262400 
Migraine variant NOS F262z00 
Other forms of migraine F26y.00 
Hemiplegic migraine F26y000 
Ophthalmoplegic migraine F26y100 
Other forms of migraine NOS F26yz00 
Migraine NOS F26z.00 
Other migraine Fyu5300 
 
Myocardial Infarction 
Description Medcode 
Acute myocardial infarction G30..00 
Attack - heart G30..11 
Coronary thrombosis G30..12 
Cardiac rupture following myocardial infarction (MI) G30..13 
Heart attack G30..14 
MI - acute myocardial infarction G30..15 
Thrombosis - coronary G30..16 
Silent myocardial infarction G30..17 
Acute anterolateral infarction G300.00 
Other specified anterior myocardial infarction G301.00 
Acute anteroapical infarction G301000 
Acute anteroseptal infarction G301100 
Anterior myocardial infarction NOS G301z00 
Acute inferolateral infarction G302.00 
Acute inferoposterior infarction G303.00 
Posterior myocardial infarction NOS G304.00 
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Lateral myocardial infarction NOS G305.00 
True posterior myocardial infarction G306.00 
Acute subendocardial infarction G307.00 
Acute non-Q wave infarction G307000 
Acute non-ST segment elevation myocardial infarction G307100 
Inferior myocardial infarction NOS G308.00 
Acute Q-wave infarct G309.00 
Mural thrombosis G30A.00 
Acute posterolateral myocardial infarction G30B.00 
Acute transmural myocardial infarction of unspecified site G30X.00 
Acute ST segment elevation myocardial infarction G30X000 
Other acute myocardial infarction G30y.00 
Acute atrial infarction G30y000 
Acute papillary muscle infarction G30y100 
Acute septal infarction G30y200 
Other acute myocardial infarction NOS G30yz00 
Acute myocardial infarction NOS G30z.00 
Other acute and subacute ischaemic heart disease G31..00 
Postmyocardial infarction syndrome G310.00 
Dressler's syndrome G310.11 
Myocardial infarction aborted G311000 
MI - myocardial infarction aborted G311011 
Acute coronary syndrome G311500 
Preinfarction syndrome NOS G311z00 
Coronary thrombosis not resulting in myocardial infarction G312.00 
Other acute and subacute ischaemic heart disease G31y.00 
Acute coronary insufficiency G31y000 
Microinfarction of heart G31y100 
Subendocardial ischaemia G31y200 
Transient myocardial ischaemia G31y300 
Subsequent myocardial infarction G35..00 
Subsequent myocardial infarction of anterior wall G350.00 
Subsequent myocardial infarction of inferior wall G351.00 
Subsequent myocardial infarction of other sites G353.00 
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Subsequent myocardial infarction of unspecified site G35X.00 
Certain current complications following acute myocardial 
infarction 
G36..00 
Haemopericardium as current complication following acute 
myocardial infarction 
G360.00 
Atrial septal defect as current complication following acute 
myocardial infarction 
G361.00 
Ventricular septal defect as current complication following 
acute myocardial infarction 
G362.00 
Rupture of cardiac wall without haemopericardium as 
current complication following acute myocardial infarction 
G363.00 
Rupture of chordae tendinae as current complication 
following acute myocardial infarction 
G364.00 
Rupture of papillary muscle as current complication 
following acute myocardial infarction 
G365.00 
Thrombosis of atrium, auricular appendage, and ventricle 
as current complications following acute myocardial 
infarction 
G366.00 
 
Portal hypertension 
Description Medcode 
Portal hypertension J623.00 
 
Prostate Cancer 
Description Medcode 
Gleason grading of prostate cancer 4M0..00 
Gleason prostate grade 2-4 (low) 4M00.00 
Gleason prostate grade 5-7 (medium) 4M01.00 
Gleason prostate grade 8-10 (high) 4M02.00 
Radioactive seed implantation into prostate 7B3CB00 
Seed implantation into prostate 7B3C900 
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Malignant neoplasm of prostate B46..00 
Carcinoma in situ of prostate B834.00 
High grade prostatic intraepithelial neoplasia B834000 
Neoplasm of uncertain behaviour of prostate B915.00 
Personal history of malignant neoplasm of prostate ZV10415 
 
Pulmonary hypertension 
Description Medcode 
Secondary pulmonary hypertension G41y000 
 
Seizure 
Description Medcode 
O/E - fit/convulsion 282..00 
O/E - a convulsion 282..11 
O/E - a fit 282..12 
O/E - a seizure 282..13 
O/E - grand mal fit 2822.00 
O/E - petit mal fit 2823.00 
O/E - focal (Jacksonian) fit 2824.00 
O/E - Jacksonian fit 2824.11 
O/E - focal fit 2824.12 
O/E - psychomotor fit 2825.00 
O/E - fit/convulsion NOS 282Z.00 
Seizure free >12 months 667F.00 
Myoclonic seizure F132z12 
Grand mal seizure F251600 
Nocturnal seizure R003400 
Seizure NOS R003z11 
Fit frequency 6675.00 
Last fit 6676.00 
Fit R003200 
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Fit (in non-epileptic) NOS R003211 
 
Smoking 
Description Medcode Smoking habit 
Tobacco consumption 137..00 Unknown 
Smoker - amount smoked 137..11 Current 
Never smoked tobacco 1371.00 Never 
Non-smoker 1371.11 Unknown 
Trivial smoker - < 1 cig/day 1372.00 Current 
Occasional smoker 1372.11 Current 
Light smoker - 1-9 cigs/day 1373.00 Current 
Moderate smoker - 10-19 cigs/d 1374.00 Current 
Heavy smoker - 20-39 cigs/day 1375.00 Current 
Very heavy smoker - 40+cigs/d 1376.00 Current 
Ex-trivial smoker (<1/day) 1377.00 Ex 
Ex-light smoker (1-9/day) 1378.00 Ex 
Ex-moderate smoker (10-19/day) 1379.00 Ex 
Ex-heavy smoker (20-39/day) 137A.00 Ex 
Ex-very heavy smoker (40+/day) 137B.00 Ex 
Keeps trying to stop smoking 137C.00 Current 
Admitted tobacco cons untrue ? 137D.00 Unknown 
Tobacco consumption unknown 137E.00 Unknown 
Ex-smoker - amount unknown 137F.00 Ex 
Trying to give up smoking 137G.00 Current 
Pipe smoker 137H.00 Current 
Cigar smoker 137J.00 Current 
Stopped smoking 137K.00 Ex 
Current non-smoker 137L.00 Unknown 
Rolls own cigarettes 137M.00 Current 
Ex pipe smoker 137N.00 Ex 
Ex cigar smoker 137O.00 Ex 
Cigarette smoker 137P.00 Current 
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Smoker 137P.11 Current 
Smoking started 137Q.00 Current 
Smoking restarted 137Q.11 Current 
Current smoker 137R.00 Current 
Ex smoker 137S.00 Ex 
Date ceased smoking 137T.00 Ex 
Smoking reduced 137V.00 Current 
Cigarette consumption 137X.00 Unknown 
Cigar consumption 137Y.00 Unknown 
Tobacco consumption NOS 137Z.00 Unknown 
Pipe tobacco consumption 137a.00 Unknown 
Ready to stop smoking 137b.00 Current 
Thinking about stopping smoking 137c.00 Current 
Not interested in stopping smoking 137d.00 Current 
Smoking restarted 137e.00 Current 
Reason for restarting smoking 137f.00 Current 
Cigarette pack-years 137g.00 Unknown 
Minutes from waking to first tobacco consumption 137h.00 Current 
Smoking cessation milestones 13p..00 Unknown 
Negotiated date for cessation of smoking 13p0.00 Current 
Smoking status at 4 weeks 13p1.00 Unknown 
Smoking status between 4 and 52 weeks 13p2.00 Unknown 
Smoking status at 52 weeks 13p3.00 Unknown 
Smoking free weeks 13p4.00 Unknown 
Smoking cessation programme start date 13p5.00 Current 
Carbon monoxide reading at 4 weeks 13p6.00 Unknown 
Expired carbon monoxide concentration 4I90.00 Unknown 
Health ed. - smoking 6791.00 Current 
Pregnancy smoking advice 67A3.00 Current 
Lifestyle advice regarding smoking 67H1.00 Current 
Tobacco usage screen 6893.00 Unknown 
Tobacco usage screen 68T..00 Unknown 
Smoking cessation therapy 745H.00 Unknown 
Nicotine replacement therapy using nicotine patches 745H000 Current 
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Nicotine replacement therapy using nicotine gum 745H100 Current 
Nicotine replacement therapy using nicotine 
inhalator 
745H200 Current 
Nicotine replacement therapy using nicotine 
lozenges 
745H300 Current 
Smoking cessation drug therapy 745H400 Current 
Other specified smoking cessation therapy 745Hy00 Current 
Smoking cessation therapy NOS 745Hz00 Unknown 
Nicotine replacement therapy 8B2B.00 Current 
Over the counter nicotine replacement therapy 8B3Y.00 Current 
Nicotine replacement therapy provided free 8B3f.00 Current 
Nicotine replacement therapy provided by 
community pharmacis 
8BP3.00 Current 
Smoking cessation advice 8CAL.00 Current 
Smoking cessation advice provided by community 
pharmacist 
8CAg.00 Current 
Referral to smoking cessation advisor 8H7i.00 Current 
Referral to stop-smoking clinic 8HTK.00 Current 
Nicotine replacement therapy contraindicated 8I2I.00 Current 
Nicotine replacement therapy refused 8I39.00 Current 
Seen by smoking cessation advisor 9N2k.00 Unknown 
DNA - Did not attend smoking cessation clinic 9N4M.00 Unknown 
Anti-smoking monitoring admin. 9OO..00 Unknown 
Stop smoking clinic admin. 9OO..11 Unknown 
Stop smoking monitoring admin. 9OO..12 Unknown 
Attends stop smoking monitor. 9OO1.00 Unknown 
Refuses stop smoking monitor 9OO2.00 Unknown 
Stop smoking monitor default 9OO3.00 Unknown 
Stop smoking monitor 1st lettr 9OO4.00 Unknown 
Stop smoking monitor 2nd lettr 9OO5.00 Unknown 
Stop smoking monitor 3rd lettr 9OO6.00 Unknown 
Stop smoking monitor verb.inv. 9OO7.00 Current 
Stop smoking monitor phone inv 9OO8.00 Current 
Stop smoking monitoring delete 9OO9.00 Unknown 
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Stop smoking monitor.chck done 9OOA.00 Unknown 
Stop smoking monitor admin.NOS 9OOZ.00 Unknown 
Exception reporting: smoking quality indicators 9hG..00 Exception 
Excepted from smoking quality indicators: Patient 
unsuitable 
9hG0.00 Exception 
Excepted from smoking quality indicators: Informed 
dissent 
9hG1.00 Exception 
Nicotine withdrawal E023.00 Unknown 
Tobacco dependence E251.00 Current 
Tobacco dependence, continuous E251100 Current 
Tobacco dependence in remission E251300 Ex 
Tobacco dependence NOS E251z00 Current 
Advice on smoking ZG23300 Current 
Fagerstrom test for nicotine dependence ZRBm200 Current 
FTND - Fagerstrom test for nicotine dependence ZRBm211 Current 
Motives for smoking scale ZRaM.00 Current 
MFS - Motives for smoking scale ZRaM.11 Current 
Occasions for smoking scale ZRao.00 Current 
Reasons for smoking scale ZRh4.00 Current 
RFS - Reasons for smoking scale ZRh4.11 Current 
Personal history of tobacco abuse ZV11600 Unknown 
Tobacco use ZV4K000 Unknown 
Tobacco abuse counselling ZV6D800 Current 
Ex-cigarette smoker 137j.00 Ex 
 
Stroke 
Description Medcode 
H/O: Stroke in last year 14AK.00 
Stroke monitoring 662M.00 
Delivery of rehabilitation for stroke 7P24200 
Ref to multidisciplinary stroke function improvement service 8HHM.00 
Referral to stroke clinic 8HTQ.00 
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Seen in stroke clinic 9N0p.00 
Stroke and cerebrovascular accident unspecified G66..00 
Cerebral arterial occlusion G64..00 
CVA - cerebral artery occlusion G64..11 
Infarction - cerebral G64..12 
Stroke due to cerebral arterial occlusion G64..13 
Cerebral thrombosis G640.00 
Cerebral infarction due to thrombosis of cerebral arteries G640000 
Cerebral embolism G641.00 
Cerebral embolus G641.11 
Cerebral infarction due to embolism of cerebral arteries G641000 
Cerebral infarction NOS G64z.00 
Brainstem infarction NOS G64z.11 
Cerebellar infarction G64z.12 
Brainstem infarction G64z000 
Left sided cerebral infarction G64z200 
Right sided cerebral infarction G64z300 
Infarction of basal ganglia G64z400 
CVA unspecified G66..11 
Stroke unspecified G66..12 
CVA - Cerebrovascular accident unspecified G66..13 
Middle cerebral artery syndrome G660.00 
Anterior cerebral artery syndrome G661.00 
Posterior cerebral artery syndrome G662.00 
Brain stem stroke syndrome G663.00 
Cerebellar stroke syndrome G664.00 
Pure motor lacunar syndrome G665.00 
Pure sensory lacunar syndrome G666.00 
Left sided CVA G667.00 
Right sided CVA G668.00 
Sequelae of cerebral infarction G683.00 
Cerebral infarct due unspecified occlusion/stenosis of  
precerebral arteries 
G6W..00 
Cerebral infarction due to unspecified occlusion/stenosis of G6X..00 
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cerebral arteries 
 
Telangiectasia 
Description Medcode 
Telangiectasia G771300 
 
Transient Ischaemic Attack 
Description Medcode 
Transient ischaemic attack clinical management plan 8CRB.00 
Transient ischaemic attack G65..12 
Other transient cerebral ischaemia G65y.00 
Transient cerebral ischaemia NOS G65z.00 
Intermittent cerebral ischaemia G65z100 
Transient cerebral ischaemia NOS G65zz00 
Personal history of transient ischaemic attack ZV12D00 
 
Venous Thromboembolism 
Description Medcode 
H/O: pulmonary embolus 14AC.00 
Open embolectomy of pulmonary artery 7A09300 
Trendelenburg pulmonary embolectomy 7A09311 
Pulmonary embolism G401.00 
Pulmonary embolus G401.12 
Recurrent pulmonary embolism G401100 
Personal history deep vein thrombosis ZV12800 
Personal history DVT- deep vein thrombosis ZV12811 
Personal history of pulmonary embolism ZV12900 
H/O: Deep Vein Thrombosis 14A8100 
Deep vein thrombosis G801.11 
Deep vein thrombosis, leg G801.12 
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DVT - Deep vein thrombosis G801.13 
Deep vein thrombosis of lower limb G801D00 
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10.3 APPENDIX 3 - Selected bias assessment plots (funnel plots) for 
assessment of publication bias in meta-analysis 
Figure 1. Funnel plot to identify publication bias in studies estimating prevalence 
of pleuritic chest pain/pleurisy after embolisation 
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Figure 2. Funnel plot to identify publication bias in studies estimating prevalence 
of ischaemic chest pain after embolisation 
 
Figure 3. Funnel plot to identify publication bias in studies estimating prevalence 
of haemoptysis after embolisation
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Figure 4. Funnel plot to identify publication bias in studies estimating prevalence 
of pulmonary infarct after embolisation 
 
Figure 5. Funnel plot to identify publication bias in studies estimating prevalence 
of an uncatheterisable/unoccludable PAVM during embolisation 
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Figure 6. Funnel plot to identify publication bias in studies estimating prevalence 
of device embolism during embolisation procedure 
 
Figure 7. Funnel plot to identify publication bias in studies estimating prevalence 
of device migration during embolisation procedure 
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Figure 8. Funnel plot to identify publication bias in studies estimating prevalence 
of stroke during/after embolisation 
 
Figure 9. Funnel plot to identify publication bias in studies estimating prevalence 
of arrhythmia during/after embolisation 
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Figure 10. Funnel plot to identify publication bias in studies estimating 
prevalence of TIA during/after embolisation 
 
Figure 11. Funnel plot to identify publication bias in studies estimating 
prevalence of groin haematoma during/after embolisation 
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Figure 12. Funnel plot to identify publication bias in studies estimating 
prevalence of air embolism during embolisation 
 
Figure 13. Funnel plot to identify publication bias in studies estimating 
prevalence of venous thromboembolism after embolisation 
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Figure 14. Funnel plot to identify publication bias in studies estimating 
prevalence of haemopericardium during/after embolisation 
 
Figure 15. Funnel plot to identify publication bias in studies estimating 
prevalence of ectopic device deposition during embolisation 
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Figure 16. Funnel plot to identify publication bias in studies estimating 
prevalence of death during/after embolisation 
 
Figure 17. Funnel plot to identify publication bias in studies estimating overall 
embolisation success rate (by patient)
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Figure 18. Funnel plot to identify publication bias in studies estimating overall 
embolisation success rate (by PAVM)
 
Figure 19. Funnel plot to identify publication bias in studies estimating 
embolisation success rate (by PAVM) when coils alone were used 
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Figure 20. Funnel plot to identify publication bias in studies estimating 
embolisation success rate (by PAVM) when follow-up protocol included CT thorax 
or pulmonary angiography, follow-up exceeded 12 months, and < 20% of 
patients were lost to follow-up 
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Figure 21. Funnel plot to identify publication bias in studies estimating overall 
recanalisation rate (by PAVM) 
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10.4 APPENDIX 4 - THIN Ethics approval letter 
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10.5 APPENDIX 5 – Genetic study: ethical approval and sponsor letter 
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10.6 APPENDIX 6 - Genetic study: patient information leaflet, consent 
form and patient questionnaire  
PARTICIPANT INFORMATION SHEET 
 
Final Version 1.0, 13th December 2011 
 
Exploring the genetic basis of Hereditary Haemorrhagic Telangiectasia 
and its associated complications  
 
Name of researchers: Dr J Donaldson / Dr A Fogarty / Prof I Hall 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would 
involve for you.  
Please read through this information sheet and if you have any questions 
contact us using the details given on the last page.  
 What is the purpose of the study? 
The purpose of this study is to try and give us a better understanding of how 
hereditary haemorrhagic telangiectasia (HHT) is passed on between families. HHT 
is a genetic (inherited) disease that can cause a variety of complications including 
severe nosebleeds and strokes. In up to 20% of people with HHT we cannot identify 
what type of mutation in their genes is causing the disease. This study involves 
looking at DNA (genetic material) from saliva (spit) samples to search for new 
undiscovered genes that may cause the disease. We hope the results from this 
study will help us to diagnose and treat HHT more effectively in the future.  
 Why have I been invited to participate? 
You have been invited to take part in this study for one of two reasons; 
 Either you are known to the Nottingham Clinical Genetics Service with a 
possible or definite diagnosis of HHT,  
 Or, you are a close relative of a person with HHT but you do not have the 
disease yourself. 
In this study we are looking for around 60 people with HHT and 60 people without 
the disease to take part. 
 What will happen to me if I take part? 
This study is conducted by post and will not require you to travel to the 
hospital or to your GP surgery at any point. 
If you are happy to take part then we would ask you to; 
 Complete (by putting your initials) and sign the consent form that will 
be sent to you 
 Complete the confidential health questionnaire (should take 5 
minutes) 
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 Provide a single sample of saliva (spit), approximately 10ml (or two 
teaspoons), in the enclosed specimen pot.  
 Post the saliva sample, questionnaire and consent form back to us 
free of charge in the prepaid envelope.  
By agreeing to take part you would also be giving us permission to access your 
hospital medical records to find out information about your health – these records 
would remain confidential. 
 Do I have to take part? 
It is up to you to decide whether to join the study. This information sheet is designed 
to explain the study. If you agree to take part but later on change your mind you are 
free to withdraw at any time, without giving a reason. This would not affect the 
standard of any medical care you receive. 
 Will I be compensated in any way for my time? 
On receipt of your completed consent form, questionnaire and adequate saliva 
sample we will post to you a £15 voucher in recognition of your assistance with this 
study. 
 What will happen to any samples I give? 
The DNA (genetic material) in your saliva sample will be analysed to look for 
variations in the genes that cause HHT. With your permission, any remaining saliva 
will be kept and stored securely under our licence and without your details 
associated with it to maintain confidentiality. 
In addition, if you agree, we may contact you directly in the future about further HHT 
related research projects although you have no obligation to take part in either this 
or any future study. 
 Will any genetic tests be done? 
Yes. DNA (genetic material) in your saliva will be analysed to look for variations in 
the genes that cause HHT. These tests will be done at the Sanger Institute in 
Cambridge on our behalf. 
 What are the possible advantages, disadvantages and risks of taking part? 
We cannot promise the study will help you directly and you will not receive any 
individual results of tests performed but we hope the information we get from this 
study will help improve the diagnosis and treatment of patients with HHT in the 
future and give us a better understanding of the cause of the disease.  
There are no significant disadvantages in taking part other than the time it will take 
to collect and post the saliva samples to us. Any medical treatment you normally 
receive will be entirely unaffected by participation in this research study.  
 What will happen if I don’t want to carry on with the study? 
Your participation is voluntary and you are free to withdraw at any time, without 
giving any reason, and without your legal rights being affected. If you withdraw then 
the information collected so far cannot be erased and this information may still be 
used in the project analysis. Any remaining samples will be destroyed if you wish. 
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 What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to Dr 
James Donaldson or another member of the research team who will do their best to 
answer your questions (telephone 0115 823 1379 or e-mail 
james.donaldson@nottingham.ac.uk).  
 Will my GP be informed about my involvement in this study? 
We will not contact your GP to inform them of your participation in this study. 
 Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be 
kept strictly confidential.  
The genetic study data will be anonymous as the DNA (genetic material) of many 
participants will be combined and analysed simultaneously. This means that it will 
not be possible to identify which genetic results are from which participant. The 
results of genetic testing will not be available and as such your participation in the 
study should not affect insurance policies. 
Study data on the results of analysing the genetic material will be stored in a secure 
database labelled with only your initials and the participant number we will allocate 
to you.  
We may, if you consent (optional), also use the DNA (genetic material) from your 
saliva samples for further genetic sequencing (analysis) with new genetic 
techniques as they become available, either within the University of Nottingham or 
with collaborators at other institutions. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it.  
 What will happen to the results of the research study? 
 
Our results will be published in scientific journals however it will not be possible to 
identify individuals who have taken part. The detailed nature of this research and 
the tests involved means that it may be a year or more before results are published.  
A summary of the study results will be on our departmental website when they are 
available. The website address is: 
http://www.nottingham.ac.uk/scs/divisions/therapeuticsmolecularmedicine/index.asp
x 
 Who is organising and funding the research? 
This research is organised by clinical academic researchers at the University of 
Nottingham and is funded by a research grant from the National Institute of Health 
Research (an NHS research body).  
 Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given favourable opinion by the Nottingham Research Ethics Committee East 
Midlands – Nottingham. 
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 Contact details for any queries or further information; 
 
 
Dr James Donaldson, Division of Epidemiology and Public Health, Clinical 
Sciences Building, Nottingham City Hospital Campus, Hucknall Road, 
Nottingham, NG5 1PB.  
E-mail: james.donaldson@nottingham.ac.uk, Telephone: 0115 823 1379. 
 
 
The contact details of the chief investigator are: Dr A Fogarty, Division of 
Epidemiology and Public Health, Clinical Sciences Building, Nottingham City 
Hospital Campus, Hucknall Road, Nottingham, NG5 1PB.  
E-mail: andrew.fogarty@nottingham.ac.uk, tel: 0115 823 1715 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
275 
 
CONSENT FORM 
Final version 2.0, 17th February 2012 
 
Title of Study:  Exploring the genetic basis of Hereditary 
Haemorrhagic Telangiectasia and its associated 
complications 
PLEASE KEEP ONE COPY OF THIS FORM AND RETURN THE SECOND BY POST 
Name of Researchers: Dr James Donaldson / Dr A Fogarty / Prof Ian 
Hall     
Participant Name:        …………………………………………….    
 
1. I have read and understand the information sheet for the above study 
(dated 17th February 2012) and have had the opportunity to ask 
questions.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason. I understand that 
should I withdraw then the information collected so far cannot be 
erased and that this information may still be used in the project 
analysis. 
 
3. I give permission for access to my medical and other health-related 
records, and for long term storage and use of this information for 
health-related research purposes, including publication. I understand 
that my personal details will be kept confidential. 
 
4. I understand and agree that a saliva sample will be taken for analysis 
of DNA (genetic material). I understand that the results will not be 
given to me as the sample will be analysed anonymously. 
 
5. I agree to my GP being informed of my participation in this study. 
 
6. I agree to take part in the above study. 
 
7. Consent for storage and use in possible future research;                                                                      
 
Please initial 
box 
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I agree that the samples I have given and the information gathered 
about me can be stored by Dr Andrew Fogarty at the Clinical 
Sciences Building, Nottingham City Hospital for possible use in future 
studies. I understand that some of these studies may be carried out 
by researchers other than the current team of Dr Fogarty, who ran 
the first study, including researchers working for commercial 
companies. Any samples or data used will be anonymised, and I will 
not be identified in any way. 
 
 I agree to be contacted directly in the future regarding other HHT 
related research projects. 
              (please tick)     Yes              No 
 
 
___________________ __________     ____________________ 
Name of Participant   Date          Signature 
 
___________________     __________            ____________________ 
Name of Person taking consent Date          Signature 
 
2 copies: 1 for participant, 1 for the project file  
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PARTICIPANT QUESTIONNAIRE 
Final version 2.1, 3rd April 2012 
Title of Study:  Exploring the genetic basis of Hereditary 
Haemorrhagic Telangiectasia and its associated 
complications 
Please complete this short questionnaire about you and your health. 
Any information you provide will be stored securely and kept confidential. 
Participant Name:           ……………………………………..   
1. What is your date of birth?                        ……………… 
2. What sex are you? (please circle)    Male / Female 
3.  To which ethnic group do you belong? (please tick) 
 White British 
 Mixed race   
  White and Black Caribbean / African 
  White and Asian 
  Any other Mixed background (please specify) …………... 
 Asian or Asian British 
 Black or Black British 
 Chinese or Chinese British 
 Other background (please specify)   …………… 
4.  Question 4 applies only to females completing this form (please 
circle); If you are male, please continue to question 5. 
a) Are you currently using or have you ever used a contraceptive containing 
oestrogen (such as the combined pill, contraceptive implant or patch)? Yes / No 
 
b) As far as you are aware, are you currently pregnant?               Yes / No 
 
c) How many previous times have you been pregnant (whether  
resulting in giving birth or not)?                  ………… 
5.  Have you been diagnosed with Hereditary Haemorrhagic 
Telangiectasia, also known as HHT?       Yes / No 
 
If you have not been diagnosed with HHT please continue to answer the 
questions below. If you have HHT please skip to question 9. 
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6.  Have you suffered from any of the following symptoms in the last 2 
years? (please circle) 
a) Severe nosebleeds that happen repeatedly Yes / No / Unsure 
 
b) Anaemia      Yes / No / Unsure 
 
c) Bleeding from the gut    Yes / No / Unsure 
 
d) Shortness of breath    Yes / No / Unsure 
 
e) Migraine      Yes / No / Unsure 
 
f) Coughing up blood    Yes / No / Unsure 
 
7.  Have you ever noticed small (less than 1cm) spider-shaped lesions on 
your skin that are cherry red in colour, normally on the nose, lips, 
inside of the mouth or fingers? 
       Yes / No / Unsure 
8.  Have you ever had a stroke or a mini stroke in the past? 
        Yes / No / Unsure 
 
If, having answered the above questions, you are at all concerned about 
whether 
you may have symptoms of HHT, we can offer further medical support. 
Please contact us via the details provided on the patient information 
sheet 
The following questions apply only to those people who have HHT. 
9. Do you currently attend a hospital outpatient clinic for any treatment or 
monitoring for your HHT? 
        Yes / No / Unsure 
10. If yes, are you seen in the respiratory / chest clinic for any lung problems 
related to your HHT? 
        Yes / No / Unsure 
11.  If no, please detail which specialist clinic you attend (eg. 
gastroenterology, clinical genetics) 
 ……………………………………………………………………………… 
12.  Have you received information about what symptoms to look out for 
in HHT (such as nose bleeds or shortness of breath)?  
        Yes / No / Unsure 
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13. If you are female and of childbearing age have you ever received any 
advice on HHT and pregnancy?     
        Yes / No / Unsure 
14. Have you ever had the following complications of HHT? 
 
a) Severe nosebleeds that happen repeatedly Yes / No / Unsure 
 
b) Coughing up blood    Yes / No / Unsure 
 
c) Bleeding from the gut    Yes / No / Unsure 
 
d) Anaemia      Yes / No / Unsure 
 
e) Malformations of blood vessels, also known as AVMs in your: 
 
I. Lungs     Yes / No / Unsure 
 
II. Brain     Yes / No / Unsure 
         
III. Liver     Yes / No / Unsure 
         
IV. Gut     Yes / No / Unsure 
 
V. Spine     Yes / No / Unsure 
 
f) Skin lesions (known as telangiectasia) on the nose,  
tongue or lips?     Yes / No / Unsure 
 
g) Stroke or mini stroke    Yes / No / Unsure 
 
h) Brain abscess     Yes / No / Unsure 
 
i) Migraine headaches    Yes / No / Unsure 
 
15.  Have you ever had a coil embolisation procedure to close  
 off an abnormal blood vessel in your lungs? Yes / No / Unsure 
 
 
 
 
THANKYOU FOR COMPLETING THIS QUESTIONNAIRE 
 
